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 i 
Abstract 
Germ cell tumours (GCTs) are a class of tumours classified 
histologically into two main types: seminoma and non-seminoma. Prior 
studies revealed that there is a significant difference in global DNA 
methylation between those two types, where non-seminomas represent 
more differentiated cells and exhibit a high level of methylation 
compared with seminomas that resemble the precursor cells of GCTs. A 
number of studies have reported that silencing of genes by DNA 
methylation is a common phenomenon in many types of cancer. 
However, the silenced genes and the genomic targets that are 
methylated in GCTs have not yet been systematically identified. 
Furthermore, many methylation studies in GCTs do not include the level 
of gene expression in their investigation. We hypothesized that the 
methylation of genes might play an important role in gene silencing in 
GCTs, so the main focus of this thesis was studying the relationship 
between the gene methylation and gene expression in GCT cell lines 
representing seminoma and non-seminoma. We analysed genome 
methylation and gene expression of these cell lines using the Illumina 
infinium Human Methylome 450 bead chip system and Affymetrix Gene 
Chip Human Genome U133 Plus 2.0 arrays, respectively. We also 
compared our results with gene expression data from primary tumours 
in order to identify which events were shared in primary GCTs tumour. 
qPCR analysis was carried out after treatment of cells with the 
demethylation agent, 5-aza-2-deoxycytidine, to confirm that expression 
of identified genes was regulated by methylation.  
These analyses showed that differential methylation of CpG islands 
between seminoma and non-seminoma cell lines correlated well with 
differential gene expression and revealed that hypermethylation of CpG 
islands near the transcriptional start site was more strongly correlated 
with low gene expression than was methylation of other regions. 
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Meanwhile, methylation analysis identified uniquely methylated genes 
and features for each cell line, which may imply an underlying 
mechanism of their development. One-hundred and forty-seven silenced 
genes which exhibited a difference in methylation and expression 
between seminoma and non-seminoma cell lines were identified, some 
of these genes were also differentially expressed in primary tumours. 
Re-expression of selected silenced genes in non-seminoma cells after 
treatment with 5-aza-2-deoxycytidine confirmed that methylation played 
a role in gene silencing. Some of the genes identified are closely 
associated with pluripotency and implicated in chemosensitivity 
(PRDM14, KLF4, TDRD12, DDX43, MNS1, and RBMXL2). Silencing of 
these genes could therefore account for the progression process from 
seminoma to non-seminoma.  
PRDM14 was given special attention as it plays an important role 
in germ cell development and maintenance of germ cell pluripotency. 
The role of PRDM14 in GCT biology was studied, revealing that high 
expression of PRDM14 in combination with 5-aza-2-deoxycytidine 
treatment increased the response of cells to chemotherapy compared 
with those that had low levels of PRDM14. In addition, this study 
supports a growing body of literature on PRDM14 suggesting that this 
gene plays a critical role in DNA demethylation.  
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Chapter 1. Introduction 
DNA methylation is a critically important epigenetic alteration that 
affects gene expression without altering the underlying DNA sequence. 
It is known that DNA methylation is involved in the normal control of 
cells. Aberrant DNA methylation is observed as a frequent event in 
cancers where it may result in transcriptional repression or silencing 
(Akhavan-Niaki and Samadani, 2013). Therefore, DNA methylation can 
be used as a way of identifying important genes that play a role in 
tumorigenesis.  
Germ cell tumours (GCTs) are malignant or benign tumours 
believed to be derived from primordial germ cells (PGCs) (di Pietro et 
al., 2005, Jeyapalan et al., 2011). GCTs affect both children and adults, 
and occur in gonadal and extragonadal regions. They are classified 
histologically into two major groups, seminomas and non-seminomas, 
where the latter group exhibits a higher degree of DNA methylation than 
seminomas (Netto et al., 2008).  
Recent studies have revealed that DNA methylation is associated 
with tumourigenesis, particularly in the silencing of critical growth 
regulators such as tumour suppressor genes (Baylin, 2005) or 
pluripotency markers, including several transcription factors (Western et 
al., 2010). However, for GCTs, the genomic targets that are methylated 
and which silenced genes are most likely to play a role in the tumours’ 
biology remain to be systematically determined. This thesis makes an 
attempt to fill this gap to provide insight into the relationship between 
DNA methylation and gene expression. 
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1.1. DNA methylation 
Over recent decades, cancer biology research has been driven by 
the genetic revolution that allowed the identification of structural DNA 
changes (mutations) that changed gene expression in hereditary and 
sporadic cancers. In the late 1967s, a hypothesis was proposed that 
there is another factor that could change gene expression without 
altering the sequence of DNA (Scarano et al., 1967), later known as an 
epigenetic alteration, including DNA methylation and histone 
modifications.  
In eukaryotes, DNA methylation involves the covalent addition of 
a methyl group to carbon five (C5) of the cytosine base within CpG 
dinucleotides of DNA (Bird, 2002). The content of GC nucleotides in the 
human genome is approximately 42% (Jabbari and Bernardi, 2004) but 
the occurrence frequency of CpG dinucleotides in the DNA sequence is 
only 1% of expected frequency (Illingworth and Bird, 2009). This low 
frequency of the CpG dinucleotide could be explained by the action of 
spontaneous deamination. The cytosines in CpG dinucleotides often 
become methylated producing methylcytosines but these methylated 
cytosines are highly susceptible to spontaneous deamination that 
converts methylcytosine to thymine (Scarano et al., 1967). Then, during 
DNA replication, the mismatched TG base pair is repaired to TA resulting 
in a permanent alteration or mutation in the DNA sequence. 
Unmethylated cytosine, on the other hand, converts by spontaneous 
deamination to uracil, which can be repaired by the cells to cytosine. 
Therefore, a high level of conversion of methylated cytosine to thymine 
decreases the amount of CpG dinucleotides over replication times 
(Cooper and Krawczak, 1989). However, although the average CpG 
dinucleotide level within the genome is low, some regions in the genome 
contain a high density of CpG dinucleotides; these include repetitive 
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sequences and regions known as CpG islands (CGIs) (Cooper et al., 
1983). 
5-methylcytosine (5-mC), sometimes classed as the fifth 
nucleotide, was first discovered by Johnson and Coghill (1925) in 
Tubercle Bacillus. Later, in 1948, Hotchkiss proved the presence of this 
methylated cytosine in the DNA of calf thymus cells using paper 
chromatography. Kelly and Smith (1970) reported that specific 
methylation sensitive restriction enzymes could be used as a useful 
method to distinguish between methylated and unmethylated cytosines 
in DNA.  
The first hypothesis that DNA methylation could play a role in 
gene expression was reported by Scarano (1973). Subsequently, many 
studies were carried out regarding this epigenetic phenomenon (Holliday 
and Pugh, 1975, Li et al., 1993, Yoder et al., 1997, Baylln et al., 1997, 
Payer and Lee, 2008, Udali et al., 2015). General reviews for this 
phenomenon are reported by Razin and Cedar (1991) as well as by 
Roberston (2005). 
However, many researchers have argued that DNA methylation is 
a secondary event in gene silencing following histone modifications. This 
argument emerged from genetic studies in the Neurospora crassa model 
(Tamaru and Selker, 2001) showing methylation of histone 
methyltransferase (H3K9) led to methylate all CGI and silence certain 
genes. Moreover, Richards and Elgin (2002) suggested that DNA 
methylation might be controlled by histone methylation. Feldman et al.  
(2006) showed that methylation of histone methyltransferase (H3K9) 
causes local heterochromatinization followed by an increase in DNA 
methylation in promotor regions by the enzymes Dnmt3a/3b, thus 
silencing specific genes.   
 4 
However, there is still more evidence required to support this 
argument because the human genome is more complex than 
Neurospora crassa. In addition, the integration of DNA methylation with 
other epigenetic modifications is a complex process and depends on 
multiple components. Furthermore, genes involved in H3K9 methylation 
could also be involved in de novo DNA methylation (Rose and Klose, 
2014).  
Whether DNA methylation is a cause or a consequence of 
downregulation of gene expression is still controversial. As a cause of 
gene repression, methylation could affect transcription factor binding 
sites. Alternatively, DNA methylation may stabilize chromatin 
modification that causes gene repression.    
1.1.1 DNA methylation machinery 
The DNA methylation machinery primarily consists of DNA 
methyltransferases, also known as DNMTases or DNMTs, a family of 
enzymes that are responsible for catalysing the transfer of methyl 
groups during the DNA methylation process. The DNA 
methyltransferases catalyse DNA methylation by initiating and 
maintaining the addition of methyl groups to the 5th carbon position of 
the cytosine ring within the CpG dinucleotide, thereby forming 5-
methylcytosine.  
There are three DNMTs responsible for the establishment and 
maintenance of DNA methylation, namely DNMT1, DNMT3a and DNMT3b 
(Gnyszka et al., 2013). DNMTs are classified as maintenance DNA 
methyltransferase (DNMT1) or de novo DNA methyltransferases 
(DNMT3a and DNMT3b). Another relevant protein, DNA cytosine-5-
methyltransferase 3-like protein (DNMT3L), is recognized as a 
regulatory factor for the de novo DNA methylation process (Cheng and 
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Blumenthal, 2008). Additionally, DNMT2 shows sequence similarity to 
DNA methyltransferases including all of the conserved methyltransferase 
motifs but cannot methylate DNA (Robertson, 2001). Recent studies 
pointed out that DNMT2 methylate tRNA in some organisms such as 
Arabidopsis thaliana (Goll et al., 2006), Schistosoma mansoni and 
Drosophila melanogaster (Raddatz et al., 2013).  
DNMT1 is the most abundant of the DNMTs, particularly in 
mammalian cells, and is recognised as a maintenance DNA 
methyltransferase. This is because it acts primarily on hemi-methylated 
DNA and maintains the pre-existing methylation patterns, to deliver 
symmetrically methylated CpG dinucleotides in the double strands of 
newly replicated DNA (Bestor, 1992). Robertson (2001) showed that 
there is no enzyme that can compensate the function of DNMT1. 
Furthermore, Jin et al. (2011) found that the deletion of both alleles of 
DNMT1 from mouse embryos at day E9 was lethal. DNMT3A and 
DNMT3B are called de novo methylases because they initiate 
methylation of unmethylated DNA (Szyf, 2009). DNMT3a methylates 
CpG dinucleotides at a faster rate than DNMT3b, but slightly slower than 
DNMT1. DNMT3L binds to the catalytic domain of de novo 
methyltransferases then accelerates their ability to attach to S-
adenosyl-L-methionine (Figure 1.1) and stimulates their ability to 
methylate DNA (Jin et al., 2011). 
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Figure 1.1: DNA methyltransferases convert cytosine to 
5methylcytosine. DNMT3L binds de novo methyltransferases then 
accelerates their ability to attach to S-adenosyl-L-methionine 
(SAM) to stimulate their ability to methylate DNA by addition of 
methyl group. Figure adapted from Meng et al. (2015) 
 
 
 
 
 
 
 
 
Other key components of the epigenetic regulation of gene 
expression by DNA methylation are the methylation mark readers known 
as methyl-CpG-binding domain (MBD) proteins (proteins with a methyl 
binding domain), such as MBD1-4 and MeCP2 (Figure 1.2). These bind 
specifically to methylated CpGs, thereby silencing transcription and 
modulating gene expression. Other proteins that bind to methylated 
CpG are classified according to their domain type. For example, the zinc 
finger protein family such as Kaiso related proteins, ZBTB4, ZBTB38, 
UHRF1 and UHRF2, use zinc finger domains to bind methylated CpGs at 
specific sequences to repress gene expression through interaction with 
histone deacetylases, to remodel chromatin into a repressive state 
(Parry and Clarke, 2011, Meng et al., 2015). 
 
 
 
DNMT3L 
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The activities of the MBD proteins are closely supported by the 
local chromatin structures, which are often primarily responsible for 
determining the repression or transcription of certain genes (Fuks et al., 
2003). Therefore, MBDs contribute to the formation of heterochromatinc 
regions in the genome thus enforcing silencing of genes in these regions 
(Rose and Klose, 2014). For example, Fuks et al. (2003) reported that 
MeCP2 could bind to the chromatin modifying enzymes, histone lysine 
methyltransferases, to modify histone H3 on lysine at position 9 
(H3K9me) resulting in a condensed chromatin structure and 
transcriptional repression of genes in that region.  In this regard, the 
state of the chromatin structure may be critically important in the 
regulation of transcription and the repression of gene. 
In addition, methylation can affect individual gene expression by 
direct blocking of transcription factor (TF) binding such as AP-2 and 
MLTF. Therefore, cytosine methylation at promoter sequences can 
prevent binding of a TF to its binding site resulting in repression of gene 
expression (Comb and Goodman, 1990). For example, in mouse 
astrocyte differentiation from neuroepithelial cells at E11.5, removal of 
methylation from CpG islands in the promoter region of GFAP (the glial 
fibrillary acidic protein gene) promotes the binding of STAT3 (signal 
transducer and activator of transcription 3) to its binding site in the 
GFAP promoter resulting in transcriptional activation of GFAP (Cheng et 
al., 2011). 
 
 
 
 
 8 
D
N
A
 M
et
h
y
la
ti
o
n
 M
ac
h
in
er
y
  
 
 
 
 
 
 
 
 
1.1.2.   DNA methylation in the human genome 
The human genome thus contains two sets of information, namely 
genetic and epigenetic. The genetic information, is primarily responsible 
for providing the needed scheme for the processing and manufacture of 
all important proteins and RNAs required for the survival of organisms 
while the epigenetic information is used to determine where, how and 
when the genetic information should be used, including its transcription 
(Esteller, 2011). DNA methylation is one of the major forms of 
epigenetic information in the human genome that is responsible for 
ensuring appropriate gene expression patterns. 
 
 
 
Figure1.2: DNA methylation machinery. DNA methyltransferases 
(DNMTs) and methyl-CpG-binding proteins (MBD) catalyse the 
transfer of methyl groups to histone and DNA sequence while 
Histone deacetylases (HDAC) remove acetyl groups from lysine 
residues making way for methylation. Figure adapted from Feinberg 
and Tycko (2004). 
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Generally, the methylation of DNA in the human genome may 
potentially affect the binding of proteins to their target DNA sequences, 
thereby resulting in a number of effects on the genome. DNA 
methylation has diverse effects on the human genome including 
epigenetic inheritance, genomic stability, transcriptional repression, X-
chromosome inactivation, and imprinting of specific DNA sequences. 
Changes in DNA methylation have in numerous cases been correlated 
with genetic lesions and genomic instability such as Rett syndrome that 
is caused by mutations in the methyl-CpG binding gene (MeCP2) which 
lead to suppress genes that are critical in normal brain function, and 
Facial anomalies syndrome which is caused by a mutation in DNMT3b 
that is associated with hypomethylation of pericentromic satellite 
regions thus genome instability (Paulsen and Ferguson-Smith, 2001). 
1.1.2.1 The role of DNA methylation in human development and 
cell differentiation 
DNA methylation is involved in the normal control of human 
development and cell differentiation. For example, many germline-
specific genes are methylated in somatic cells but not in germ cells. DNA 
methylation reprogramming involves regulation of transcription factors 
that are important in early development (Wagner et al., 2014).  
Normal germ cells undergo many processes, including the 
reprogramming of DNA methylation during embryogenesis (Mochizuki et 
al., 2012). DNA methylation is removed during zygote formation and re-
established after implantation (Jin et al., 2011) to regulate gene 
expression in germ cells during embryogenesis (Messerschmidt et al., 
2014) (Figure 1.3).  
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During embryogenesis, expression of certain genes is regulated by 
DNA methylation in a phenomenon called genomic imprinting resulting in 
parent-of-origin specific manner. Genomic imprinting is a process where 
a gene is silenced in one allele that inherited from one parents while 
other allele that inherited from other parent is expressed (Reik et al., 
2003). For example, IGF2 (Insulin-like growth factor 2) expressed from 
the paternal allele while H19 expressed from the maternal allele 
(Bartolomei et al., 1991).    
 
Figure 1.3: DNA methylation changes during embryogenesis: Maternal and 
paternal DNA in the zygote undergo reprogramming of DNA methylation. 
Figure adapted from Saadeh and Schulz (2014). 
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1.1.2.2 Aberrant DNA methylation in cancer 
Compared with the role of DNA mutation, there are relatively few 
studies on the role of DNA methylation in the development of cancer. 
The genetic hypotheses of cancer, which focus on the effect of 
mutations, have guided cancer research for many decades. In 1983, 
Feinberg and Vogelstein discovered loss of DNA methylation at CpG 
dinucleotides in tumour sample. This effort was the first evidence that 
aberrant methylation could play a role in cancer. That study triggered 
interest in the role of epigenetics in cancer. The widely accepted 
‘multiple-hits’ hypothesis, was proposed by Carol O. Nordling, states 
that cancer is the result of accumulations of mutations (Nordling, 1953). 
This hypothesis formulated by Knudson who performed a statistical 
analysis on 48 cases of retinoblastoma and noted that a cancer is 
formed by two mutational hits leading to inactivation of tumour 
suppressor gene (TSG). Knudson (1971) pointed that the inherited form 
mutation of one of the two copies of a specific tumour suppressor gene 
is inherited in the germline and the second hit occurs in somatic cells. 
While the nonhereditary form, both mutations occur in somatic cells 
therefore, this hypothesis called the ‘two-hit’ hypothesis or the Knudson 
hypothesis. Later, in 2001, Knudson pointed out that a hit event that 
lead to silencing of gene expression might be caused by methylation of 
TSG (Knudson, 2001). 
Tumorigenesis occurs as a result of both genetic and epigenetic 
alterations. Genetic mutations are a sequence change in the genomic 
DNA such as substitution, deletion or insertion of nucleotides. On the 
other hand, the epigenetic modifications that characterise the onset of 
cancer are generally attributed to the disruption of mechanisms such as 
DNA methylation and post-translational modifications of nucleosome 
positioning and histone modifications, all of which result in activation or 
inactivation of particular genes without changing DNA sequence.  
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However, tumourigenesis is widely believed to involve a complex 
interaction between the two sets of mechanisms: genetic or epigenetic 
factors (You and Jones, 2012). A number of studies revealed that DNA 
methylation is a crucial player in both aberrant DNA repair and genome 
instability in cancer by two distinct pathways, through a mechanism of 
DNMT1-PCNA (Proliferation cell nuclear antigen) interaction leading to 
hypermethylation and silencing of the mismatch repair gene (hMLH1) or 
by a methylation proficiency mechanism that reduces DNA methylation, 
thus increasing genome instability (Jones and Laird, 1999, Rizwana and 
Hahn, 1999, Robertson and Jones, 2000) 
Single locus DNA hypermethylation  
Curtin et al. (2011) reported that CGI hypermethylation of TSGs is 
a common marker of human cancers and Esteller (2007) claimed that 
identification of hypermethylated TSGs for each human cancer could be 
a target for treatment of those cancers. According to Sproul et al. 
(2012), a study that analysed the methylation profile of 1,154 cancers 
from seven different tissue types, more than a thousand genes are 
subject to CGI hypermethylation in these tissues and half of these genes 
show some degree of tissue specificity of gene expression. 
In cancer cells, hypermethylation of CGIs located in the promoter 
region of TSGs can lead to transcriptional silencing or downregulation of 
expression that may reduce the function of that gene such silencing 
could contribute to dysfunction of cell signaling, DNA repair, remodeling 
or apoptosis for almost all types of tumour facilitating progression of 
tumourigenesis (Ehrlich and Jiang, 2005, Heyn and Esteller, 2012). 
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In other findings, it was documented that the DNA methylation 
pattern is similar in inherited and sporadic cancers of the same type of 
tumour (Esteller et al., 2001). DNA methylation associated with cancer 
varies according to tumour type (Esteller, 2011). However, there is an 
opinion that regulation of genes by methylation is different in each 
cancer and certain CpGs are more important than other in silencing of 
genes (Esteller, 2002). 
 DNA hypermethylation not only causes local silencing for specific 
genes but this repression can also extend to large regions of 
chromosomes (more than 1 Mb), leading to suppression of neighbouring 
unmethylated genes. This effect is referred to as long range epigenetic 
silencing (LRES) and might also be important in the initiation and 
progression of cancer (Clark, 2007, Swami, 2010, Forn et al., 2013).  
Global genomic hypomethylation 
The first epigenetic change described in human cancer was the 
loss of DNA methylation throughout various areas of the genome. This 
was demonstrated using methylation-sensitive restriction enzyme 
digestion followed by Southern blotting (Feinberg and Vogelstein, 1983). 
This study reported that adenocarcinomas of the colon had low global 
DNA methylation compared with ordinary colonic epithelium. Later the 
same year, Gama-Sosa et al. (1983) used methylation-sensitive 
restriction enzyme digestion analysis followed by high-performance 
liquid chromatography and showed that low content of 5mC was 
associated with tumour progression.  
Since this discovery, many cancer studies have revealed that 
tumours have low 5mC compared to normal tissue. This difference is 
associated with low methylation in intergenic repetitive regions that can 
accelerate the instability of the genome. Global DNA hypomethylation in 
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malignancy is significantly connected with hypomethylation of certain 
DNA repeatitive sequence or single-duplicate DNA arrangements (Ross 
et al., 2010). Several studies reported that a low level of DNA 
methylation (which refers to hypomethylation) is seen in the early stage 
of many types of cancer (Hernandez-Blazquez et al., 2000, Kinney et 
al., 2008, Park et al., 2009). 
In contrast to hypermethylation of TSGs, Okamoto (2012) noted 
that hypomethylation of CGIs of an oncogene may lead to increasing 
gene expression (Bert et al., 2013) and can contribute to an increase 
proliferation and tumour formation. It should be noted that during 
carcinogenesis the hypomethylation status is not only restricted to 
oncogenes but also has an effect on the whole genome. For example, 
when Gaudet and colleagues (2003) introduced a hypomorphic DNMT1 
allele in mice, they found increased loss of heterozygosity, aneuploidy, 
chromosomal instability, and the mice eventually developed aggressive 
T cell lymphomas. This information should be kept in mind during cancer 
therapy by demethylation drugs, as these might cause increased 
genome instability (Tang et al., 2009).  
Hypomethylation has been proposed as a biomarker because it 
satisfies three requirements of a successful biomarker: the need to be 
an early change in a disease, showing an early discrimination of the 
tumour, and being detectable in the background of molecular changes in 
DNA of normal cells (Wilson et al., 2007). 
Although many studies have reported that hypermethylation is 
associated with the suppression of specific genes, there are a few 
studies revealing that hypomethylation has the same action. For 
example, inactivation of the synuclein γ gene (SNCG) in ovarian and 
breast cancers is associated with regional hypomethylation of a CGI of 
this oncogene (Gupta et al., 2003). However, the majority of studies 
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involving the role of methylation in cancer pay attention primarily to 
hypermethylation status in CGIs. 
In conclusion, both the abnormal hypermethylation of promoter 
CGIs and global hypomethylation (Figure 1.4) are likely together to 
initiate or progress tumours (Bariol et al., 2003, Lujambio et al., 2008). 
In general, detecting hypermethylation of specific genes could be used 
as a prognostic marker while DNA hypomethylation might be helpful in 
distinguishing between subtypes of tumours or between normal and 
cancer cells where most tumours can be classified according to their 
degree of methylation. 
 
 
 
 
 
 
 
    
 
 
 
 
Figure 1.4: The role of DNA methylation in tumourigenesis:  
Hypomethylation of repetitive elements leads to genomic instability 
and could activate oncogenes, while hypermethylation of CGI at the 
promoter region leads to silencing of tumour suppressor genes. 
Taken from Roberston (2005). 
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1.1.3 CpG island methylator phenotype (CIMP) 
Methylation of DNA mainly occurs in cytosine residues within 
dinucleotide CpG sites. CpG rich regions are called CpG islands (CGIs). 
The bulk of lone CpG are found in intronic and intergenic regions of the 
DNA sequence within the transposable elements and the repeat 
sequences (Wilson et al., 2007). 
The generally accepted definition of CGIs is a region in the human 
genome with high concentration of CpG dinucleotides (Juo et al., 2014), 
where GC content is greater than 50% and an observed CpG to 
expected CpG ratio is greater than 60% (Gardiner-Garden and 
Frommer, 1987). These conspicuous islands overlap the promoter 
regions or are near transcription start site (TSS) of 60–70% of human 
genes particularly housekeeping genes and about 40% of tissue specific 
genes (Larsen et al., 1992, Wang and Leung, 2004, Shen et al., 2007).   
As CGIs are frequently associated with the 5’ end of a gene, 
Antequera and Bird (1993) and Bird (2002) considered them as gene 
markers and used them to estimate the number of genes in the 
genome. Although the genome size and gene number of different 
vertebrates such as human, rat, and mouse are very similar, the 
distribution and number of CGIs among their genomes are varied (Gibbs 
et al., 2004, Han et al., 2008). The number of CGIs is approximately 
27000, 19600, and 15500 within the genome of human, rat, and mouse, 
respectively.  
About 60-90% of CpG dinucleotides are methylated in normal cells 
(Bogdanović and Veenstra, 2009), with the exception of CGIs (Ghoshal 
et al., 2005). Many studies reported that CGIs are differentially 
methylated in different tissues (tissue-specific differentially methylated 
regions, TDMs) and those tissues show differential gene expression 
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(Feltus et al., 2003, Bock et al., 2006, Previti et al., 2009). These 
findings suggest that methylation features could be related to 
differentiation of the cells and/or their specific function.  
The CpG island methylator phenotype (CIMP), defined as 
widespread CpG island promoter methylation of a subset of genes, has 
received a lot of attention. It is predicted that the CIMP could be used as 
a biomarker for patients under medication (Zhang et al., 2011). CIMP is 
recognized as a common feature of human cancers (Weisenberger et al., 
2006, Shinjo et al., 2012). But why, where, and when this phenomenon 
occurs remains poorly understood.  
The first study describing a CIMP was in colorectal cancer by 
Toyota and colleagues (1999), where they used bisulfite-PCR reactions 
and methylation-sensitive restriction enzyme digestion, followed by 
southern blotting. They found that colorectal cancer samples showed 
aberrant and extensive CpG island promoter methylation in several 
tumour-suppressor genes. Moreover, they showed that this CIMP was 
implicated in genetic instability. Silencing of the mismatch repair gene 
(MLH1) resulted in the silencing of hundreds of genes, including TSGs. 
Furthermore, they pointed out that CIMP-associated cancers had a 
distinct histology, epidemiology, and molecular features.  
Since that time, extensive studies have supported the CIMP 
hypothesis and confirmed the original finding that CIMP is associated 
with promoter hypermethylation in many TSGs. Several studies 
observed that different types of cancers with varying phenotypes, such 
as glioblastomas, gastric cancer, pancreatic cancer, ovarian cancer and 
liver cancer shared common CIMP-associated genes (Issa et al., 2005, 
Teodoridis et al., 2008, Wu et al., 2010). For example, Herman et al. 
(1995) found suppression of the CDKN2/p16/MTS1 complex is 
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associated with aberrant DNA methylation in all common human cancers 
including breast cancer, prostate cancer, renal cancer and colon cancer.  
In addition, a variety of TSGs such as MINT1/MINT2/ 
CDKN2/MLH1 were observed to be methylated at their promoter CpG 
islands in colorectal cancer, gastric cancer, pancreatic adenocarcinoma, 
and a range of human cancer cell lines (Teodoridis et al., 2008). 
Moreover, relationships between CIMP and various parameters, 
including microsatellite instability (MSI), rates of mutations for p53, 
BRAF, and KRAS, and tumour recurrence after transplantation, were 
identified (Samowitz et al., 2005, Ogino et al., 2009, Noushmehr et al., 
2010, Wu et al., 2010).  
However, a few studies did not support the CIMP. Anacleto et al. 
(2005) looked for CIMP in five genes (DAPK, MGMT, hMLH1, p16INK4a, 
and p14ARF) in primary colorectal cancers. That study is not compatible 
with the independent existence of CIMP and suggested that the 
association between methylation and colorectal cancers was indirect due 
to the correlation with MSI. Another study examined the promoter 
methylation of six genes (hMLH1, MGMT, p16INK4A, p14ARF, APC, and 
CDH1) in colorectal cancer and the corresponding normal tissue using 
methylation-specific PCR (Yamashita et al., 2003). They reported that 
their results did not support the CIMP hypothesis.  
The existence of this phenotype remains controversial. Issa et al. 
(2005) pointed out that all studies that did not find the CIMP phenotype 
used unselected genes and non-appropriate statistical analysis methods. 
When Issa (2004) reanalysed the data in those papers with appropriate 
statistical analysis, they found a clustering of methylation of specific 
genes such as CDKN2A and MLH1, therefore suggesting that appropriate 
analysis is important to reveal a CIMP.  
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The fact that different cancers, such as acute lymphocytic 
leukaemia (Garcia-Manero et al., 2002), acute myeloid leukaemia    
(Toyota et al., 2001), gastric carcinomas (Kim et al., 2003), liver cancer 
(Shen et al., 2002), and ovarian cancer (Strathdee et al., 2001), have 
significantly different rates of CIMP in TSGs implies that the occurrence 
of aberrant methylation of CGIs at promotor regions is not random.  
The causes of CIMP are not well-understood and the genes that 
are implicated in this aberrant methylation have not generally been 
elucidated. However, there are other suggestions which need more 
studies. For example, mutations in DNA methyltransferases are 
considered as strong candidates for causing CIMP in cancer (Issa, 
2004). Kanai et al. (2001) reported that overexpression of DNMT1 was 
significantly associated with CIMP in colorectal and stomach cancers.  
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1.2 Germ cell tumours 
Germ cell tumours (GCTs) are malignant or benign tumours 
believed to be derived from primitive germ cells (Amatruda et al., 
2013), a cell type in which extensive methylation reprogramming 
occurs. GCTs are the most common tumours in young men (Koul et al., 
2002) and represent about 3% of all children’s cancers (Echevarria et 
al., 2008). The incidence of malignant testicular GCTs has increased 
over the past few decades (Huyghe et al., 2003, Goedert et al., 2007).  
1.2.1 Origin of GCTs 
GCTs represent a heterogeneous group of neoplasms that are 
believed to arise from undifferentiated primordial germ cells (PGCs) 
(Palmer et al., 2010) that normally form gametes. During embryonic 
development, PGCs normally migrate to the gonads but it has been 
hypothesized that some may follow a midline path but instead of 
descending into the ovaries or testes, they may settle in extragonadal 
sites such as the abdomen, chest, head and pelvis. However, the origin 
of some types of germ cell tumours is still controversial (Scholz et al., 
2002, Scotting, 2006).  
Germ cells normally migrate along the midline of the fetus before 
they finally settle into a place in reproductive organs where they 
eventually produce eggs in females and sperm in males. However, 
abnormal groupings of the germ cells can cluster together and form a 
tumour within and outside the testis and ovary. In adults, more than 
90% of GCTs occur in the gonads, while the rest develop in 
extragonadal regions (Raddatz et al., 2013). The most common sites for 
GCTs outside of the reproductive tract are mediastinum, abdomen, 
sacrococcyx, and pelvis (Elzinga-Tinke et al., 2015), while some GCTs 
can also found in the central nervous system (Kersh et al., 1988).  
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PGCs are pluripotent cells, which undergo three key processes 
during specification to oocytes or spermatozoa; repression of somatic 
genes such as the Hox family genes (Ohinata et al., 2005), regulation of 
potential pluripotency genes, and genome wide epigenetic 
reprogramming (Yamaji et al., 2008). Therefore, any disruption of these 
regulatory processes can result in abnormal PGC development which 
could lead to tumourigenesis. 
In humans, PGCs arise from pluripotent epiblast cells in the 
embryonic yolk sac during week 3-4 after conception (Mamsen et al., 
2012), induced by signalling from extraembryonic tissues  (Ohinata et 
al., 2005)(Figure 1.3). The signals involved in the specification and 
migration of human PGCs are not fully understood. However, the 
specification of the PGCs in mice is initiated by expression of B-
lymphocyte-induced maturation protein-1 (Blimp-1), also known as 
PRDM1, followed by several pluripotency markers such as Stella, Eras, 
c-Kit, Oct4, and Nanog (which also controls migration) (Hayashi et al., 
2007, Gu et al., 2009, Magnúsdóttir et al., 2013). Expression of these 
pluripotency markers decreases in neighbouring somatic cells (Yabuta et 
al., 2006). 
PRDM14 also has a key role in the maintenance of pluripotency of 
PGCs, through repression of fibroblast growth factor (FGF) signalling, 
which is necessary for cellular differentiation (Grabole et al., 2013). 
Yamaji et al. (2008) revealed a critical function of Prdm14 in 
establishment of the germ cell lineage in mice during the migration of 
PGCs from the dorsal mesentery of the hindgut along midline to the 
gonadal ridge, where PGCs undergo epigenetic reprogramming and 
proliferation to develop into mature germ cells.  
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Nettersheim et al. (2015) pointed out that undifferentiated GCTs 
share features with PGCs in the expression of pluripotency markers such 
as the transcription factors NANOG, OCT4 and SOX2 (West et al., 2010). 
Therefore, studying the relationship between DNA methylation and the 
expression of these regulatory genes in GCTs could reveal more about 
the role of DNA methylation in tumourigenesis. 
1.2.2 GCT classification 
Human GCTs are classified into two groups according to where 
they occur anatomically. The majority of tumours are in a gonadal site 
in the testes or ovaries while the minority are in extragonadal sites such 
as the thorax (mediastinal tumours) and sacrococcygeal area. In adults, 
95% of GCTs occur in gonads while the remaining five percent are in 
extragonadal tissues. While in children, 50% of GCTs is gonadal and 
another 50% is in extragonadal sites (Kucukoner et al., 2012, Vasdev et 
al., 2013). Regardless of location, GCTs are classified histologically into 
two major groups: seminomatous (also called germinomatous) and non-
seminomatous (also called non-germinomatous). The latter group is 
subdivided into: differentiated teratomas (exhibiting a degree of 
‘embryonic’ cellular phenotype), undifferentiated embryonal carcinomas 
(EC), extra-embryonic yolk sac tumours (YST) and choriocarcinomas 
(Oosterhuis and Looijenga, 2005). A germ cell tumour with a 
combination of the different histologies can be classified as a mixed-type 
GCT (Sesterhenn and Davis Jr, 2004). 
GCTs can also be classified into five subtypes (I-V) (Figure 1.5), 
which incorporate multiple features (Rijlaarsdam et al., 2015). Each 
subtype has specific molecular, clinical and histopathological properties. 
In brief, type I (paediatric) clinically presents as a teratoma or YST 
which arise in children before the age of 5 years. Type I present in 
gonadal or extragnadal sites where extra-gonadal, sacral teratomas, 
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occur most frequently and are mostly benign. Type I have been believed 
to arise from PGCs at an early stage (Rijlaarsdam et al., 2015). Type II 
(adult) refers to testicular GCTs, described as seminomas or non-
seminomas, and presents most frequently in the gonads where the 
diagnosis is most frequently in males and females between 25-35 years. 
The median age of clinical diagnosis of type II GCTs in males is higher 
than in female. The common precursor of this type is Carcinoma In Situ 
(CIS) (Oosterhuis and Looijenga, 2005). However, Type III, IV, and V 
originate from more differentiated germ cell progenitor. Type III (elderly 
males) is known as spermatocytic seminoma (SS), which arise after the 
age of 50 years and is generally benign, localised in the testis. This type 
is believed to originate from mature germ cells (spermatogonium or 
spermatocyte) and does not occur in females (Rijlaarsdam et al., 2015). 
Type IV arises only in female after the age of 50 years old and is 
hypothesized to originate most often from meiotic germ cells in the 
ovary that underwent maternal imprinting. The type V is believed to 
originate from the fertilization of an empty ovum by two sperm cells, 
resulting in completely paternally imprinted mature male germ cells. 
This type usually presents in the placenta or uterus (Oosterhuis and 
Looijenga, 2005).  
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1.2.2.1 Seminomas 
These are malignant tumours and can be further classified, 
according to location, into seminomas (testis), dysgerminomas (ovary), 
and extragonadal germinomas (brain). They are very sensitive to 
chemotherapy and radiotherapy, and are therefore highly curable 
(Boujelbene et al., 2011). The dysgerminomas and seminomas are not 
seen in children until they reach puberty, but they are common in young 
people aged between 15-44 years (Arora et al., 2012). A subtype of the 
seminomas, spermatocytic seminomas (SS), which arise exclusively in 
the testis, is usually found in the elderly and are not regarded as true 
GCTs as may do not arise from ITGCNU (Raiss et al., 2011).  
1.2.2.2 Non-seminomas 
Teratoma 
These are the most common GCTs in fetuses (Frazier et al., 2012) 
and children (Curto et al., 2007). They may contain different types of 
tissues or organs such as skin or bone that are derived from the three 
germ layers, endoderm, mesoderm and ectoderm. Teratoma is usually a 
benign tumour but it can behave in a malignant fashion, especially in 
testes, depending on maturity and the other types of the cells involved 
(Ulbright, 2004). The sacrococcygeal (the tail bone of the distal end of 
the spinal cord) teratomas are the common GCTs found in children. Due 
to the fact that the sacrococcygeal tumours are sometimes visible from 
outside of the body, the diagnosis is usually made early and the 
treatment initiated early, making the prognosis of teratomas very 
favourable (Michael et al., 2000). In children, most ovarian GCTs are 
teratomas, followed by the YST, EC, and mixed-type tumours (Horton et 
al., 2007). 
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Embryonal carcinoma (EC) 
The EC is an uncommon malignant GCT that most often occurs in 
testis, more rarely in the ovary and very unusually in neonates (Singh, 
2002). It is usually mixed with other types of GCTs.  
Endodermal sinus or yolk sac tumour (YST) 
YST is often very aggressive and malignant when it is found in 
testes, ovary or sacrococcygeal regions (Yao et al., 2012). It can spread 
rapidly through the lymphatic system to any organ in the body revealing 
its aggressive nature (Wobbes et al., 1981). 
Choriocarcinoma 
This is a very rare malignant GCT that recapitulates the chorion 
layer of the placenta (namely, trophoblastic). Although rare, it is the 
most clinically dangerous GCT because it can grow and spread quickly to 
any part of the body (Worster et al., 2002). These cells can form a 
tumour in the placental cells during pregnancy, so they may spread to 
the infant and the mother. When the tumour develops during 
pregnancy, it is referred to as gestational choriocarcinoma. However, If 
young children develop choriocarcinoma from chorion cells that come 
from the placenta, this is termed non-gestational choriocarcinoma (Chen 
et al., 2003). 
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1.2.3 The development of GCTs 
It is generally accepted that both testicular seminomas and non-
seminomas GCTs originate from precursor lesions termed carcinoma in 
situ (CIS) (also called intratubular germ cell neoplasia unclassified 
(IGCNU)) (Skakkebaek et al., 1987, Looijenga et al., 2007). IGCNU is 
believed to arise from PGCs during embryogenesis by blocking or 
delaying maturation into gametes (Eckert et al., 2008, De Felici, 2013). 
The reason for this mis-maturation is not yet entirely understood. It is 
probable that both environmental factors and aberrant epigenetic 
regulation during early embryogenesis play a role in endocrinological 
imbalances and an excess of oestrogens, that stimulate PGCs to acquire 
the tumourigenic features of CIS cells (Sonne et al., 2008, Elzinga-Tinke 
et al., 2015). Pluripotent cells in CIS resemble PGCs in morphology and 
embryonal markers (both cells express OCT3/4, PLAP, c-KIT, NANOG, 
SOX17 and AP-2ɣ) (Dieckmann and Skakkebaek, 1999, Rajpert-De 
Meyts, 2006, Sonne et al., 2008). Moreover, several studies revealed 
that CIS is the precursor lesion of GCTs, based on the finding of 
development of CIS to invasive GCTs in patients within 5 years (von der 
Maase et al., 1986, Dieckmann and Skakkebaek, 1999) and the 
similarity in both CIS and GCTs in gene expression profiles (Summersgill 
et al., 2001) , epigenetic profiles (Netto et al., 2008, Furukawa et al., 
2009) and chromosomal gain of 12p (Looijenga et al., 2003). The arrest 
of PGC differentiation and aneuploidy of 12p are the first detected 
events in the development of CIS (Rosenberg et al., 2000, Oosterhuis et 
al., 2002, Ottesen et al., 2003). Therefore, it has been accepted that 
PGCs are the cells of origin for all GCTs regardless of their locations. The 
development of GCTs is summarised in figure 1.6. 
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Primordial germ cell (PGC) Normal germ cell  
Intratubular Germ Cell Neoplasia, 
Unspecified (ICGNU) 
Non-seminomas (NSEM) Seminomas (SEM) 
Embryonal carcinomas (EC) 
Choriocarcinomas 
Yolk sac tumours (YST) 
Teratomas 
Figure 1.6: The development of testicular GCTs: Both seminomas 
and non-seminomas develop from intratubular germ cell neoplasia 
unclassified (IGCNU). Adapted from Cusack and Scotting (2013). 
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1.2.4 Treatment of germ cell tumours 
In general, the plan for treatment of cancer depends on several 
factors, such as the type and location of tumour, the time of diagnosis of 
the tumour (newly diagnosed or recurrence after treatment), the stage 
of the tumour which is based on the extent of cancer cells spread and 
the age of the patient.  
For GCTs, treatment may include standard treatments such as 
surgery, chemotherapy, and radiation (Gobel et al., 2000). 
Chemotherapy is used often as the first treatment if the tumour is large 
but not in gonadal site. Surgery is generally performed as standard for 
teratomas and residual tumours (Sugawara et al., 1999). Radiation 
therapy uses high-energy radiation from X-rays, gamma rays or the fast 
moving subatomic particles to target and destroy the cancer cells 
(Bamberg et al., 1999). In addition to the killing of the cancer cells, 
radiation therapy can destroy normal cells leading to physical side 
effects such as nausea, fatigue and hair loss.  
Children with benign GCTs usually undergo surgery to remove the 
tumour. However, those with malignant tumours may need to receive 
further treatment after the staging process. The staging process is the 
classification system that helps doctors to determine the extent of 
cancer progression. These consider factors such as size of the tumour 
and the extent of tumour spread to other organs (Sturgeon, 2002). 
1.2.5 Incidence of GCTs 
The incidence of malignant GCTs is higher in males than females 
(Raddatz et al., 2013). This difference might be due to the dissimilarity 
of gametogenesis mechanisms between males and females. In general, 
non-seminomas occur more frequently in children while seminoma is 
 30 
more common in younger adults and adolescences (Echevarria et al., 
2008).  
Furthermore, the incidence of the several histological subtypes of 
testicular GCTs have increased significantly and consistently over the 
past few years (Huyghe et al., 2003).   
1.3 The role of DNA methylation in GCTs 
The role of DNA methylation in GCT development and progression 
are not fully understood. Some investigations suggest that aberrant 
methylation is a key factor in the development of GCT subtypes (Smith-
Sørensen et al., 2002, Honorio et al., 2003, Netto et al., 2008). 
Although the tumour subtypes (seminoma and non-seminoma) are 
presumed to originate from the same progenitor cells, they differ 
histologically, follow different progression pathways, and vary in 
molecular alterations. For example, seminomas are considered as 
hypomethylated and exhibit a relatively similar histology to the germ 
cell precursor (Netto et al., 2008), while non-seminomas are 
hypermethylated, tend to be more aggressive and resistant to 
chemotherapy and exhibit differentiation into forms resembling somatic 
tissues (teratomas) or extraembryonic structures such as yolk sac (yolk 
sac tumour) or placenta (choriocarcinoma) (Chen and Amatruda, 2013) 
The progression of testicular GCTs from CIS to seminoma or non-
seminomas  (Hoei‐Hansen et al., 2005, Eckert et al., 2008) is 
accompanied by profound changes in methylation levels (Almstrup et 
al., 2010). The difference in the DNA methylation levels during this 
progression could be an important key for understanding how these 
tumours occur. Identifying the methylated driver genes that play a role 
in this progression could lead to new powerful and specific epigenetic 
therapies.  
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Recent genome-wide studies of paediatric GCTs (Jeyapalan et al., 
2011, Amatruda et al., 2013) revealed large differences in the level of 
methylation of many TSGs between GCT subtypes, where seminomas 
showed a lower methylation level than non-seminomas for those genes. 
The regions within these silenced genes that related to 
hypermethylation still needs more investigation. 
Abnormal DNA methylation has been implicated in the aetiology of 
various classes of malignancy such as colon tumours and gliomas and 
can possibly be particularly applicable in GCTs because of the broad 
epigenetic reprogramming that happens in the germ line and early fetus 
during embryogenesis. Rijlaarsdam et al. (2015) suggested that the 
genome wide DNA methylation profile for GCTs subtypes provides clues 
to the origin and underlying developmental biology of this tumour. 
Previous reports suggested a hypothesis that the methylation 
status of GCTs reflected the embryonic developmental phase of the PGC 
when the tumour emerged, with seminomas emerging from a 
hypomethylated PGC and non-seminomas beginning after methylation of 
PGCs. However, the hypomethylation status detected in IGCNU, which is 
accepted as the precursor of both testicular seminomas and non-
seminomas, suggests that both seminomas and non-seminomas arise 
from a hypomethylated PGC (Amatruda et al., 2013). 
Peltomaki et al. (1991) provided the first evidence of differences 
in methylation between seminoma and non-seminoma testicular GCTs. 
They inspected X-chromosomes by Southern blotting after methylation-
sensitive restriction digestion. They found that specific gene promoters 
are hypermethylated in non-seminomas but not in seminomas. 
Moreover, non-seminomas generally demonstrated a hypermethylation 
status similar to that found in the inactive female X-chromosome and 
seminomas were normally hypomethylated, like the active X-
 32 
chromosome. Peltomaki et al. (1991) studied the methylation of the 5’ 
region of two X-chromosome genes, hypoxanthine 
phosphoribosyltransferase (HPRT) and phosphoglycerate kinase (PGK), 
and demonstrated a contrasting pattern: seminomas were virtually 
unmethylated while on the contrary, non-seminomas were generally 
hypermethylated.   
Smiraglia et al. (2007) utilized global restriction landmark 
genomic scanning (RLGS), which is a useful method used to identify 
aberrant CGIs hypermethylation in cancer and tissue specific 
methylation of CGIs, and revealed that seminomas contain much lower 
levels of 5mC (an average level of 0.08%) than non-seminomas (an 
average of 1.11%). 
Others have inspected the CGIs of particular genes (non-X linked) 
and found that non-seminomas have a tendency to resemble numerous 
adult non-GCTs in that they frequently contain hypermethylation in 
these regions, while seminomas show hypomethylation of these genes 
(Koul et al., 2002, Okamoto and Kawakami, 2007).  
In imprinting, which involves silencing of parental allele-specific 
methylation of particular CpG regions, many studies have demonstrated 
that postpubertal testicular GCTs show an absence of imprinting at both 
the H19 and IGF2 loci (Mishina et al., 1996, Looijenga et al., 1998, 
Sievers et al., 2005). 
 The study of Koul et al. (2002) on the two major histologies of 
GCT, seminomas and non-seminomas, identified distinct 
hypermethylation patterns in the promoter region of MGMT. They 
revealed that MGMT was silenced or downregulated in the majority of 
non-seminoma samples and in a wide variety of cancers (Esteller et al., 
2000).  
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Many studies revealed that striking feature of all invasive TGCTs is 
gaining of the short arm of chromosome 12 (12p) and they suggested 
that (12p) contains relevant genes of which their overexpression is 
crucial for the development of this cancer (Mostert et al., 1998, 
Rosenberg et al., 2000, Looijenga et al., 2003). Rodriguez et al. (2003) 
analyzed (12p) in TGCTs samples using a global approach to expression 
profiling targeting chromosomes for identifying particularly genes in this 
region that amplified and the result pointed that highly overexpression 
of BCAT1 was specific to non-seminomas and upregulated other genes 
such as CMAS, EKI1, KRAS2, SURB7, therefor this study represented 
BCAT1 as a candidate gene for TGCT development. 
Furthermore, several methylation studies applied in testicular 
GCTs showed that YST had higher number of hypermethylated promoter 
genes than seminomatous GCTs. Nine genes that were identified (APC, 
RASSF1A, HOXA9, XPA1, EMX2, MSX1, NME2, SCGB3A1 and HIC1) were 
hypermethylated in all YST samples analysed in those studies (Koul et 
al., 2002, Lind et al., 2007, Furukawa et al., 2009). BCAT1 is a target 
gene for CMYC, which is involved in cell proliferation, differentiation and 
apoptosis, and plays an important role in many tumours. 
A recent study on malignant GCTs in children showed a CpG 
methylator phenotype in YST including silencing of genes associated 
with Caspase-8-dependent apoptosis and correlated with increased 
expression of DNMT3B (Jeyapalan et al., 2011). This finding suggested 
that DNMT3B overexpression could be a strong candidate to cause the 
methylator phenotype in YSTs.  
Ushida et al. (2012) reported that despite non-seminomas 
exhibiting higher methylation than seminomas, both show significant 
hypomethylation of LINE-1 repeat elements compared to normal cells or 
other tumours of somatic tissue origin. This study supports the previous 
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suggestion for using serum LINE-1 hypomethylation as a potential 
prognostic marker for cancer (Estecio et al., 2007, Tangkijvanich et al., 
2007, Jeyapalan et al., 2011). Tangkijvanich et al. (2007) revealed that 
a high level of LINE-1 hypomethylation was significantly associated with 
tumor progression using measurement of COBRA LINE-1 in the serum of 
hepatocellular carcinoma patients. 
Recent studies revealed the important role of PRDM14, not only in 
demethylation activity of germ cell development (Yamaji et al., 2008, 
Okashita et al., 2014) but also in PGC specification (Magnúsdóttir et al., 
2013) and maintenance of pluripotency of PGCs by suppressing DNA 
methylation and fibroblast growth factor (FGF) signalling which led to 
suppression of cellular differentiation (Grabole et al., 2013, Fan et al., 
2015). 
Studies of PRDM14 showed its fundamental role in repressing the 
expression of the methyltransferase family members, especially 
DNMT3B and DNMT1 (Magnúsdóttir et al., 2013). Moreover, PRDM14 
promotes DNA demethylation through interaction with Ten-eleven 
translocation (TET) proteins (Okashita et al., 2014). Additionally, Hu et 
al. (2005) found that higher levels of PRDM14 expression correlated 
with decreasing methylation levels in breast cancer. PRDM14 may also 
regulate pluripotency factors such as NANOG and KLF4 (Grabole et al., 
2013).  
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1.4 Recent global DNA methylation studies in GCTs 
Two recent studies analysed global DNA methylation in GCT cell 
lines and provided insight into the aetiology and underlying 
developmental biology of GCTs. First, van der Zwan et al. (2014) 
studied the interaction between gene expression and CpG methylation 
but only in seminoma versus EC cell lines. Second, Rijlaarsdam et al. 
(2015) identified specific and global methylation differences between 
GCT subtypes, although they did not assess the relationship between 
methylation and gene expression.  
In this study, the Illumina infinium HumanMethylome450 bead 
chip system and Affymetrix expression arrays were used for four GCT 
subtypes in order to gain a comprehensive view of the correlation 
between methylation and gene expression. In addition, to confirm that 
key genes were silenced by methylation, their expression was 
determined after treating the hypermethylated cells lines with the 
demethylating agent, 5- azacytidine (5-aza). The data were compared 
to gene expression in a cohort of primary GCT samples to identify how 
many genes differentially expressed in YST versus seminoma were 
common in primary tumour and cell lines. Through this approach, my 
study was able to determine whether silencing of methylated genes was 
a general phenomenon in this type of tumour. 
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1.5 Project Aims 
The overall aim of this study is to assess the relation between DNA 
methylation and gene expression in GCTs, in order to determine the role 
of DNA methylation in GCT development through regulation of gene 
expression and to identify the methylated genes that most likely play a 
role in tumours biology.  
The specific aims were: 
- To investigate the global differences in methylation between 
seminoma and non-seminoma cell lines and detect the genomic 
targets that are methylated using whole genome approaches.  
- To assess the correlation between methylation and gene 
expression. 
- To identify dysregulated genes that might be silenced by 
methylation in GCT cell lines.  
- To identify which genes were most likely to contribute towards 
the phenotypic differences between hypo- and hypermethylated 
cell lines. 
- To investigate which candidate gene (s) could play a role in 
tumour pathology, or be a promising target for therapeutic 
applications. 
 
 
 
 
 
 37 
Chapter 2. Materials and methods 
2.1 Materials 
2.1.1 Equipment 
2100 Bioanalyzer                            Agilent technologies, Uk       
Autoclave                                      Thermo Fisher Scientific, Uk   
C1000 thermal cycler (qPCR)           Bio-Rad, UK 
Centrifuge 5804                             Eppendorf, UK 
CO2 Incubators                              LabX, Canada        
Dry heat block                               Labnet international Inc,UK 
Electroporation (ECM830)                BTX, US                    
Geldoc Gel Light Imaging System     Bio-Rad, UK  
Gel electrophoresis equipment         Appleton woods, UK 
Haemocytometer                           Weber Scientific, UK 
Laminar air flow cabinet                 MACH-AIRE, UK 
Microscope with Camera Eclipse      Nikon, Japan 
Minicentrifuge                               Labnet, UK 
NanoDrop spectrophotometer         Thermo Scientific, UK 
PCR-Thermal cycler TC-3000          TECHNE, UK 
PCR-Thermal cycler GS1                G-Storm, UK 
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PH-Meter GP353                                     EDT instrument, UK 
Pipette autoclaved (0.5-1000 µl)               Nichiryo, Japan 
Power Pac mini-protean tetracell               Bio-Rad, UK 
Refrigerated Centrifuge Hawk15/05           MSE, UK 
2.1.2 Consumables 
6,12,24,96 well plates                             Corning incorporated, US 
40 μM cell strainer                                  MWG, UK 
96-well PCR plates (0.2 ml)                      Thermo scientific, UK    
Adhesive PCR sealing sheets                     Thermo scientific, UK      
Cell culture vented cap flasks                   Corning incorporated, US 
Coverslips (22mm)                                 VWR, US 
Cryotube vials                                        Thermo Scientific, UK 
Electroporation cuvettes                          Flowgen Bioscience, UK 
Eppendorf (0.5, 1.5 ml)                           Star lab, UK 
Hybond Extra Nitrocellulose roll                 Amersham Biosciences, uk 
Microscopic Superfrost Slides (1MM)          VWR, US 
Parafilm M (4" X 125')                             Pechiney, Chicago 
Pipette tips DNase /RNase free                 Star lab, UK 
Serological Pipette (1, 10, 25 ml)              Greiner bio-one, UK                                          
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2.1.3 Reagents and Standards 
2-Mercaptoethanol                           Sigma, UK 
Ammonium persulfate (APS)             Sigma, UK         
Chloroform                                     Fisher Scientific, UK 
Crystal violet dye                            Sigma, UK                  
Dimethyl sulfoxide (DMSO)               Sigma, UK 
Ethanol                                          Sigma, UK 
Hi-Res standard agarose                   Geneflow, UK                                      
Isopropanol                                     Fisher Scientific, UK   
Methanol                                         Sigma, UK 
Mounting medium with DAPI              Vector, UK 
Oligo(dT)18 Primer                           Thermo Scientific, UK 
Paraformaldehyde (PFA)                    Sigma, UK 
Phosphate buffered saline (PBS)         Sigma, UK  
Proteinase K                                    Sigma, UK 
Random primer                                Promega, UK 
RedSafe DNA stain                           Chembio, UK 
Sequencing grade solution dNTP’s      Amersham, Biotech Inc, USA  
Tri reagent                                     Sigma, UK 
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Tris base                                                      Invitrogen, UK 
Triton x-100                                                 Sigma, UK 
Trypsin-EDTA                                               Sigma, UK 
Trypan blue solution (0.4%)                           Sigma, UK                  
Tween 20                                                     Sigma, UK               
2.1.4 Chemicals 
Cisplatin (cis-diamminodichloroplatinumII)       Accord, UK 
Decitabine (5-aza-2’deoxycytidine)                 Sigma-Aldrich, UK    
2.1.5 Marker and ladder   
DNA ladder (1Kb, 100bp)                              NEB, UK 
Protein ladder (SeeBluePlus2Prestained)          Life Technologies,UK 
2.1.6 Enzymes and Kits 
DNasa1, Amplification grade                          Invitrogen, UK       
GenElute PCR clean-up kit                             Sigma, UK 
GenElute plasmid miniprep kit                        Sigma, Uk 
Phusion High-Fidelity PCR Master mix              BioLab, UK        
QIA quick Gel extraction kit                            Qiagen, UK                   
Restriction endonucleases                              NEB, UK 
RNeasy mini kit                                            Qiagen, UK   
QIA Shredder                                               Qiagen, UK   
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SensiFAST SYBR No-Rox kit                        Bioline, Uk 
SuperScript III Reverse Transcriptase          Invitrogen, UK     
T4 ligase                                                 Invitrogen, UK                                                      
2.1.7 Antibiotics  
Ampicillin                                                 Sigma-Aldrich, UK 
G418 (Geneticin)                                      Sigma-Aldrich, UK 
Kanamycin                                               Sigma-Aldrich, UK 
Penicillin/streptomycin                               Sigma-Aldrich, UK 
2.1.8 Antibodies 
-Primary antibodies  
Mouse Anti 5-methylcytidine                      AbD serotec, Bio Rad, UK      
Myc-Tag (9B11) Mouse mAb                      Cell Signaling Technology,UK 
Anti-PRDM14 antibody                              Abcam, UK 
-Secondary antibodies  
Alexa Fluor®488 Goat anti-Rabbit IgG        Thermo Scientific, UK 
Donkey anti-Mouse IgG, IRDye®800CW      LI-COR, USA 
TEXAS RED® anti-Mouse IgG                     VECTOR, USA 
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2.1.9 Plasmids 
pcDNA 3.1                                               Invitrogen, UK 
pEGFP GFP-C1                                         Clontech Laboratories, UK 
2.1.10 E. coli strain   
Competent cells (E.coli Laboratory strains, alpha selected silver 
efficiency Bioline, UK).    
2.1.11 Cell lines 
Human testicular germ cell tumour (TGCT) cell lines analysed in this 
study were purchased from the Institute for Cancer Research, Sutton, 
London. 
TCAM2                  Seminoma (SEM) 
GCT44                  Non-seminoma yolk sac tumour (YST) 
GCT27                  Non-seminoma embryonal carcinoma (EC) 
NT2D1                  Non-seminoma teratocarcinoma (TERT) 
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2.1.12 Database and software  
The following data bases were used to annotate or identify gene and 
protein features as pointed:  
Promoter 
prediction      
Eukaryotic Promoter 
Database 
http://epd.vital-it.ch 
CpG sites and 
islands   
MethPrimer  http://www.urogene.org/methprimer/ 
Primer design Primer3web  version 4.0.0 http://primer3.ut.ee/ 
BLAT Search 
Genome 
UCSC Genome Browser  
NCBI Build 36.1 
Feb 2009(GRCh37/hg19) 
http://www.genome.ucsc.edu/cgi-
bin/hgBlat 
 
Biological 
process & 
molecular 
function 
Atlas of genetics and 
cytogenetics in oncology 
and haematology 
www.atlasgeneticsoncology.org/index.
html 
www.genecards.org 
www.geneontology.org 
 
Venn diagram GeneVenn software 
developed at the University 
of Kent 
www.cs.kent.ac.uk/people/staff/pjr/Eu
lerVennCircles/EulerVennApplet.html 
Gene Sequence 
for designing 
primer 
CDS to get cDNA sequence http://www.ncbi.nlm.nih.gov/gene/ 
Nucleotide 
BLAST 
Standard Nucleotide BLAST http://blast.ncbi.nlm.nih.gov/blast.cgi 
Check 
Restriction 
Enzymes cutting  
NEBcutter V2.0  http://nc2.neb.com/NEBcutter2/ 
Convert DNA 
sequence into 
its reverse 
Reverse Complement www.bioinformatics.org/sms/rev_com
p.html 
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2.1.13 Primers 
Gene Forward  (5        3) Reverse (5       3) Product 
size (bp) 
PCR Primers 
Beta-actin TCTACAATGACCTGCGTGTG ATCTCCTTCTGCATCCTGTC 684 
CTHRC1 AAACTGGAAATGAACGGCCC TGTGAAATACCAACGCTGACA 381 
EPCAM CTGGCCGTAAACTGCTTTGT TCCAGATCCAGTTGTTCCCC 629 
OCT4 TCCCTTCGCAAGCCCTCAT TGATGTCCTGGGACTCCTC 474 
Sox17 GCGCCCTTCACGTGTACTA TAATATACCGCGGAGCTGGC 351 
RT-qPCR Primers 
BST1 GCTGGTGTCGACAGAAAAAT TTTTCCAAAAGGAATCCACA 96 
CTHRC1 ACACCCAACTACAAGCAGTG GCATTTTAGCCGAAGTGAGC 141 
CYCLO-
PHILIN-B 
AACAGCAAATTCCATCGTGT TCACCGTAGATGCTCTTTCC 96 
DDX43 CCAGACTGGAACAGGAAAGA AATTCCCGAGTGGGAGTTAG 126 
EPCAM CAAAACTTGGGAGAAGAGCA CACTGCTTGGCCTTAAAGAG 103 
GGCT  AGGGATAGCCACCATTTTTC AAGGGTGATTTCCCTGATTC 140 
HIST1H4C TCCAGGGCATTACAAAACCG CCTTAAGCACACCTCGAGTC 102 
HPRT AATTCTTTGCTGACCTGCTG TATGTCCCCTGTTGACTGGT 136 
KLF4 ACGGCTGTGGATGGAAATTC TTCATGTGTAAGGCGAGGTG 136 
L1TD1 TGGGGACTCTGGGAAGAAAA GTGCCAGTTCCTTGACTTGT 99 
Ly75 TGATCAGGCATTGCACAGTT TTCCCTCATCAGTCTGCTCA 124 
MGMT AGGTGTTATGGAAGCTGCTG GACAGGATTGCCTCTCATTG 128 
PON3 TTACCAACTCCCTCCTGTCA CCATTGGCACTACAAAATCC 118 
PRDM14 TTTATCGCCAAAGGAGTC GTACCTCCTTTTCCATCT 146 
RBMXL2 CTCCTGATGAAAGACCGAGA GACTTGCCGTTCATGTCTCT 107 
RPRM TAGCCTGTACATAATGCGCG ACGAGGAAGTTGATCATGCC 129 
SOX15 TTCCCACTGCAAACTGGAAG TAGTGGGTATAGGTGGGCAG 93 
SOX17 ATGACTCCGGTGTGAATCTC TCACACGTCAGGATAGTTGC 101 
TDRD12 CATTGACTTCTGCCGAGACA TCCACAGCACATAATCTGGC 126 
TRIL TGGAGAGTCTAGTCAAGCTG ACTCCAGATGTAGGTAGAGCA 102 
TRIM95 CAAGGCGATAAGGAAGCTGT CAACATCACAGAGAGCCGTT 97 
Cloning primers 
PRDM14 
AGTAGAATTCATGGCTCTACCC
CGGCCA  
TGATCTCGAGGTGAGTCATTG
TGCCTGGC 
1862 
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2.2 Methods 
2.2.1 Cell culture  
2.2.1.1 Preparation of growth media 
Seminoma cells were cultured in RPMI-1640 medium while non-
seminoma cells were grown in DMEM (Dulbecco’s Modified Eagle 
Medium). Both media were routinely supplemented with 10% FBS (Fetal 
Bovine Serum) and 1% P/S (Penicillin/streptomycin). Cells were 
incubated in a humidified 5% CO2 incubator at 37 °C and passaged 1:2 
or 1:4 in fresh medium when they reached around 80% confluence. All 
media, supplements and antibiotics were purchased from Sigma-Aldrich, 
UK.    
2.2.1.2 Recovering cells from frozen cell stocks 
Cells were thawed from frozen cryotube stocks by defrosting them 
in a 37 °C water bath for about 10s then transferring them quickly to a 
centrifuge tube containing 10 ml of medium. After that, cells were 
subjected to centrifugation at 100 x g for 5 min, supernatant was 
removed and the cell pellet was resuspended in 1ml of fresh medium 
then transferred to a culture flask containing pre-warmed complete 
medium. 
2.2.1.3 Maintenance and passage of cells 
Media were changed every 2-3 days. Once the cells were 80% 
confluent, they were passaged in fresh media in a ratio of 1:2 or 1:4 
depending on the growth rate.  To split cells, media were removed and 
cells were washed with 2 ml of 1xPBS (phosphate buffered saline) 
followed by 2-4 ml of Trypsin-EDTA to detach cells from the flask 
surface, cells were left for 4-5 minutes or until they were dissociated. 
Medium was added and subjected to centrifugation at 100×g for 5 min. 
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1mm 
Supernatant was removed and cell pellets were resuspended in 1 ml of 
medium. For continuation of cell line, cells were transferred to new 
culture flasks with pre-warmed media. For biomolecular experiments the 
resuspended cells were counted and harvested for further analysis or 
stored at -80°C. 
2.2.1.4 Cell counting 
To determine the number of viable cells, after resuspending the 
cells in 1 ml of medium, 10 µl of cell suspension was mixed with 10µl of 
Trypan blue stain, then transferred to a haemocytometer. Under the 
microscope, cells were counted in the 5 red squares (as in the figure 
below). Cells on the bottom line and left hand line of the square should 
be included- the average was taken then multiplied by 25 to give the 
number of cells present in the 1mm² area. In addition, cells in the 4 
blue squares were counted and the average was taken and multiplied by 
16 to give the number of cells in the 1mm² area. The average of these 
two numbers (in two areas) was taken and multiplied by 10
⁴
 to give the 
number of cells in 1ml of culture. 
2.2.1.5 Storage of cells  
To store cells, cells were detached using Trypsin-EDTA then 
subjected to centrifugation at 100× g for 5 min. Pellets of approximately 
1×10⁶ cells were resuspended in a cold mixture of 6ml FBS and 10% 
DMSO (dimethyl sulfoxide) then stored in cryotubes at -80 °C then after 
24 hours the cryotubes could be transferred to liquid nitrogen for longer 
storage. 
2.2.1.6 Cell staining and fixation 
In a 6-well plate, medium was removed then cells were fixed by 
using 1ml/well of 4% PFA (paraformaladehyde) then incubating at room 
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temperature for 20 minutes. After that, PFA was removed and 0.5 
ml/well of 0.1% crystal violet was used for 5 minutes to stain the cells. 
Wells were washed with distilled water then left to dry at room 
temperature. 
2.2.2 Cell treatments 
2.2.2.1 Decitabine (5-aza-2’deoxycytidine (5-aza))  
For the cytotoxicity assay, cells were seeded at a density of 2x104 
cells/well in 6-well plates. Next day, cells were exposed to different 
concentrations of 5-aza ranging from 0.1 to 20 µM. After 24h, the viable 
cells in each well were counted using a haemocytometer.  
For DNA demethylation and re-expression studies, cells were 
cultured in 6-well plates, and when they reached approximately 30-50% 
confluence, they were treated with a range of 0.1-20 µM 5-aza. Media 
supplemented with 5-aza were changed for 1-3 days. Media were 
replaced subsequently with a drug-free media then cells were harvested 
in a time course assay and stored for later nucleic acid extraction. 
Untreated control cells were also prepared. 
2.2.2.2 Cisplatin (cis-diamminedichloroplatinumII) 
Cells which had been transfected with a gene of interest were 
subsequently exposed to cisplatin at a range of 5 to 30 µm for 2 h then 
the medium was refreshed with drug-free medium. For each treatment, 
three independent biological and technical replicate experiments were 
performed. 
2.2.2.3 Generating an antibiotic (G418) kill curve   
To determine the optimal concentration of antibiotic for selecting 
stable transfected cell lines, cells were plated in 6-well plates at the 
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density of 2 × 10⁴ per well in complete growth medium. When cells 
reached 60-70% confluence, media was removed and replaced with a 
medium containing antibiotic (G418) with different concentrations (from 
0 to 100µg/ml) while one well was left without treatment as a control. 
The medium containing antibiotic was replaced every three days for one 
week. The culture was examined every day for signs of visual toxicity 
using light microscope to assess the appearance of cell dead comparing 
to untreated cell. The`low´dose was considered when the minimal visual 
toxicity was apparent even after seven days of treatment while a dose 
was considered `high´ when the visual toxicity was apparent within 2-3 
days of treatment and all cells were dead before the seventh days. The 
optimal dose was selected when all cells were dead after one week of 
treatment. 
2.2.2.4 Clonogenic Survival Assay 
A clonogenic assay was used to assess the response of cells to 
treatment with chemotherapy, by determining the ability of a single cell 
to grow and form a colony after treatment (the definition of a colony is 
one consisting of approximately at least 50 cells). Once cells had 
become confluent in a T75 flask, they were harvested using trypsin-
EDTA then resuspended with 3 ml medium. Cells were passed through a 
40 μM cell strainer to ensure the formation of a single cell suspension. 
To plate 100 cells/well in 6-well plate, 10 μl of cells were taken then 
mixed with 10μl of Trypan blue then the number of cells in 1ml was 
determined using a haemocytometer (as in section 2.2.1.4) then 
calculation was done using the formula:  
                          C1V1 = C2V2 
                      A* X V1 = (300 cells/ 3ml) X 60ml 
                             V1 = 33.3 cells/ml X 60ml 
                                 = (0.1998/ A) ml 
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                                 = (199.8/A) μl                     
 
A*: the number of cells in 1 ml 
The cells were transferred to a T75 flask containing 60 ml 
medium. The cells were mixed thoroughly before transferring 3 ml into 
each well of a 6-well plate. Plates were incubated at 37 °C overnight to 
allow cells to attach. Next day, cisplatin was added at a range of 2 to 30 
µM for 2h, medium was changed with drug-free completed medium. 
Cells were incubated for 1-2 weeks until colonies containing 
approximately 50 cells were formed. 
When colonies were visible, fixation and staining was carried out 
(as in section 2.2.1.6). Under the microscope, the number of colonies 
that survived after the treatment were counted (where a colony was 
defined as with at least 50 cells) then the following equation was applied 
to investigate any improvement in response towards chemotherapy. 
 
 
 
Where 
 
 
 
 
 
                                        Number of colonies formed after treatment  
Surviving fraction (SF) =  
                                                   Number of cells seeded x PE 
 
                                        Number of colonies formed  
Plating efficiency (PE) =                                                X 100 
                                           Number of cells seeded  
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2.2.3 General molecular biological methods 
2.2.3.1 Genomic DNA Extraction 
300μl lysis buffer (Tris-EDTA buffer) and 3.3μl Proteinase K 
(10µg/μl) were added to cell pellets and mixed. Samples were incubated 
at 37 °C for 1 hour. Samples were subjected to centrifugation at 13,000 
x g for 5 min and supernatants were transferred to clean Eppendorf 
tubes. 300μl isopropanol was added to samples and mixed. DNA 
precipitates were transferred to new tubes and washed with 500μl of 
70% ethanol then subjected to centrifugation at 13,000 x g for 5 min. 
Ethanol was removed and left to dry at room temperature. Finally, 20-
40μl of distilled water was added to resuspend the DNA which was 
stored at -20 °C. 
2.2.3.2 RNA Extraction            
Cell pellets (2X10⁶ cells) were resuspended in 1ml TRI reagent 
then incubated at room temperature (RT) for 5 minutes. 200μl 
chloroform was added to this mixture, the tube was inverted at least 
three times till the mixture become cloudy then incubated at RT for 10 
min. To separate the layers, the mixture was subjected to centrifugation 
at 13,000 x g for 15 min at 4 °C. The top aqueous layer was transferred 
into a new ml tube containing 300μl isopropanol. The tube was inverted 
five times then incubated at RT for 5 min. To pellet RNA, the solution 
was subjected to centrifugation at 13,000 x g for 15 min at 4 °C. After 
discarding the supernatant, 300μl of 70% ethanol was added to the 
pellet without mixing, then subjected to centrifugation at 13,000 x g for 
5 min at 4 °C. Ethanol was removed and the pellet was left to dry for 
five minutes at room temperature. The pellet was resuspended in 20-
40μl sterile deionized water then stored at -80°C or treated with DNAase 
to remove DNA. 
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For RT-qPCR experiments, total RNA was isolated using the 
RNeasy mini kit and QIA Shredder according to the manufacturer’s 
instructions. RNA concentration was determined with the NanoDrop 
spectrophotometer. The quality of RNA was assessed by using the 
Agilent Bioanalyzer according to the manufacturer’s instructions. 
2.2.3.3 DNAase treatment 
Contaminating DNA was removed from RNA by adding 2μl of 10× 
DNAase reaction buffer and 2.3μl of DNAaseI to 20μl of RNA sample 
then incubating at RT for 10 min. 1μl EDTA was then added and the 
tube was incubated at 65 °C for 10 min then on ice for one min. RNA 
concentration was measured using Nano drop then stored immediately 
in -80 °C or converted to cDNA.   
2.2.3.4 cDNA synthesis 
To convert RNA to cDNA, a mixture of 0.5μl of each of Random 
primer, oligo(dT)₁₈ primer, dNTP (10µM), and ddH2O were added to 1-
2μg of RNA then sterile water was added up to 14µl. The mixture was 
incubated at 65 °C for 5 min then on ice for 1 min. 4µl of 5×First strand 
buffer and 1µl of 0.1M DTT were added to the mixture. 1µl of 
superscriptIII was added to all samples except No-RT samples. Samples 
were incubated in a Techne thermal cycler, at 25 °C for 5min, 50 °C for 
45min and 70 °C for 15min. cDNA was stored at -20 °C. 
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2.2.3.5 Measuring DNA and RNA concentration 
DNA and RNA concentrations were measured using a Nanodrop 
where the 260/280 nm reading should be 1.8-2.2 for pure DNA and 1.7-
2.0 for pure RNA. 
The quality and concentration of RNA for microarray experiments 
was further analysed using an Agilent 2100 Bioanalyzer which gives 
measurements for the RNA integrity number (RIN) which should be 
between 8-10. 
2.2.4 Gene expression analysis 
2.2.4.1 Gene expression microarray 
After extracting RNA and determining the concentration and 
quality of RNA samples, approximately 100 ng/μl of RNA sample was 
sent to Nottingham Arabidopsis Stock Centre at Sutton Bonington 
campus at the University of Nottingham to perform a gene expression 
assay using Affymetrix HumanGeneChip U133 Plus 2.0 arrays. Raw data 
reflecting the fluorescence intensities were statistically analysed to 
determine fold changes as compared to control samples. 
2.2.4.2 Primer design 
Primers were designed using the NCBI Genome Browser to get the 
sequence of the interested gene. Then, the sequence was inputted into 
Primer3 Software to set length and sequence of primer, PCR product 
size, and relative annealing temperature (Tm). The specificity of 
choosing primer pairs was checked by using BLAST function (blast 
nucleotide) of the NCBI Genome Browser Software. Optimising the 
annealing temperature of primers was achieved by using gradient 
function of PCR G-Storm machine testing across a range of Tm to 
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determine the optimum annealing temperature where non-specific 
bands and insufficient primer-template hybridization were not seen. 
2.2.4.3 Polymerase chain reaction (PCR) 
PCR was generally carried out in 0.2ml PCR tubes with a reaction 
volume of 10-50µl in a PCR-Thermal cycler TC-3000. A quick spin was 
applied to the mixture in the PCR reaction tube. Phusion High-Fidelity 
PCR master mix with HF buffer was used with the following reaction 
conditions: 
 
 
 
 
General thermocycling conditions for settings a PCR are summarised as: 
Step Temp Time 
Initial denaturation 98 °C 30 sec 
                             Melting 
25-40 Cycles      Annealing 
                             Extension 
95 °C 
56-72 °C 
72 °C 
1 min 
1 min 
30 sec/kb  
Final extension 72 °C 5 min 
Hold 4 °C  
 
2.2.4.4 Gradient annealing temperature optimization 
A gradient PCR reaction was performed on all primer pairs to test 
the best annealing temperature. In each tube, 10 μl mixture was made 
as follow: 4.5 μl of sterile water, 0.25 μl of forward primer (10 µM), 
Component 10µl 
Reaction 
25µl 
Reaction 
Final 
concentration 
10µM Forward Primer 0.25 µl 0.5 µl 0.5 µM 
10µM Reverse Primer 0.25 µl 0.5 µl 0.5 µM 
Phusion master mix 5 µl 12.5 µl 1x 
Template DNA 100ng 100ng <250ng 
Nuclease-free water 4.5 µl 11.5 µl  
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0.25 μl of reverse primer (10 µM) and 5 μl of Phusion High-Fidelity PCR 
master mix with HF buffer. Then 1 μl of cDNA template was added to 
each tube. A gradient PCR reaction was designed as follows: initial 
denaturation at 95 °C for 1 minute, and then 40 cycles at 95 °C for 1 
min, annealing (a gradient) between the lowest and highest 
temperature that would be appropriate for the primers (for example 
between 54-72 °C) for 1min, and extension at 72 °C for 30 seconds and 
final extension at 72 °C for 5 minutes. 
2.2.4.5 Reverse transcriptase qPCR (RT-qPCR) 
RT-qPCR was used to quantify cDNA after reverse transcription. 
The relative amount of amplified cDNA is measured through the 
emission of SYBR green dye fluorescence when it is intercalated into 
double-stranded DNA. qPCR was carried out using a C1000 thermal 
cycler with SensiFast SYBR No-ROX kit. Primers were designed using the 
Primer3 web site and choosing optimal primer pairs according to the 
following rules: 
-Sequence: complementary sequences within and between     
  primers, mismatches, and T base at the 3’end of the primer  
  should be avoided. 
-% GC content: should be between 40-50% 
-Length of PCR product: should be less than 150 bp 
-Length of primers: should be between 18-30 bp 
-Melting temperature: should be around 56-60 °C 
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A master mixes for each primer pair was prepared by mixing 11µl 
of nuclease-free water, 0.25µl of each primer (10µM), and 12.5µl of 2x 
SensiFast SYBR No-ROX Mix. 24µL of master mix was placed into each 
well of 96-well plate then 100 ng of cDNA, no-RT sample, and NTC (non 
template control) were added to assigned wells. After that, the plate 
was placed in C1000 thermal cycler machine and the program was set to 
PCR cycling condition as follows: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
cycles Temp. Time Notes 
1 95 °C 2 min Polymerase activation 
40 
95 °C 
58 °C 
72 °C 
5 sec  
10 sec  
20 sec  
Denaturation 
Annealing 
Extension 
NTC 
No-RT 
1 
1:5 
1:25 
1:125 
1:625  
1:3125 
Gene D Gene C Gene B Gene A 
cDNA 
Figure 2.1: The design of standard curve plate to assess 
primer efficiency: Serial dilutions of cDNA were carried out to 
assess the efficiency of each primer. No-RT (No reverse 
transcriptase) and NTC (No template control) were used as 
negative controls. The sample was applied in three triplicate 
for each gene.  
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The data was analysed using C1000 thermal cycler software and 
nonspecific amplification was detected by melting-curve analysis. All 
qPCR results were imported into Microsoft Excel 2010. To determine the 
standard threshold and amplification efficiency of each set of primers, a 
standard curve was generated for each primer pair by amplifying six 
serial dilutions of template cDNA (1, 1:5, 1:25, 1:125, 1:625, 1:3125). 
To confirm the accuracy and reproducibility of qPCR results, three 
independent experimental runs were performed for each gene. To 
accept the qPCR results, the efficiency of the primer was required to be 
90-110%, the R2 of the standard curve was closed to 1, and the slope 
of the curve was between -3.2 and -3.6. The single melt curve peak of 
each primer sets was important for assay specificity validation. 
The threshold cycle (Ct) represented the cycle number at which 
the fluorescent signal crosses the threshold of the background level. Ct 
level was inversely proportional and correlated with the amount of the 
initial template (cDNA) concentration. The threshold cycle (Ct) value of 
each sample was calculated compared to the housekeeping gene (ß-
actin) using the Pfaffl equation (Pfaffl, 2001). The Pffafl equation was 
used to determine the relative amount of RNA of the target gene in 
different samples.  
    
 
    
 
 
 
                               ΔCPtaregt   
(control-sample)
 
               (Etarget     )  
                           
                              ΔCPref   
(control-sample)
 
              (Eref         )       
 
 Ratio = 
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In the above equation, ratio refers to the expression ratio between 
the sample and calibrator. ΔCPtarget (calibrator-test) = (Ct of the target 
gene in the calibrator - Ct of the target gene in the test sample. ΔCPref 
(calibrator-test) = (Ct of the reference gene in the calibrator - Ct of the 
reference gene in the test sample). 
Etarget and Eref are equal to 1+E where E is the efficiency value in 
a standard curve of exponential amplification of target and reference 
genes, respectively. Target means gene of interest while reference 
means control gene (housekeeping gene). 
2.2.5 Molecular cloning and transformation 
2.2.5.1 Restriction enzyme digestion 
To clone insert cDNA into plasmid, both were digested with the 
appropriate restriction enzymes. The restriction sites were introduced 
flanking a gene of interest sequence by adding the appropriate 
recognition sequences to the primer sequences. The digestion was 
carried out in a total reaction of 50µl by incubating the mixture in the 
water bath at 37 °C for 1 hour as follows: 
 
 
 
 
After digestion, DNA and vector fragments were purified from the 
digestion mixture by using GenElute PCR clean-up kit and GenElute 
plasmid miniprep kit respectively following the manufacturer’s 
instructions.                       
 50µl Reaction 
10XBuffer  5µl 
DNA 1µg 
Enzyme  2µl/enzyme 
ddH2O Up to 50µl 
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2.2.5.2 Gel extraction 
To obtain DNA/plasmid, agarose gel electrophoresis was carried 
out then both desired bands were cut out viewing with an UV 
illumination box. A QIA quick Gel extraction kit was used according to 
the manufacturer’s instructions to extract cDNA or plasmid. 
2.2.5.3 Ligation reaction 
DNA of interest was ligated into vector at a molecular ratio of 1:3 
vector to insert using T4 ligase as followed: 
 
 
 
 
 
The mixture was mixed briefly and subjected to centrifugation at 
13,000 x g for 30 sec then incubated at RT for 2 hours then chilled on 
ice. 
 
 
 
 
Component 20 µl Reaction Control 
10x T4 DNA ligase buffer 2µl 2µl 
Vector 50ng  50ng 
Insert DNA 150ng - 
Nuclease-free water Up to 20µl Up to 20µl 
T4 DNA ligase 1µl 1µl 
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2.2.5.4 Transformation 
Competent E. coli (25µl) were defrosted on ice then ligation 
reaction were transformed into competent cells as follows: 5μl of 
cDNA/plasmid-ligation was added once competent cells had just 
defrosted, mixed gently, then placed on ice for 30 min. Afterwards, the 
tube was placed on heat block at 42 °C for 40 sec then immediately 
cooled on ice for 5 min. 1ml of SOC medium was added to the mixture 
and incubated at 37 °C with shaking for 1 hour. 1ml of mixture was 
transferred to a new tube and subjected to centrifugation at 13,000 x g 
for 1 min. The supernatant was removed and the pellet was 
resuspended with 100μl of Mu medium. Finally, the mixture was spread 
onto LB agar plates containing the appropriate antibiotic. The plate was 
left inverted at 37 °C for 12-18 hours for selection of transformed cells.  
The next day, single colonies were picked and cultured in tubes 
containing 4ml of Mu media and 4μl of appropriate antibiotic, then 
incubated overnight at 37 °C with vigorous shaking. To isolate and 
purify DNA from bacteria culture, plasmid Mini prep kit was used 
according to manufacturer’s instructions. 
2.2.5.5 DNA Sequencing 
Sanger DNA sequencing was carried out by sending 5µl of purified 
plasmid (100ng/µl) or PCR product (1ng/100bp) and 5µl of appropriate 
primers to Source Bioscience Technology. Sequence files were analysed 
by using FinchTV 1.4.0 program and aligned with the Blast function of 
the NCBI genome browser. 
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2.2.5.6 Transfection by electroporation  
Electroporation was used for both transient and stable transfection 
of mammalian cells. When cells in T75 flasks were at high confluence 
(70-90%), cells were harvested and subjected to centrifugation. Pellets 
of approximately 1×10⁷ cells were resuspended in 500 µl of medium 
(without serum) then 10 µg of plasmid (containing gene of interest and 
antibiotic selection) and 8 µg of GFP plasmid were added and mixed 
then placed into an electroporation cuvette with 4 mm gap. The cuvette 
was placed into the electroporation apparatus and shocked once at high-
voltage electrical pulse of defined magnitude and length. The cells were 
then placed in normal complete cell growth medium (set in section 
2.2.1.1) in T75 flask and incubated at 37 °C and 5% CO2. The number 
of shocks, the voltage and capacitance settings were adjusted to 310 
volt with one pulse at length 10msec. Transfected cells could be 
visualized by observation of GFP expression (green) under fluorescence 
microscope over 24-72 hours to determine the efficiency of transfection. 
2.2.5.7 Generation of stable cell lines 
48-72 hours post transfection, selection antibiotic was added at 
low, optimal and high dose (set in section 2.2.2.3) to three transected 
flasks and to 6-well plate as follows: one well was left without antibiotic 
as control, one with low dose, two with optimal dose, and two with high 
dose of antibiotic. Every 2-3 days, medium with the appropriate 
concentration of antibiotic was replaced and cells were examined 
visually for toxicity. By 9 days post transfection, surviving cells were 
frozen with medium lacking selection antibiotic as a polyclonal cell line. 
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2.2.6 Bacteria culture 
2.2.6.1 Preparing bacteria growth medium 
- LB-Agar plate: 5g NaCl, 5g tryptone, 2.5g Yeast Extract and 7.5 
Agar were mixed together then ddH2O was added to make up to 500ml 
then autoclaved for 121 °C for 20 min. Medium was cooled to 50 °C 
then appropriate antibiotic was added. The solution was poured in 10 cm 
petri dishes then stored inverted at 4 °C. 
- 1Liter of LB-media (Luria broth): 0.5 g of NaCl, 10 g of Bacto 
Tryptone, and 5 g of Yeast extract were dissolved in 1L of ddH2O then 2 
ml of 1M NaOH was added then the mixture was autoclaved at 121 °C 
for 15min.  
-1Liter of Mu medium: as same as LB media but 10 g of NaCl 
instead of 5g. 
-1Liter of SOC medium: 20 g (2%) BactoTrypton, 5 g (0.5%) 
BactoYeastExtract, 0.6 g (10 mM) NaCl, 0.2 g (3 mM) KCl were 
dissolved in 1 L of ddH2O then autoclave at 121 °C for 15min then 
added to the cooled sterile filtered solution: 10 ml of each of (10 Mm) 
MgCl2 , (10 mM MgSO4) , and (20mM) Glucose. 
2.2.6.2 Making glycerol stocks 
500 µl of an overnight culture of bacteria transformed with 
plasmid containing gene of interest was added to 500 µl of 90% 
glycerol, mixed and stored at -80°C for long term storage.  
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2.2.7 Protein analysis 
2.2.7.1 Coverslip preparation 
Coverslips were soaked in 38% 1M HCl for 30 minutes then rinsed 
with sterile distilled water followed by 95% ethanol. They were left to 
dry in the hood and were stored at room temperature in a sterile 
container. The coverslips were placed in a 6-well plate and covered with 
2ml of 100µg/ml Poly-D-Lysine then incubated overnight at 37 °C. Next 
day, the coverslips were washed with sterile 1x PBS before plating cells. 
 2.2.7.2 Immunofluorescent staining              
Cells were plated at the density of 2×10⁵ per well in complete 
growth medium in a 6-well plate containing prepared coverslips. Next 
day, culture medium was removed and cells were fixed with 4% PFA for 
10 minutes. PFA was removed and wells were washed with 1x PBS. After 
removing 1x PBS, cells were permeabilised by incubating them with 
0.2% Triton X-100 in 1x PBS for 10 minutes at room temperature. The 
solution was removed and cells were incubated with blocking solution 
(5% marvel milk and 0.1% triton X-100 in 1x PBS) for 30 minutes at 
room temperature then washed twice with 1x PBS. All subsequent steps 
were carried out on parafilm. Coverslips were removed from the plate 
and placed cell-side down on a sheet of parafilm containing drops of 
about 20µl of primary antibody for each coverslip and incubating for 1 
hour at room temperature or overnight at 4 °C in humidified chamber. 
Coverslips were washed 3 times in 1x PBS. Then, coverslips were 
incubated with fluorescently labeled secondary antibody for 1 hour at 
room temperature followed by 3 washes in 1x PBS. Coverslips were 
mounted by placing cell-side down onto microscopic slides containing 
one drop of mounting medium with DAPI (4’,6-Diamidino-2-
phenylindole) then sealing around coverslips perimeter with nail polish.  
 63 
2.2.7.3 Western blot 
- Sample preparation 
Cell pellets were dissolved and mixed well by pipetting in 30-50 µl 
cold 1x PBS then 50µl of boiling 2x Laemli buffer and mixed quickly. 
Samples were boiled at 100 °C for 10 min then incubated on ice for 10 
min.  
2.2.7.4 SDS-PAGE  
Base resolving gel     
Reagent 12.5% 2x (12.5%) 
Acryl-Bis 29:1 2.14ml 4.28ml 
Solution B* 1.43ml 2.86ml 
Water (SDW) 1.44ml 2.88ml 
APS 10%  75µl 150µl 
TEMED (add last) 7.5µl 15µl 
      
Stacking gel 
Reagent 12.5% 2x (12.5%) 
Acryl-Bis 29:1 0.65ml 1.3ml 
Solution C* 1.25ml 2.5ml 
Water (SDW) 1.73ml 3.46ml 
APS 10%  75µl 150µl 
TEMED (add last) 7.5µl 15µl 
 
 
* Solution C:  
-0.5M Tris HCl Ph6.8 
(6.06g in 100ml) 
-0.4% SDS (Sodium 
Dodecyl Sulfate) 
* Solution B:  
-1.57M Tris HCl 
pH8.8 (19g in 100ml) 
-0.4% SDS (Sodium 
Dodecyl Sulfate) 
- APS (Ammonium 
persulfate) freshly 
prepared 
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First, base resolving gel was poured between two glass plates in a 
gel caster then quickly overlaid with 70% ethanol until set to flatten the 
top of the base gel then left for around 20 minutes till the gel solidified. 
Ethanol was removed and stacking gel was poured. The comb was 
quickly inserted before the stacking gel polymerized. 
The gel and plate were transferred to a gel tank filled with SDS 
running buffer. The comb was removed and wells were rinsed with 
running buffer to remove excess acrylamide. 5µl of protein ladder and 
5-20µl of samples were loaded per well. The samples were run at 40 
volt until the marker reached the base gel, then the voltage was 
increased to 80V for 2-4 hours.    
Running Buffer (10X) 
  30.3g Tris 
  188g glycine 
  10ml 10% SDS 
  Make up to 1L with sterile water. 
-Protein transfer 
When markers reach the bottom of the gel, the gel was removed 
from the tank then rinsed with a transfer buffer. The nitrocellulose 
membrane was cut to gel size and wet and soaked with filter paper and 
sponge in transfer buffer. The gel was transferred to transfer tank and 
run at 30V (~400A) overnight or 100V for 2 hours.   
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Transfer Buffer (10x) 
  30.3g Tris 
  144g glycine 
  Make up to 1L with sterile water 
Transfer buffer (1X) 
 100ml of transfer buffer (10X) 
  200ml methanol 
  Make up to 1L with sterile water. 
-Protein detection  
The apparatus was dismantled and the membrane was removed 
from the tank and placed in a container containing 20 ml of blocking 
buffer for 1 hour at room temperature with rocking. The membrane was 
washed once with PBST (PBS with Tween20) for 5 minutes. Primary 
antibody was diluted to appropriate concentration in 20 ml of 2% Marvel 
milk/PBST and membrane was incubated in this solution at room 
temperature in rotator for 2h. The membrane was then washed with 
PBST four times for 5 minutes each on a rocker. After diluting of 
fluorescently-labelled secondary antibody to the required concentration 
in 20 ml of PBST, the membrane was incubated in this solution for 2h on 
the rotator at room temperature. Four washing steps of the membrane 
with PBST in a covered plate for 5 minutes on a rocker were preceded 
the detection of target protein. 
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Blocking buffer 
  1g of Marvel milk dissolved in 20 ml PBST* 
  *PBST: 1.25 ml of 20% Tween20 mixed in 500 ml of 1x PBS. 
-Detection of protein signal 
Using LiCor secondary antibody, membrane was left in wash buffer 
and taken to the LiCor scanner. The stained membrane was scanned 
using software (Odyssey infrared image) to visualise protein bands.  
2.2.8 Preparing standard reagents  
2.2.8.1 Agarose gel 
- Preparation of 1L of 0.5M EDTA stock solution: 186.12g of EDTA 
was dissolved in 800ml of distilled water then NaOH was added to adjust 
pH to 8 then deionized water was added to reach 1000ml. 
- Preparation of 1L of 50× TAE buffer: 242g of Tris base was 
dissolved completely in 750ml deionized distilled water then 57.1ml of 
glacial acetic acid and 100ml of EDTA stock solution (pH 8) were added 
to solution to make up 1 liter. 
- Preparation of 1L of working solution 1×TAE buffer: 20ml of 50× 
TAE buffer was mixed with distilled water to bring the final volume up to 
1 liter.  
- Preparation of agarose gel: To prepare 1% agarose gel, 0.6g of 
agarose was added to 60ml of 1×TAE buffer. The solution was dissolved 
by boiling in the microwave at high temperature for 5 minutes. The 
solution was left to cool at room temperature to around 50 °C then 1µl 
of RedSafe was added before pouring the solution into a gel casting tray 
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with a comb and was left to solidify at room temperature. The gel was 
then submerged into a gel tank containing 1X TAE buffer. 
2.2.8.2 Chemicals 
-Decitabine (5-aza-2’deoxycytidine)  
A stock solution of 50mM of 5-aza was made by diluting 5mg of 5-
aza stock with 438µl 1x PBS. Then, we prepared a working solution of 
5mM by mixing 100µl of stock solution with 900µl of DMEM. 
- Cisplatin (cis-diamminedichloroplatinumII) 
A working solution of 0.33mM was made by adding 150µl of 
cisplatin (stock was 1mg/ml) to 1,350µl of 0.9% NaCl. 
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2.2.9 Statistical analysis  
Affymetrix expression array data was received as CEL. file format. 
This data was first preprocessed using the using R programme with 
‘Affy’ package in the bioconducter package provided by 
www.bioconductor.org (Bioconductor version 2.11 -BiocInstaller 1.8.3) 
(this analysis was performed in collaborated with MSci student, Claire 
Wallace). Data was normalised using the RMA (Robust multi-array 
average) method and filtered to exclude the probes that their expression 
were below control background levels. Fold changes in expression 
between each probe of each cell lines relative to seminoma were 
calculated. The data was exported as a .txt file in order to be read and 
analysed in Excel (full details of the workflow in Appendix II). The Excel 
tool PivotTable was used to assign average expression intensity values 
to each gene.  This data was then processed in Excel and a right-tailed 
Welch’s T-test was performed (by MSci student,Matthew Carr) for each 
gene comparing seminoma samples to non-seminoma samples. 
Illumina infinium methylome 450k array data was obtained in 
Excel file. Pivot table and V-LOOKUP function were used to calculate β 
value.  
To analyse the significance of the findings and compare the 
difference before and after treatment, the data were statistically 
calculated using two tailed paired t-test. 
 
 
 
 
 69 
Chapter 3. Genome-wide methylation profile of GCT cell 
lines  
3.1 Introduction 
Aberrant DNA methylation has been shown in many tumours 
including GCTs (Vega et al., 2012, Brait et al., 2012). Two recent 
studies of the global methylation of paediatric GCTs demonstrated the 
hypermethylation of many candidate TSGs (Jeyapalan et al., 2011, 
Amatruda et al., 2013). However, both studies were limited by the use 
of an array platform, Illumina GoldenGate arrays, which analysed only 
1-3 CpGs of 807 genes. The former study, which was applied in our lab, 
demonstrated that there was a significant difference in methylation 
between seminomas and YST, where the seminomas exhibited a lower 
level of DNA methylation than non-seminomas. Thus, in this chapter I 
sought to confirm and extend this result using an array system, the 
Infinium Human Methylation450 BeadChip platform, which covers 99% 
of the Reference Sequence (RefSeq) genes with an average of 17 CpG 
sites per gene to gain a comprehensive view of the methylation 
differences between subtypes of GCT cell lines. 
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3.2 Results 
3.2.1 DNA methylation level across the genome  
In order to investigate the methylation features in the four main 
histologic subtypes of adult testicular GCT cell lines, the Infinium Human 
Methylation450 BeadChip platform was used. This Infinium array 
platform measures DNA methylation levels using >485,000 probes 
which cover 99% of the Reference Sequence (RefSeq) genes (National 
Center for Biotechnology Information (NCBI), Bethesda, MD, USA). 
There is an average of 17 CpG sites per gene region distributed across 
gene regulatory regions, such as the promoter, 5'UTR (untranslated 
region), first exon, gene body, and 3'UTR. Sites near the transcription 
start site (TSS) labelled as TSS 1500 (1500bp upstream of the TSS) and 
TSS200 (200bp upstream of the TSS) were covered. This platform 
covers 96% of CGIs where the CGI refers to a region of at least 500bp, 
with greater than 55% GC content and an observed-to-expected CpG 
ratio >0.65. The other gene regions were: shores which are regions 2kb 
either side of an island, shelves which indicate regions 2kb outside of 
the shores and finally other (open sea) indicate the remaining 
sequences (Figure 3.1). 
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CpG island 
> 500bp in length 
 GC percentage >55%  
Observed/expected CpG ratio >0.65 
S Shore 
(2kb) 
Open sea/Other Open sea/Other 
N Shelf 
(2kb) 
N Shore 
(2kb) 
S Shelf 
(2kb) 
   TSS1500          TSS200  5’UTR  1exon               Gene body               3’ UTR  
Transcription start site (TSS) 
Figure 3.1: Diagrams illustrate gene regions and Illumina-
annotated probes: A) Based on gene regions: sites in the 
promoter region, 5’UTR, gene body, and 3’UTR. B) Based on 
their sites relative to CpG island: shores were 2kb up and down- 
stream of islands while shelves were 2kb outside of the shore. 
Open sea probes were not annotated into any of the other 
Illumina classes. S refers to south, N refers to north. 
A) 
B) 
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The Infinium Human Methylation 450 BeadChip combined two 
Infinium assays, I and II, to cover most islands in the whole genome 
(Figure 3.2). The Infinium I assay uses two probes, one for methylated 
DNA (M) and other for the unmethylated (U), for each CpG site. The 
attachment process of each probe to the DNA strand depends on the 
bisulfite converted genomic DNA where the 3’ terminal end of each 
probe is designed to attach to either a cytosine base when it is 
methylated or to a thymine base when the cytosine in the DNA is 
unmethylated and not protected from bisulfite conversion. The Infinium 
II has one probe for both alleles. The 3’ terminus of the probe is 
designed to be complementary to DNA bisulfite conversion strand by 
incorporation of an A or T base (unmethylated site) in red (U) and the 
incorporation of C or G signals (methylated site) in green (M). Another 
feature of Infinium II is that it can measure the methylation level of up 
to three underlying CpG sites. Using the two bead types in the Infinium 
Human Methylation 450 BeadChip covers more of the CpG sites in the 
whole genome.  
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A) 
B) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2: Infinium Human Methylation450 array scheme: It 
combines two technically distinct assays in one platform, the 
Infinium I assay and the Infinium II assay. A) The Infinium I assay 
uses two probes. One for methylated and the other for the 
unmethylated locus. B)  The Infinium II assay uses only one probe 
with a two-labelled base signal: a green signal for a methylated and 
a red signal for an unmethylated locus (www.illumina.com). 
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This assay was carried out (by our lab colleague, Dr. D. Noor) by 
extracting genomic DNA (500ng) from four subtypes of TGCT cell lines 
(representing seminoma, YST, EC and teratoma) as mentioned in 
section 2.2.3.1. The genomic DNA was first subjected to bisulfite 
modification using a Zymo EZ DNA methylation kit according to the 
manufacturer’s protocol. Subsequently, the samples were sent to Queen 
Mary’s University of London to carry out the Infinium methylation 450 
array. The raw data was received as an Infimum dataset with values 
representing a level of methylation at individual CpG sites as a beta-
value (β) ranging from 0 (unmethylated) to 1 (fully methylated). Each 
probe is defined according to the Illumina website (www.illumina.com) 
as a measure of location relative to UCSC-reference-group. This 
indicates the location in relation to the closest gene as within 1500 or 
200 base pairs from the transcription start site (represented as TSS 
1500 or TSS 200), 5` UTR, gene body and 3` UTR) and as a measure of 
location relative to UCSC- CpG-Island (island, north/south shore (within 
2kb up/downstream of an island respectively), north/south shelf (2-4kb 
up/downstream of an island, respectively), and blank indicating away 
from an island). 
Analyses were carried out using the Excel programme. The Excel 
tool `Pivot Table` was used to determine average methylation (β-value) 
and differential methylation (delta-β-value) to each gene in relation to 
locations with respect to CpG islands and gene regions. Before analysis, 
probes that could lead to biological and technical bias such as a gender-
specific bias were excluded from the analysis and also probes that were 
labelled for multiple gene names. Therefore, data for X and Y 
chromosomes and probes that represent multiple gene names or that 
did not represent any gene symbol were excluded. The analysis utilised 
two criteria which have previously been used in many investigational 
studies (Bibikova et al., 2011, Shen et al., 2013).  
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First, a beta value (β), obtained as a quantitative reading that 
varies between 0 (fully unmethylated) and 1 (fully methylated), was 
used to estimate the methylation level of the CpG locus using the ratio 
of intensities between the methylated and unmethylated probe. 
According to the Illumina website (www.illumina.com) that describes the 
methylation level in Infinium Methylation450 data, a methylation score 
of 0.3 or less represents unmethylated sites, scores of 0.6 and above 
represents methylated sites and values between 0.29 and 0.59 
represents partially methylated sites.  
Second, delta-beta values were calculated which in our study 
indicate the difference in methylation between seminoma and non-
seminoma samples by subtracting the average beta value of seminoma 
from that of non-seminoma samples.  
Initially, the distributions of differentially methylated regions 
across the genome for four testicular GCT cell lines were determined to 
investigate the regions that could be affected by methylation. Some 
previous studies reported that specific regions of some genes have 
methylated features such as methylation of promoter CpGs which may 
suppress gene expression (Irizarry et al., 2009). As the Infinium Human 
Methylation450 BeadChip array covers different regions of genes (such 
as island, shore, shelf) we calculated the average methylation level in 
the four GCT cell lines in different regions of genes by using the ‘pivot 
table’ function of Excel for the data of this array. As shown in Figure 3.3, 
the CGI regions in all cell lines had the lowest level of methylation while 
the methylation level increased in regions outside the CGI. However, 
when comparing non-seminoma to seminoma cell lines, non-seminoma 
had higher numbers of methylated CpGs in islands (where β-value ⩾0.6) 
than the seminoma cell line. The YST cells showed lower number of 
methylated CpGs in shelves and others `open sea` than the seminoma 
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Methylation level of CpG site across gene regions 
cells. For the EC and teratoma cell lines, the number of methylated 
CpGs was also higher compared with seminoma in all regions.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3: Percentage of CpG sites methylated (β-value ≥0.6) 
relative to CGIs. Methylation level of CpG sites across gene regions 
shows that island region had the lowest level of methylation in all 
cell lines. TERT and EC had a similar degree of methylation level at 
all regions and had higher level of methylation compared to 
seminoma. The YST cells had lowest level of methylation in shelves 
and open sea while their methylation was higher than seminoma in 
island region. 
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Several studies have reported that methylation of CpGs at 
promoter regions is associated with transcriptional repression (Fouse et 
al., 2008, Bird, 2011, Deaton and Bird, 2011, Vavouri and Lehner, 
2012). Therefore, the data was re-analysed to assess the methylation 
level of CpGs at regions relative to the transcription start sites (TSS). 
The average β value for each cell line was plotted (Figure 3.4). There 
was a clear reduction of methylation level near the TSS (TSS155, 
TSS200, 5’UTR, and 1st exon) and the level increased in regions more 
distal from TSS (3’UTR and gene body). In general, methylation of CpG 
sites in SEM showed low in all regions (Figure 3.4) compared to the non-
seminomas in general which indicated that seminomas have lower levels 
of methylation compared with non-seminomas. This finding for the 
whole genome is consistent with the previous study by Jeyapalan (2011) 
that used arrays in which fewer genes were analysed. 
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Figure 3.4: Methylation levels at CpG site at regions relative to 
TSS: Average methylation levels in four TGCT cell lines shows 
low level of methylation of CpGs near the TSS (TSS155, TSS200, 
5’UTR, and 1st exon) comparing to regions away from TSS 
(3’UTR and gene body). 
Figure 3.5: Methylation levels when removing islands and 
shores:  Average methylation level after removing island and 
shores were similar either near or away from TSS  
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The results also showed that islands and shores had the lowest 
level of methylation compared with other regions (Figure 3.3), therefore 
these were removed from the analysis and the graph was re-plotted 
(Figure 3.5). The result showed that the methylation levels were similar 
in all regions. This result illustrated that the methylation level for YST 
were lower than the SEM cell line after removing CpG site at islands and 
shores. Also, this finding demonstrated that the low level of methylation 
in regions near TSS was due to low methylation of CpG site in islands 
and shores. 
3.2.2 Methylome profile across four cell lines  
I next compared the methylation levels between the four cell 
lines to establish similarities and differences between them, based on 
average methylation of CGIs near the TSSs. From the previous 
quantitative standpoint, there were considerable differences in the 
methylation between seminoma and non-seminoma and between the 
non-seminoma cell lines themselves.  
To determine the association between tumour types and normal 
cells in terms of their methylation, the CpG methylation level in 20 
normal cells samples obtained from The Cancer Genome Atlas project 
TCG (TCGA-07-0227-20A-01D-XXXX-05), where XXXX represents the ID 
for each normal cell as (1 Brain (1481) , 1 Central Nervous System 
tissue (1467), 2 colon (1651 and 1407), 2 Head/Neck (1433 and 1511), 
7 Kidney (1500, 1670, 1275, 1418, 1536, 1590, and 1424), 4 lung 
(1626, 1633, 1551, and 1440), 1 Prostate (1578), 1 Rectum (1658), 1 
Stomach (1601)) (http://cancergenome.nih.gov/), and the four GCT cell 
lines included in this study was compared. This is represented by Dr. 
Jeyapalan as a heat map with Ward’s hierarchical clustering that 
consists of columns and rows representing the samples and the CpG 
sites respectively (Figure 3.6). It is clear that YST cells had a high 
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proportion of methylation compared to SEM and control samples. Also, 
the seminoma sample was the most similar in methylation to the control 
samples. This result demonstrated that the YST cell line was associated 
with a high level of global methylation (hypermethylation) whereas the 
SEM was hypomethylated and there was much less difference in 
methylation between SEM and normal cells (Figure 3.6). Interestingly, 
the distribution of DNA methylation showed a similar pattern in all 
normal cells from different patients and different tissues which gave 
more evidence that the methylation patterns that were seen in tumour 
cell lines was aberrant and could be associated with development of 
cancer. With respect to the methylation level in normal cells compared 
with GCT cell lines, the high degree of similarity in methylation of 
normal cells and undifferentiated SEM cells and the presence of a 
difference in both EC and TERT, in addition to a substantial difference in 
differentiated YST cells suggests that aberrant methylation could be a 
key factor in the differentiation of GCTs. 
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Figure 3.6: Heat map represents methylation of CpGs in normal cells and 
the four cell lines in this study. The highest methylation is shown in blue, the 
lowest in yellow, and partially methylated in green. The heat map shows that 
YST has a highest density of methylation compared to SEM and controls 
(Image kindly provided by Jennie Jeyapalan). 
  Data ordered according to high-low β-value in YST 
 
                                          Normal cells    (controls, N=20)                                           
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3.2.3 Anti-5-methylcytidine immunostaining showing    
differences in total methylation between SEM and YST 
To verify the difference of global methylation between SEM and 
YST cell lines, anti-5-methyl-C immunostaining was performed (as 
section 2.2.7.2). To detect nuclear 5-methyl-C, a primary antibody 
(Mouse Anti-5-methylcytidine, Bio Rad, UK) was used. Fluorescently 
labelled secondary antibody (TEXAS RED® anti-mouse, Vector, USA) 
was then applied for visual analysis using a fluorescent microscope. 
Stronger nuclear staining intensity for anti 5-methylcytidine was done in 
YST cells compared with SEM. To obtain further evidence for the 
presence of methylation difference between cells, YST cells were treated 
with 5µM 5-aza (set in section 2.2.2.1) and compared with untreated 
YST cells. The result revealed a strong reduction in the anti-5-
methylcytidine staining in YST cells after using a demethylation agent 
(5-aza) (Figure 3.7). These results provide clear confirmation that YST 
cells have a hypermethylation feature and thus this methylation can be 
substantially reduced by treatment of the cells with 5-aza.  
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Figure 3.7: Immunostaining using anti-5-methylcytidine: There was 
a strong staining intensity of anti 5-methylcytidine in YST cells 
compared to SEM and 5-aza-treated YST. Red fluorescence is Anti-5-
methylcytidine staining. DAPI is blue staining. 
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3.2.4 Identification of methylated genes in GCT cell lines  
          According to the results presented above, which showed that the 
most differentially methylated regions in the GCT cell lines were near 
the TSSs, the number and percentage of genes hypermethylated at 
CpGs near TSS were calculated (in collaboration with a MSci student, 
Matthew Carr) for each cell line. A gene was considered to be 
hypermethylated when the average of β-value across all CpGs near the 
TSS ≥0.6. This analysis showed that the highest number of 
hypermethylated genes was in the EC cell lines (935), then YST (806), 
followed by TERT (631) and SEM (358) (Figure 3.8-A). 
The similarities and differences between the cell lines were 
summariSed in a Venn diagram (Figure 3.8 B). This shows the numbers 
of methylated genes which were common among four cell lines and the 
numbers which were uniquely methylated for each cell line. A gene was 
considered to be uniquely methylated when the average of β-values 
across all CpGs near TSS ≥0.6 in one cell line and < 0.6 in the other cell 
lines. It was apparent from the Venn diagram that 94% of genes 
(337/358) methylated in the seminoma cell line were also methylated in 
EC and TERA cells and 62% of these genes (222/358) were methylated 
in all subtypes. For YST, 66% of genes (536/805) methylated in the YST 
cell line were methylated in EC and TERA cells, with 27% (222/805) of 
them methylated in all cell lines (Figure 3.8-B). The YST cell line had the 
highest number (270 genes) of uniquely methylated genes relative to 
others, whereas only 16 genes were uniquely methylated in the SEM cell 
line.  
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Figure 3.8: The population of methylated genes in GCT cell lines.  
Gene methylation based on the average of β-values across CpGs 
located near the TSS region. (A) Represents a percentage of 
methylated genes in each cell line, where values above bars 
indicate the number of methylated genes. (B) Venn diagram 
represents the overlap between genes methylated in each cell 
line.  
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3.3 Discussion 
Global hypomethylation and promoter hypermethylation are core 
characteristics of many tumours and there is expanding evidence that 
these epigenetic changes could play role in cancer development (Vega et 
al., 2012, Brait et al., 2012). More recent studies for germ cell tumours 
revealed that hypermethylation of particular areas of DNA in addition to 
global hypomethylation could play a critical role in tumorigenesis 
(Jeyapalan et al., 2011, Amatruda et al., 2013). In this study, 
measurements of global methylation level of adult testicular GCT cell 
lines using high-throughput approaches reveals that seminomas have a 
low level of global methylation (hypomethylation) while non-seminomas,  
represented by three types YST, EC, and TERT, showed higher level of 
global methylation (hypermethylation). This finding was consistent with 
the general pattern described by Jeyapalan et al. (2011) and Amatruda 
(2013) studies that used paediatric germ cell tumours samples.  
Furthermore, the methylation levels in normal control tissues were 
relatively similar to those of SEM (Figure 3.6). The low level of 
methylation in SEM is consistent with studies revealing that seminomas 
resemble PGCs and CIS (Skakkebaek et al., 1987, Eckert et al., 2008, 
De Felici, 2013, Elzinga-Tinke et al., 2015).  
Analysis for different gene regions of four cell lines showed that 
the CGI region in all cell lines had the lowest level of methylation while 
the methylation level increased in regions outside the CGI. However, 
comparison of non-seminoma to seminoma cell lines showed the three 
non-seminomas had higher levels of CGI methylation than the 
seminoma cell line. This finding supported other studies suggesting that 
CGI methylation could have a central role in tumourigenesis, in 
particular, the methylation status of CGIs may be associated with the 
expression of critical genes that play roles in the development of cancer, 
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or differentiation of tumour cells (Brown and Strathdee, 2002, Feltus et 
al., 2003, Bock et al., 2006, Previti et al., 2009). 
The regulatory importance of CGI methylation in gene expression 
may reflect their location in the promoter region, where the promoter 
has been proven for its role in regulation of gene expression. Many 
studies have reported that genes with a CGI promoter have 
transcriptional regulatory features where the methylation of promoter 
CpGs may suppress gene expression (Bird, 2011, Deaton and Bird, 
2011, Vavouri and Lehner, 2012).   
Both the EC and TERT cell lines, which are clinically more 
differentiated than seminomas (Cusack and Scotting, 2013), showed 
higher methylation than the SEM cell line and had a similar degree of 
methylation at all regions that were analysed as above in Figure 3.3. It 
is striking to see the high similarity in methylation level at all regions in 
these two cell lines where in fact the teratoma cell line (NT2D1) used in 
this analysis was derived from an EC component of a teratoma (Yao et 
al., 2007, Boucher and Bennett, 2003).  
Regarding YST, it was clear that CpG sites near promoter regions 
had more methylation than seminomas. In addition, when comparing 
the methylation level at different regions, the islands and shores in YST 
were more methylated than those in SEM. This finding pointed to island 
and shores playing a critical role in global methylation difference 
between SEM and YST. Also, the result showed that the YST cell line had 
the highest number of uniquely methylated genes relative to the other 
cell lines which suggested that those uniquely methylated genes could 
contribute to the differences in phenotype seen between SEM and YST 
(Feltus et al., 2003).  
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Chapter 4. Relation between methylation and gene 
expression in GCT cell lines 
4.1 Introduction 
Many studies have described changes in the DNA methylation 
pattern in varies types of cancer cells compared with normal cells from 
the same tissues and identified the effect of methylation on gene 
expression (Goel et al., 2004, Zöchbauer-Müller et al., 2001, Herman et 
al., 1995). Furthermore, it was noted that the reduced methylation level 
of a whole genome (global hypomethylation) is related to proto-
oncogene activation and chromosomal instability, whereas increased 
methylation levels of the CGIs associated with specific genes (regional 
hypermethylation) is associated with the silencing of tumour suppressor 
gene expression (Subramanian and Govindan, 2008). 
Recently developed methylation and expression arrays have 
revealed a correlation of methylation and expression of many genes in 
many classes of tumours analysed (Martin-Subero et al., 2009). 
Therefore, in this chapter, I sought to determine the correlation between 
methylation and gene expression in GCT cell lines using microarray 
analysis. 
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4.2 Results 
4.2.1 The correlation between differential expression and 
methylation in different gene regions between seminoma and 
non-seminoma cell lines 
Gene expression analysis was performed in collaboration with my 
colleague (Dr. D.Noor) on the same four GCT cell lines using Affymetrix 
Human GeneChip U133 Plus 2.0 arrays. RNA was isolated from the four 
cell lines using the RNeasy Mini Kit and QIAshredder, according to 
manufacturer instructions. The quality of RNA was assessed using the 
Agilent Bioanalyzer. Samples with an RNA integrity number (RIN) of 
more than 9.0 were selected for the Affymetrix gene expression array 
(Figure 4.1).  
Arrays were performed at the Nottingham Arabidopsis Stock 
Centre, University of Nottingham Sutton Bonington Campus, using 
Affymetrix GeneChip Human Genome U133 Plus 2.0 arrays. The high 
quality RNAs were labelled and hybridised to probes designed to attach 
to more than 30,000 genes for an analysis of over 47,000 transcripts 
with respect to GenBank®, dbEST, and RefSeq.  
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Figure 4.1: The RNA integrity number (RIN) for one TGCT cell line 
sample: The RNA integrity measurement was performed by Agilent 
2100 Bioanalyzer software, which showed a high integrity of RNA 
(9.5) 
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The expression data sheet was obtained as a CEL file and was 
then analysed in collaboration with MSci student in our lab (Claire 
Wallace) using the statistical software R, with packages provided by 
www.bioconductor.org. Data was preprocessed using the RMA method 
to normalize the data (AppendixII). The data was exported as a .txt file 
then analysed using Excel. Probes that had expression outputs below 
control background were excluded. The Excel tool `pivot table` was 
used to assess the average expression intensity values of each gene. 
The fold change in expression for each cell line was calculated relative to 
seminoma.   
The methylation data that was obtained from the Illumina Infinium 
HumanMethylome450 array were analysed using Excel spreadsheets 
(the analysis of data was explained previously in chapter 3, page 69-
70). In brief, quantitative measurements of methylation across CpGs 
sites were assigned as beta values (0<beta<1, 0 represents an 
unmethylated site, and 1 represents an methylated site). Delta-beta 
values of differential methylation were calculated as the difference in 
methylation between seminoma and non-seminoma by subtracting the 
average beta value of seminoma from that of non-seminoma.  
Expression and methylation data were merged in a single 
spreadsheet in Excel using the Excel function `VLOOKUP`. Further 
statistical analysis was carried out using functions in Excel. According to 
previous results and investigations that showed that methylation of CGI 
promoters results in gene silencing, I focused on average beta-value 
methylation of islands and their flanking regions (shores and shelves) 
relative to regions near the TSS (TSS1500, TSS200 and 5`UTR). 
To determine whether there was a statistically significant 
correlation of differential gene expression with each level of differential 
methylation between seminomas and non-seminomas under the null 
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hypothesis that lower gene expression does not correlate with 
methylation, calculations of Pearson’s Chi-squared test and student’s t-
tests with p-values (a p-values of 0.05, 0.01, and 0.001, represented as 
*, **, and *** respectively, were chosen as significance markers) were 
applied for association of methylation with gene expression between the 
two samples over a range of delta-β-value categories (Δβ intervals 
ranging from no methylation difference (0-0.05) between the two cell 
lines to fully methylated in non-seminoma cell line and unmethylated in 
seminoma (0.9-0.95)). Contingency tables were created for the 
observed and expected number of genes differentially expressed 
between seminoma and non-seminoma cell lines. For each category, the 
expected frequency of genes showing more than two fold differential 
expression were calculated under the null hypothesis that lower gene 
expression does not correlate with methylation. Correlation was 
measured by counting the number of genes in each category of 
differential methylation that were also differentially expressed, then the 
percentage correlation was calculated for each delta-beta category. The 
data and degree of correlation between the level of differential 
methylation of the various gene elements (islands, shores and shelves) 
and differential gene expression was presented in (Table 4.1) then 
plotted graphically using Excel graph tools showing the percentage of 
genes with more than two fold differential expression for each delta-β-
value category (Figure 4.2) (See Appendix I for other Tables and 
Figures).  
The most striking result to emerge from these data is that a delta-
β-value of above 0.7 in the EC and TERT, and 0.65 in the YST 
consistently correlated significantly with a difference in expression 
greater than two-fold, which is clear when comparing YST with 
seminoma cells (Figure 4.2-A), where the correlation percentage was 
over 40%. For all non-seminoma cell lines, the correlation between 
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differential methylation and differential expression was stronger in 
islands near the TSS than other regions which revealed that methylation 
of islands is likely to be of biological significance with respect to gene 
silencing. 
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Table 4.1: The contingency table shows observed and expected 
numbers of genes differentially expressed for ranges of 
differential methylation.  
 
 
 
Delta 
beta 
SEM/YST 
No 
difference 
No 
difference 
YST/SEM 
  
Total 
  
P-value Sig. Genes >2 
fold 
Genes >2 
fold 
Genes > 2 
fold 
Genes     > 
2 fold 
Observed Expected Observed Expected Observed Expected 
Chi 
squared 
(2df) 
  
0.9-0.95 2 0.75 2 2.86 0 0.39 4 0.2537   
0.85-0.9 3 1.31 4 5.01 0 0.68 7 0.2157   
0.8-0.85 16 5.42 10 20.75 3 2.82 29 0 *** 
0.75-0.8 16 4.86 8 18.6 2 2.53 26 0 *** 
0.7-0.75 16 5.61 9 21.47 5 2.92 30 0 *** 
0.65-0.7 11 5.42 16 20.75 2 2.82 29 
2.93E-
02 
* 
0.6-0.65 12 6.55 21 25.04 2 3.41 35 
5.57E-
02 
  
0.55-0.6 7 5.05 17 19.32 3 2.63 27 0.5819   
0.5-0.55 13 7.67 26 29.34 2 3.99 41 0.0789   
0.45-0.5 15 9.17 30 35.06 4 4.77 49 0.1018   
0.4-0.45 21 10.66 29 40.79 7 5.55 57 0.001 *** 
0.35-0.4 16 13.66 49 52.23 8 7.11 73 0.6998   
0.3-0.35 29 16.46 47 62.97 12 8.57 88 0.0006 *** 
0.25-0.3 29 20.02 64 76.56 14 10.42 107 0.0257 * 
0.2-0.25 40 28.43 90 108.76 22 14.81 152 0.0033 ** 
0.15-0.2 34 34.98 128 133.8 25 18.22 187 0.2458   
0.1-0.15 57 50.88 185 194.62 30 26.49 272 0.4326   
0.05-0.1 96 78.57 279 300.52 45 40.91 420 0.0545   
0-0.05 339 466.53 1939 1784.54 216 242.93 2494 
0.00E+
00 
*** 
Total 772 772 2953 2953 402 402 4127     
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Figure 4.2. The histograms represent the correlation between 
differential gene expression of over two-fold and differential 
methylation between seminoma and non-seminoma at islands, 
shores and shelves: the observed (blue) and expected (red), 
percentage correlation for each delta-β-value was calculated as 
(Number of correlating genes/total number of genes *100) for 
seminoma versus YST (A), EC (B) and TERT (teratoma) (C). 
Significance of the chi-squared tests of association are shown 
(p=0.05*, 0.01**, 0.001***), and the total number of genes in 
each category is displayed above the bar. 
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These analyses revealed that the observed correlation differs 
greatly from the expected level at high delta-beta values (>0.6) and 
become more similar to expected or no difference at low delta-beta 
values Figure 4.2. Some lower delta-β-value categories show a 
statistical significant association due to a large number of genes in these 
categories thus in fact they did not reveal the real correlation where the 
percentage level of association is much smaller means that a correlation 
reflects a random association. For example, when comparing the 
correlation percentage with statistical significance in YST at different 
regions (CGIs, shores, shelves) (Table 4.2), there were 152 genes 
exhibiting delta-β-values between 0.2-0.25, with only 26% (40/152) 
showing a correlation with decreased expression, but this still has a p-
value less than 0.05. On the other hand, some categories with the 
highest differential methylation values correlated with decreased 
expression and the percentage levels of association is high but these 
categories did not show a statistical significant association due to the 
small numbers of genes in these categories. For example, comparing 
YST with seminoma, seven genes exhibit delta-β-values between 0.85 
and 0.9, of which three (43%) show a correlation with decreased 
expression. In addition, in comparing the YST and SEM cell lines, there 
was greater than two times the value expected at random. Therefore, 
regarding those outputs, a threshold of differential methylation was 
established to >0.65 and genes whose differential methylation <0.65 
was excluded for further analysis. 
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Table 4.2: Comparing correlation percentage and significance in YST 
 
 
 
 
 
 
Delta 
beta 
No. of 
genes 
CGIs No. of 
genes 
Shores No. of 
genes 
Shelves 
% p-value % p-value % p-value 
0.9-0.95 4 50 0.254 - - - - - - 
0.85-0.9 7 43 0.216 2 0 0.696 - - - 
0.8-0.85 29 55 0 *** 4 25 0.555 - - - 
0.75-0.8 26 62 0 *** 8 25 0.711 6 0 0.687 
0.7-0.75 30 53 0 *** 12 25 0.171 6 0 0.432 
0.65-0.7 29 38 0.029 ** 7 14 0.617 8 13 0.585 
0.6-0.65 35 34 0.056 19 58 0 *** 13 15 0.727 
0.55-0.6 27 26 0.582 20 25 0.176 14 14 0.781 
0.5-0.55 41 32 0.079 29 21 0.678 16 38 0.001 * 
0.45-0.5 49 31 0.102 82 18 0 *** 14 36 0.004 ** 
0.4-0.45 57 37 0.001 *** 45 36 0 *** 33 24 0.026 * 
0.35-0.4 73 22 0.699 66 17 0.769 41 10 0.125 
0.3-0.35 88 33 0 *** 83 18 0.323 58 12 0.180 
0.25-0.3 107 27 0.026 * 127 18 0.584 75 19 0.017 
0.2-0.25 152 26 0.003 ** 145 12 0.696 101 8 0.372 
0.15-0.2 187 18 0.246 216 15 0.405 176 11 0.411 
0.1-0.15 272 21 0.433 308 13 0.617 280 9 0.367 
0.05-0.1 420 23 0.055 485 14 0.582 570 9 0.627 
0-0.05 2494 14 0 *** 994 13 0.008 ** 864 9 0.147 
Total 4127   2652   2275   
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4.2.2: Identifying genes that are both differentially methylated 
and differentially expressed between seminoma and non-
seminoma cell lines      
Based on the results indicating that the methylation of CGIs near 
the TSS could contribute to the expression of genes, genes were 
identified and listed in Figure 4.3 that were both differentially 
methylated and reciprocally differentially expressed between non-
seminoma and seminoma cell lines (these data presented in 
collaboration with MSci student, Matthew Carr). Genes were selected 
only when the difference of expression between seminoma and non-
seminoma was two-fold greater in SEM according to the microarray 
array data and was significantly differentially methylated with a delta-β-
value ≥0.65 at CGI near the TSS. 
The YST cell line had the most genes that were uniquely 
methylated and which exhibited a reduced expression compared with 
seminoma (84 genes) as shown in Venn diagram (Figure 4.3-A). EC and 
teratoma had 23 and 11 methylated and less strongly expressed genes, 
respectively, whereas three genes were methylated with reduced 
expression showed in both EC and teratoma. 
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Figure 4.3: Venn diagram represents significantly correlating genes which 
were both differentially methylated and expressed in all three 
nonseminomas, relative to the seminoma cell line : A) Tables contain 
genes that are expressed (≥2-fold difference in expression) and also 
differentially methylated (delta-β ≥0.7 for EC and teratoma, ≥0.65 for 
YST). Colours in the tables match those of the Venn diagram.  B) The 
numbers of genes which showed differential expression and were 
differentially methylated.  
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4.2.3 Correlation between methylation of CpG islands in gene 
bodies and gene silencing       
Some researchers have argued that the methylation of CGIs in 
gene bodies is more correlated to activation of genes than to depression 
(Aran et al., 2013, Yang et al., 2014). However, using the same criteria 
to analyse the correlation between methylation of CGIs and gene 
expression as applied to the promoter regions where delta-β- value 
>0.65 for differential methylation and a two-fold difference in gene 
expression, the results revealed that increased methylation of CGIs in 
the body was more strongly associated with gene silencing than 
activation (Figure 4.3-B). The result of this numerical assessment 
indicated that 45 out of 128 genes in the YST cells line exhibiting 
increased methylation of CGI in the body compared with the seminoma 
cell line showed a decrease in gene expression by two-fold or greater 
and a similar relationship was seen in the EC and teratoma cell lines 
(Figure 4.3-B). There was a strong correlation between high methylation 
of CGIs in the gene body and low levels of expression in the identified 
genes, regardless of whether this association was seen also in CGI 
promoter region near TSS. 
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4.2.4 Optimizing conditions for RT-qPCR experiment 
In order to validate the difference in expression levels of genes 
that were analysed in the microarray assay (section 4.2.2), RT-qPCR 
was used. First, RT-qPCR experiment required optimization steps 
including designing optimal primer pairs, determining primer efficiency 
and the standard threshold of each set of primers.  
The primer pair used in SYBR RT-qPCR was designed using the 
primer3 web site http://primer3.ut.ee/ according to the specific rules 
(following the protocol in section 2.2.4.2). The standard threshold of 
each set of primers was determined according to the qPCR results of five 
fold serial template cDNA dilution from the seminoma cell line sample 
following the protocol in section 2.2.4.5 (Figure 4.4).  
The standard curve plots showed the PCR cycle number (CT) 
versus log cDNA quantity, which should produce a straight line with a 
slope of -3.3 with acceptable limits between -3.1 to -3.6 (Fraga et al., 
2008). In addition to the efficiency value which is between 90 and 110, 
R² value (a statistical term that indicates how good one value is at 
predicting another) should be >0.99 (Fraga et al., 2008) . Moreover, the 
`no reverse transcriptase control` (-RT) and the `no template control` 
(NTC) samples should not show any fluorescent signal. The best primer 
efficiency is determined when the melting curve of each primer shows 
only one peak which means it is specific and producing no primer dimers 
(Figure 4.5). 
Each RT-qPCR experiment was performed in three triplicates for 
each selected gene (Figure 4.6).  All the RT-qPCR expression results of 
target genes were normalized against the expression of the 
housekeeping gene β-actin because the expression of this gene was 
relatively stable for all cell lines and treated cells used in this study 
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while others examined housekeeping genes (GAPDH, Cyclophilin B, and 
HPRT1) were not (data not shown). The Pffafl equation was used to 
determine the relative expression of the target gene (Pfaffl, 2001). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4: Example of optimization of primer efficiency for EPCAM 
primer. Optimization was performed by using five fold serial dilutions 
of cDNA from seminoma cell line as template.  
Figure 4.5: Example of melting curve for β-actin: A symmetrical 
curve of a single peak represents the ideal melting curve. 
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SEM 
Untreat -YST 
Treat-YST-2day 
Treat-YST-8day 
 
Figure 4.6: Example of graphs represent the amplification plots for β-
Actin and EPCAM, respectively. Relative fluorescence (RFU) is plotted 
against PCR cycles number for treated and untreated samples. 
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4.2.5 Identifying genes that could implicated in a phenotypic 
difference between seminoma and YST cell lines 
Some genes that were methylated and repressed in YST relative 
to SEM could play a potential role in the phenotypic difference between 
those cell lines. To validate whether those genes are indeed implicated 
in a phenotypic difference between seminoma and YST, the result in this 
study was compared with the Affymetrix expression data of Palmer et al. 
(2008) study which included primary tumour samples of a cohort of 
paediatric seminomas and YSTs from many different anatomical 
locations using the same array that I used in this study, the Affymetrix 
HumanGeneChip U133 Plus 2.0 arrays (Figure 4.7).  
Table 4.2 shows 17 out of 147 genes which revealed a significant 
correlation between differential methylation and differential expression 
in YST versus SEM cell lines. Gene ontology (www.geneontology.org) 
along with the possible biology importance of these genes showed their 
importance in development and differentiation. Notably, several of these 
genes are involved in pluripotency and male gamete production: KLF4, 
PRDM14, DDX43 and TDRD12. Twenty one genes were consistently and 
significantly expressed at higher levels in primary seminomatous 
tumours than in YST (Table 4.3). 339 genes were differentially 
expressed in both studies. Eleven of those genes also were highly 
expressed in the seminoma cell line compared with YST in this study. 
The overlap of genes which showed differential expression in the cell line 
study and the primary tumour study indicated that the cell lines could 
be used as a good model for studying gene expression in this tumour 
type.  
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Figure 4.7: Methods overview to identify the list of genes (Table 
4.3) that were methylated and repressed in YST relative to SEM 
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Table 4.3: Genes methylated and repressed in YST relative to SEM 
 
 
Gene 
Infinium Methylation450K 
Array 
Affymetrix      
gene 
expression Function/Importance 
β-value Delta     
β-value 
Fold change 
(SEM/YST) YST SEM 
EPCAM 0.907 0.125 0.782 9.13 
Induces cell proliferation (Münz et al., 
2004) – Oncogenic signalling molecule 
(Baeuerle and Gires, 2007) 
SOX17 0.949 0.108 0.841 5.36 
Regulation of embryonic development 
(Kamachi et al., 2000) 
HIST1H4C 0.942 0.123 0.819 4.09 
Core component of nucleosome (Churikov 
et al., 2004) 
SOX15 0.949 0.108 0.841 1.80 
Protein binding regulation of transcription 
(Maruyama et al., 2005) 
GGCT 0.859 0.064 0.795 6.91 Cell proliferation (Oakley et al., 2008)  
CTHRC1 0.944 0.064 0.88 8.35 
A novel secreted protein in injured 
arteries and promotes cell migration 
(Pyagay et al., 2005) 
TRIM59 0.895 0.134 0.761 4.72 
Ubiquitin-protein ligase activity- Play role 
in innate immunity (Ozato et al., 2008) 
LY75 0.841 0.172 0.669 2.57 Immune response (Kurup et al., 2007) 
PRDM14 0.898 0.203 0.695 1.67 
Transcription factor- Germ cell 
development- pluripotency- epigenetics 
reprogramming (Yamaji et al., 2008) 
KLF4 0.733 0.082 0.651 5.09 
Transcription factor- maintaining 
embryonic stem cells (Okita et al., 2007) 
DDX43 0.872 0.098 0.774 5.22 
RNA helicase is associated with RNA 
processes (Abdelhaleem, 2004) 
BST1 0.923 0.152 0.771 2.12 
Promotes pre-B-cell growth (Yokoyama et 
al., 2015) 
RPRM 0.838 0.052 0.786 1.59 Induces cell cycle arrest (Xu et al., 2012) 
PON3 0.949 0.229 0.72 1.61 
Anti-oxidative mechanism- protects 
against  apoptosis (Schweikert et al., 
2012) 
TRIL 0.853 0.103 0.75 4.31 
Innate recognition of microbial 
products  (Carpenter et al., 2009) 
TDRD12 0.953 0.329 0.624 6.39 
ATP-binding RNA helicase- Unique piRNA 
biogenesis factor (Pandey et al., 2013) 
MGMT 0.179 0.061 0.118 1.14 
Involved in DNA repair (Sharma et al., 
2009) 
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 Table 4.4: List of genes that were differentially methylated and 
expressed in my study and significantly differentially 
expressed in the Palmer et al (2008) study 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Gene Fold change 
Palmer 
fold change 
Palmer 
P-value 
GGCT 120.36 1.78 0.01483 
TDRD12 84.38 7.90 0.00002 
RBMXL2 43.48 1.78 0.00359 
DDX43 37.32 4.15 0.00562 
KLF4 19.41 6.07 0.00004 
ECHDC3 14.53 1.59 0.00173 
TRIL 14.14 1.43 0.01529 
OXCT1 17.24 1.68 0.00007 
TMEM168 9.87 1.67 0.00324 
GUCA1A 7.14 1.63 0.00121 
LY75 5.95 3.86 0.00308 
PARP12 4.35 2.97 0.00086 
MNS1 3.61 1.10 0.00613 
SOX15 3.49 2.37 0.00017 
PRDM 14 3.18 1.40 0.00329 
PON3 3.04 2.62 0.00246 
RPRM 3.01 2.54 0.00011 
LRRFIP1 2.83 1.24 0.00600 
ARPC1B 2.60 2.41 0.00015 
NAAA 2.42 1.20 0.01633 
AMPD3 2.06 1.52 0.03360 
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4.2.6 Validation of the relationship between methylation and 
gene silencing       
Seventeen of those genes that showed significant correlation of 
differential methylation and differential expression between the non-
seminoma and seminoma cell lines were analysed for further validation. 
The methylation level of CGI near TSS according to methylation data of 
Infinium array for these genes is presented in Figure 4.8-A. This shows 
that the average methylation level (β-value) at the CGIs was high in 
non-seminoma cell lines, particularly in YST, versus SEM. Conversely, 
the expression level as analysed by Affymetrix expression arrays is 
presented in figure 4.8-B showing that those genes are highly expressed 
in SEM and downregulated in non-seminoma or silenced in YST. 
The results verified a significant negative correlation between CGI 
methylation near TSS and expression for all of those genes. In cases 
where hypermethylation was detected, transcription was often 
downregulated in tumour cell lines (as in YST) compared with high 
expression when the gene was hypomethylated (as in SEM).  
In order to validate the expression of those candidate genes that 
were identified by the Affymetrix array, reverse transcriptase PCR 
experiment was performed. RNA was extracted from the same four cell 
lines used in the microarray analysis using the TRI reagent and 
chloroform protocol as described in section 2.2.3.2. Any contaminating 
DNA was removed by applying DNAase treatment then cDNA synthesis 
was carried out using Superscript III. PCR products were analysed by 
agarose gel electrophoresis (Figure 4.8-C). The results indicated that 
Affymetrix expression array data truly reflected the expression changes 
of those genes. 
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The positions of all the CpG sites and islands within each 
candidate gene were identified with reference to the gene sequence 
(regarding to NCBI website) by submitting that sequence to the 
MethPrimer programme (http://www.urogene.org/methprimer/). The 
locations of the transcription start site (TSS) and the promoter region 
were predicted using the Eukaryotic Promoter Database 
(http://epd.vital-it.ch). From Figure 4.8-D, it is clear that the 
methylated CGIs were concentrated near TSS. Moreover, a high level of 
methylation at CGIs near the TSS was strongly correlated with gene 
silencing as shown in Figure 4.8-E  meaning that methylation of CGI 
around the promoter regions could play an important role in silencing of 
the methylated genes.  
Furthermore, the methylation level of the identified CGIs located 
near to TSSs was analysed (Figure 4.8) to determine to which extent 
this level related to gene expression, most of the genes which showed 
hypermethylation of CGIs in non-seminomas correlated with silencing of 
the gene (such as GCCT, KLF4, and PON3). However, for some genes, 
such as TRIL, only some of CpGs-associated CGI in EC and TERT were 
methylated while others were not and the gene was downregulated in 
EC and expressed in TERA. On the other hand, when the CGIs of 
TDRD12 were analysed, approximately half of the CpGs were 
hypomethylated in SEM and TERT and the other half were 
hypermethylated but the gene was expressed in both cell lines. We 
conclude from this result that some CpGs could be more important than 
others in relation to gene expression.  
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Figure 4.8: Figure represents a side by side comparison of level of CGI 
methylation to gene expression: a significant negative correlation 
between CGI methylation and expression were detected for each 
candidate gene. (A) methylation level across CGI in the four cell lines 
(B) expression level from microarray analysis (C) RT-PCR analysis (D) 
graph of CpG density across the gene structure where green bar and +1 
indicate position of the promoter and TSS, respectively. (E) Methylation 
level at each CpG included in 450K chips relative to CpG site features in 
panel (D). 
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4.2.7 Validation of genes silenced by methylation 
This study revealed a negative correlation between gene 
methylation and expression, indicating DNA methylation could play a 
role in silencing of those genes. To confirm that those genes were 
silenced by methylation, the expression of five selected genes was 
examined after treating the YST cells with a demethylating agent, 5-
aza-2-deoxycytidine (5-aza), that has been widely used as a DNA 
methylation inhibitor to induce gene expression (Christman, 2002). The 
YST cell line was chosen for this analysis because it was highly 
methylated (Figure 4.8). YST cells were treated with 5µM of 5-aza for 2 
days. Following treatment, expression of five out of the 17 genes (in 
Table 4.3), which their expression was highly in seminoma comparing to 
YST (fold change >4), was re-examined by RT-PCR and RT-qPCR. The 
primer efficiencies for candidate genes that were used in the Pfaffl 
equation are shown in Table 4.4. The result showed that all five genes 
were re-expressed following 5-aza treatment which verified that 
methylation of these genes could be associated with their silencing. The 
greatest effect of demethylation was seen for HISTH4C1, SOX17 and 
TDRD12, which were induced more than 200-fold in treated cells with a 
significant difference compared with untreated cells with p-value <0.001 
using a paired t-test (Figure 4.9). 
 
 
 
 
 
 120 
Table 4.5: Primer efficiency values obtained from standard curves for 
candidate genes 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Gene name 
Primer 
efficiency value 
% 
R2 
Slope of 
standard curve 
ACTNB 98.9% 0.994 -3.349 
EPCAM 100.4% 0.993 -3.313 
TDRD12 100.5% 0.997 -3.309 
HIST4H1C 99% 0.998 -3.384 
SOX17 98.3% 0.986 -3.363 
KLF4 99% 0.993 -3.443 
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Figure 4.9: Gene expression analysis for selected genes in YSTs 
following treatment with 5-aza: (A) Gel image for PCR showing 
re-expression of 5 genes following treatment with 5-aza (B) RT-
qPCR results for the same experiments. *denotes p-value <0.01 
and **denotes p-value <0.001 using paired t-test. Error bars 
represent standard deviation. 
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4.2.8 Potential relationship between methylation and cancer 
To detect which of the genes that show correlation between 
hypermethylation and reduced expression might be implicated in 
cancer-related events, the methylation levels of TSS-associated CGI 
were compared between GCT cell lines and a series of normal tissue 
samples for those genes. Infinium HumanMethylome450 array 
methylation data, including 21 normal tissues samples which included 4 
prostate samples, 5 whole blood samples and 12 blood samples from 4 
new born, 5 adults, and 3 adults >80 years old, was provided by Dr. 
Jeyapalan. High similarity in methylation patterns was found between all 
the normal samples and the seminoma cell line. Only three genes 
(DDX43, RBMXL2, and TDRD12) that showed a difference in methylation 
were hypomethylated in SEM versus normal tissue. Those genes known 
as testis-specific genes and were also highly methylated in all control 
samples and non-seminoma cell lines compared with seminoma (Figure 
4.10).  
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Figure 4.10: Comparison of the methylation level (β-value) 
between GCT cell lines and normal tissues. Red colour represents 
high methylation while green represents low methylation. C1-C4: 
normal prostate tissue, C5-C9: Whole blood samples, C10-C12: 
Blood samples from > 80 year olds, C13-C15 and C20-C21: Adult 
blood samples, and C16-C19: new-born blood samples. 
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4.3 Discussion 
In this chapter, one of the most significant findings of this study 
that emerged from combining methylation and expression array data is 
a correlation of CGI hypermethylation with reduced gene expression in 
the non-seminomas compared with the seminoma cell lines, which 
agrees with the hypothesis that methylation of CGIs correlates with 
gene silencing (Robertson and Jones, 2000, Baylin, 2005, Esteller, 
2007). The methylation of islands showed a stronger correlation with 
reduced expression than the methylation of shores or shelves.  
A list of genes that were both differentially methylated and 
differentially expressed in non-seminoma cell lines relative to the SEM 
cell line was identified. The YST cell line had the most genes that were 
uniquely methylated and exhibited a reduced expression compared to 
seminoma (59 genes). Among genes differentially methylated at a TSS-
associated CGI between non-seminoma and seminoma cell lines, about 
half showed a correlating decreased expression in the non-seminoma 
cell lines. Thus, it seems that differential methylation could play a 
substantial role in the differential gene expression seen between 
seminoma and non-seminoma cells. 
Furthermore, when comparing the relationship between 
hypermethylation of CGIs in gene bodies to gene expression, the 
correlation was more often associated with silencing of genes rather 
than activation.  
147 genes, out of 7242 that produced reliable signals in the 
expression array data, are both differentially methylated and expressed 
in non-seminoma relative to seminoma. 21 genes in our data set were 
also differentially expressed in cohorts of primary tumour. Nine of those 
genes have known importance in development and differentiation 
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processes. Moreover, some of these genes are involved in pluripotency 
and male gamete production such as KLF4, PRDM14, DDX43 and 
TDRD1. These genes could play a potential role in gene silencing that 
lead to the phenotypic difference between those cell lines.  
Based on previous findings that explored a negative correlation 
between methylation and expression, we investigated whether 
methylation played a critical role in silencing of genes using the DNA-
demethylating agent 5-aza-2-deoxycytidine. The expression of 
candidate genes was reactivated after treatment with 5-aza which 
verified that methylation played a role in regulation of gene expression 
of those genes that were tested and showed a negative correlation 
between methylation and expression. As genes were re-expressed after 
treatment using just a DNA demethylating agent (5-aza), DNA 
methylation in GCTs may regulate gene expression by a mechanism 
which does not involve modifying chromatin. 
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Chapter 5. The role of PRDM14 in GCTs  
5.1 Introduction 
From the analysis described in chapter 4, PRDM14 was found to be 
both differentially methylated and expressed between the seminoma 
and YST cell lines, where it was methylated and down regulated in YST. 
PRDM14 is a key regulator of PGC specification. Interestingly, recent 
studies found that PRDM14 has a significant role in the conversion of 
embryonic stem cells (ES) to PGCs by many mechanisms such as 
activating PGC genes, suppression of somatic genes, and promotion of 
DNA demethylation (Magnúsdóttir and Surani, 2014, Okashita et al., 
2014, Nakaki and Saitou, 2014). 
It is also noteworthy that PRDM14 demethylates DNA directly 
through two mechanisms, repression of de novo DNA methytransferases 
(DNMT3a and DNMT3b), DNMT3L, and DNMT1 cofactor (UHRF1) 
(Grabole et al., 2013) and activation of the TET enzymes (Okashita et 
al., 2014).  
The cure rate for patients with GCTs is about 95% at early tumour 
stages but this is reduced for late-stage tumour and those with non-
seminoma. Seminomas are considered very sensitive to chemotherapy 
such as cisplatin (di Pietro et al., 2005, Duale et al., 2007) while non-
seminoma cells (especially YST) are less sensitive to therapy 
(Houldsworth et al., 1998).  
 O’Byrne et al. (2011) demonstrated that epigenetic changes, 
including DNA methylation, are associated with resistance to standard 
chemotherapies such as cisplatin. Moreover, Zeller et al. (2012) 
identified some DNA methylation drivers that play critical roles in 
chemoresistance. However, the actual mechanism of resistance of 
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cancer cells to cisplatin is still unclear but it is known that cisplatin 
induces cell death by trigging apoptosis.  
Cancer cells can evade apoptosis by utilising a variety of 
mechanisms; some are specific to particular tumour types. One of these 
mechanisms, related to this study, is methylation-induced silencing of 
tumour suppressor pathways that promote evasion of cell death (Anglim 
et al., 2008). Interestingly, recent evidence suggested that 
overexpression of PRDM14 facilitates apoptosis in HPV-positive cancers 
through upregulating the apoptosis regulators NOXA and PUMA  
(Snellenberg et al., 2014).  
Collectively, these studies suggest that PRDM14 could play a key 
role in GCT progression and demethylation of DNA in addition to 
sensitive to chemotherapy. Therefore, in this chapter, the potential 
function of PRM14 in germ cell carcinogenesis and chemosensitivity has 
been studied by generating YST cells stably overexpressing PRDM14.  
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5.2. Results  
5.2.1 Production of YST cells stably overexpressing PRDM14  
To study the role of PRDM14 in DNA methylation and GCTs 
biology, a PRDM14 expression construct was generated and transfected 
into the YST cell line (GCT44). The full-length PRDM14 coding region 
was amplified from the SEM cell line (TCAM-2) by reverse transcription-
PCR (RT-PCR). The PCR product was cloned into myc-pcDNA3.1 vector 
(Invitrogen, UK) to create the myc-pcDNA3.1-PRDM14 expression 
construct. The cloning site for PRDM14 was introduced using EcoR1 and 
Xba1 restriction enzymes (Figure 5.1). The sequence of myc-pcDNA3.1-
PRDM14 was verified by sequencing (Appendix II). 
To determine the transfection efficiency, GFP plasmid was 
transiently transfected alone and with myc-pcDNA3.1-PRDM14 
expression construct into YST cells using electroporation following 
(section 2.2.5.6). The percentage transfection efficiency was determined 
visually under the fluorescent microscope 24 hour after transfection, by 
calculating proportion of cells that expressed GFP. The transfection 
efficiency was more than 80% (Figure 5.2).  
Stable transfection was achieved using G418 antibiotic after 48 
hour post transfection followed section 2.2.5.7. As shown in Figure 5.3, 
a kill curve for G418 was generated. The lowest concentration of G418, 
that minimal visual toxicity was apparent even after seven days of 
treatment, was 20 µM. While the highest concentration was 100 µM, 
when all cells were dead within 2-3 days of treatment. The optimal 
concentration of G418 was 80µM, chosen as all cells were dead after one 
week of treatment. Three independent polyclonal stably-PRDM14 
expressing cell lines were generated for YST. 
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Clone Name: PRDM14 (Full-length)  
Vector: pcDNA3.1/myc tag- size 5.5 Kb            
Resistance: Ampicillin-Neomycine 
Source: cDNA from seminoma (TCam2) cells 
Gene: PRDM14: PR Domain-Containing Protein 14 (Homo sapiens) 
Cloning sites: EcoR1 and Xba1 
Insert length: 1737bp 
Total: 1737 + 5.5 =7.237 
Sequence: 
 
GAC  TTG  GGA  TCC  AGT GTG GTG  GAA TTC  GCC CGC  ATG GCT………………………TACTAG   TCT AGA 
Myc Tag     BamH1                              EcoR1                               PRDM14   Sequence           Xba1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1: pcDNA3.1/Myc-tag expression vector map: Human 
PRDM14 was cloned from seminoma cell line and inserted into the 
pcDNA3.1 expression vector with Myc-tag at the 5’ end.  
 130 
0
20
40
60
80
100
120
0 10 20 30 40 50 60 70 80 90 1oo
Su
rv
iv
al
 p
e
rc
e
n
ta
ge
 o
f 
ce
lls
 
(%
) 
Concentration of G418(µM) 
0
20
40
60
80
100
Control GFP GFP-PRDM14
%
 E
xp
re
ss
io
n
 E
ff
ic
ie
n
cy
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3: Generation of a kill curve for (G418): YST cells were 
exposed to increasing concentration of G418 for one week and 
percentage survival was calculated. Surviving cells were counted 
using trypan blue staining assay. The values were expressed as 
mean. Error bars represent standard deviations of three 
microscopic fields were counted. 
 
Figure 5.2: Transfection efficiency of PRDM14: Assessing the 
transfection efficiency by counting the cells that expressed GFP 
versus the total cells in the same population by fluorescent 
microscope. Images showed cells that expressed GFP. The graph 
showed high expression efficiency (≥ 80%). Error bars represent 
standard deviations of three microscopic fields were counted. 
 
GFP                 GFP-PRDM14 
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Polyclonal stably-PRDM14 expressing cells in addition to transient 
transfection were selected for PRDM14 expression analysis by RT-PCR 
(Figure 5.4) and RT-qPCR (Figure 5.5) compared to control 
(untransfected YST) and SEM cell line. The data showed that there is 
expression for PRDM14 in transient and stable transfected YST cells 
comparing to the control YST cells which means that these samples 
could be sufficient for further analysis.  
The purpose of using three independent polyclonal populations is 
to investigate the consistency of expression of PRDM14 in stably 
transfected YST cells comparing to untransfected YST. The PRDM14 
expression was observed in all three populations in addition to transient 
transfected cell and SEM cell lines (Figure 5.4 and 5.5). However, 
variability was observed in signal intensity with three polyclonal stable 
transfected cell populations. This may be due to survival and outgrowth 
of the nontransgenic cells within the polyclonal cell population or due to 
differences in heterogeneity of these populations rather than 
transfection efficiency. 
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                                              Stable transf. 
               Transient               ( tPRDM14) 
Cont.  1d      3d      5d       (1)      (2)      (3)    SEM   -ve 
 
YST 
BACTN 
 
PRDM14 
 
-RT 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.4: RT-PCR for PRDM14 expression after transfection: 
PRDM14 expression was shown in both transient and stable 
transfected YST cell lines. At first day (1d) of transfection, 
PRDM14 expression was clear but in third day (3d) the expression 
decreased and no expression in fifth day (5d). While in stable 
transfection, there was a clear expression in three independent 
samples compared to control (Cont.), untransfected YST. (SEM) 
represents seminoma cell line where PRDM14 is expressed.(-ve) 
negative control for PCR experiment. B-actin (BACTN) was used 
as loading control. (–RT) no reverse transcriptase samples. 
Figure 5.5: RT-qPCR for assessing YST cells stably overexpressing 
PRDM14: Bar graphs showing PRDM14 expression level after stable 
transfection comparing to untransfected YST. Experiment was 
performed for three independent samples. All three independent 
transfections revealed significantly increased in PRDM14 expression.   
*** denotes p-value <0.001 using paired t-test. Error bars 
represent standard deviation. 
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5.2.2. Validation of expression of PRDM14 protein using western 
blot 
Expression of PRDM14 protein in the transfected YST cell line was 
evaluated by western blot analysis. After transient and stable 
transfection with myc-pcDNA3.1 tagged PRDM14, cells were harvested 
then cell lysates were used to investigate protein expression of PRDM14. 
The samples were run on SDS-PAGE to separate the proteins according 
to their molecular weight followed by western blot analysis as described 
in section 2.2.7.4. Primary mouse polyclonal antibody (Myc-Tag Mouse 
mAb) was used to bind to the Myc tagged proteins. Secondary antibody 
(Donkey anti-Mouse IgG, IRDye®800CW, LI-COR, USA) was used to 
visualise the primary antibody that bound to a target protein. 
Western blot analysis showed the presence of myc-tagged 
PRDM14 in the transfected YST cell lines. In Figure 5.6, bands for 
PRDM14 protein were detected in lanes 6-9 that presented myc-tagged 
PRDM14 protein expression at approximate 77kDa which proved that the 
PRDM14 protein was expressed in the transfected YST cell. In addition, 
protein signals detected for stable transfection samples showed greater 
intensities compared to the protein signals of transient transfected 
samples at 7 days where protein was assumed to have degraded after 
that time. This observation provided evidence that polyclonal cultures 
stably expressed PRDM14 protein.  
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Figure 5.6: RT-PCR and western blot analysis of PRDM14 expression in 
transfected YST cell lines.  
A) RT-PCR showed expression of PRDM14 in transient transfection for 1-7 
days (1d-7d) which showed decreasing of PRDM14 expression after 3 day 
(3d) while stable transfection (st.) showed increased of expression. 
Untransfected YST cells (Con.), seminoma cells (SEM)  
B) Western blot: PRDM14 protein expression in YST cells was detected 
after transfection using anti-Myc. Both transient and stable transfected 
YST cell lines were tested. Transient transfection at 5 and 6 days (lanes 6 
and 7, respectively) showed expression of PRDM14 while in 7 day of 
transient transfection (lane 8), the expression of PRDM14 protein 
decreased. Stable transfection (lane 9) showed increased expression of 
PRDM14 protein. Ladder (lane 1), Untransfected YST cells (Con.) (lane 2), 
transient transfection for 1-3 days (lanes 3-5, respectively), and 
seminoma cells (SEM) (lane 10). 
 
Lanes   1    2      3      4      5      6     7      8     9    10 
 YST 
          Transient                                    Stable 
Myc-tag 
77KDa 
 YST 
          Transient                                    Stable 
 YST 
          Transient                                    Stable 
A) 
B) Con.  1d    2d     3d   5d    6d   7d    st.  SEM 
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5.2.3. Overexpression of PRDM14 is associated with changes in 
the expression of other genes 
To investigate the effect of PRDM14 on regulation of other genes, 
RT-qPCR analysis was performed to examine the effect of 
overexpressing PRDM14 on the expression of some candidate genes; 
these were found to be methylated and silenced in YST compared with 
SEM and are known to have an important role in germ cell progenitors 
and/or pluripotency. In this study, expression levels of these genes in 
YST cells stably overexpressing PRDM14 were compared with those in 
untransfected YST cells. All quantification data were normalized to β-
actin which acts as an internal control. All three independent stable cell 
lines that significant overexpressed PRDM14 showed an increase in the 
expression of KLF2, OCT4, RASSF2, TDRD12, and KLF4 with a  2-4x fold 
change for KLF2 (p < 0.01), OCT4 (p < 0.001) and TDRD12 (p < 0.05),  
and a 7-17x fold change for RASSF2 (p < 0.01) and KLF4 (p < 0.001) 
(Figure 5.7). All of these genes in addition to PRDM14 were methylated 
and downregulated in YST compared with SEM cell lines, but after 
overexpression of PRDM14, those genes were up-regulated in all 
transfected YST samples. This revealed that their expression levels were 
positively correlated with PRDM14 expression levels. Therefore, we 
suggest that PRDM14 could be involved in regulation of these genes.  
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Figure 5.7: Gene expression analysis in YST cells overexpressing 
PRDM14. Bar graphs showing the average fold change of gene 
expression for selected genes after overexpression of PRDM14 in 
all three independent transfected YST samples compared with 
untransfected YST cell lines. Error bars represent standard 
deviation of three technical replicates. 
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5.2.4. Assessing the global DNA methylation level after 
overexpression of PRDM14 in YST     
To further assess the effect of PRDM14 on GCT biology, the DNA 
methylation level in YST cells stably overexpressing PRDM14 was 
investigated. Stably transfected and untransfected YST cells were fixed 
and subjected to immunostaining with primary antibody (mouse Anti 5-
methylcytidine) and secondary antibody (TEXAS RED® anti-mouse IgG) 
for methylation detection in addition to primary antibody (Anti-PRDM14 
antibody) and secondary antibody (Alexa Fluor®488 Goat anti-Rabbit 
IgG) for PRDM14 detection (as mentioned in section 2.2.7.2). The 
methylation level of overexpressing PRDM14 YST cells to SEM and 
untransfected YST was compared. Immunohistochemical examination of 
5mC can be used to assess global DNA methylation, especially when the 
number of samples available for assessment is small or when the 
methylation status of cancer cells cannot be normalized to normal 
tissues (Piyathilake et al., 2000, Wermann et al., 2010).  
The results indicated that global methylation of overexpressed 
PRDM14 YST cells was decreased compared with untransfected YST 
(Figure 5.8), which revealed that PRDM14 could play a key role in 
demethylation machinery.  
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Figure 5.8: Immunostaining analysis to assess the methylation level after 
PRDM14 transfection: It showed that methylation levels decreased in all 
three independent YST-PRDM14 samples compared with untransfected YST. 
All samples recorded in the same camera setting. 
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5.2.5. Clonogenic survival assay for YST cells stably expressing 
PRDM14 following treatment with cisplatin  
The clonogenic cell survival assay (or a colony formation assay) is 
an in vitro assay based on evaluating the ability of a single cell to form a 
colony after treatment with ionizing radiation or chemotherapy agents 
such as etoposide and cisplatin. This assay was described initially in the 
1950s for studying the effectiveness of radiation on cells (Franken et al., 
2006) but can also be used for other cytotoxic agents. This assay was 
used to assess the effect of PRDM14 overexpression on YST sensitivity 
to cisplatin. 
To determine whether PRDM14 overexpression improved the 
response of the YST cell line towards cisplatin, untransfected and stably 
transfected cells were grown until confluent then subjected to clonogenic 
assay (section 2.2.2.4). In brief, 100 cells/well were plated in each well 
of a 6-well plate and when cells had adhered to the surface of the well, 
they were treated with cisplatin at a range of 2 to 30 µM for 2h. The 
medium was then replaced with drug-free medium. Cells were then 
incubated for 1-2 weeks. Cells were fixed with 4% paraformaldehyde 
then stained with 0.5% crystal violet to identify the surviving cells.  
The number of colonies that survived after the treatment was 
counted under microscope. The following equation was applied to 
measure the surviving fraction which determines the significant 
improvement in response towards chemotherapy. 
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Using this assay, YST-PRDM14 cell lines showed no consistent 
response to cisplatin treatment with different concentrations compared 
to untransfected YST. YST-PRDM14 cells showed more sensitivity to 
cisplatin with low concentrations compared to untransfected YST cell (10 
and 15µM) then showed resistance to cisplatin with high concentrations 
(20-30µM) (Figure 5.9).  
 
 
 
 
 
 
 
 
 
                                        Number of colonies formed  
Plating efficiency (PE) =                                                X 100 
                                           Number of cells seeded  
 
                                       Number of colonies formed after treatment  
Surviving fraction (SF) =  
                                                   Number of cells seeded x PE 
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Figure 5.9: Colongenic assay: A) Surviving fraction after 
cisplatin treatment showed that there is no significant change in 
response to cisplatin after overexpression of PRDM14. B) 
Average number of colonies after cisplatin treatment showed 
that PRDM14 did not improve response to cisplatin treatment. 
Error bars represent standard error of three biological triplicates. 
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5.2.6. Sensitivity towards cisplatin after inhibition of DNA 
methylation in PRDM14 positive YST cells  
It has been suggested that hypermethylation is related to 
resistance to chemotherapy in many cell lines such as ovarian cancer 
and NSCLC (Yu et al., 2011, Zeller et al., 2012, Zhang et al., 2014). 
Also, demethylating agents (5-aza) enhance sensitivity of several 
tumour cell lines towards cisplatin (Appleton et al., 2007).  
In this study, it was confirmed that PRDM14 is highly expressed in 
hypomethylated seminomas and silenced in hypermethylated YST and 
re-expression of PRDM14 in YST cells led to demethylation of DNA. 
Therefore, we expect from reviewing previous literature and from our 
results that overexpression of PRDM14 may reduce methylation in YST 
and so promote sensitivity of YST cells towards cisplatin (as summarised 
in Figure 5.10). Untransfected YST cells and stably transfected PRDM14 
cells were treated with (5µM) of 5-aza for 24 hours then the medium 
was changed with drug-free medium for one day after that the cells 
were subsequently exposed to cisplatin at a range of 10 to 30 µM for 2 h 
then the medium was refreshed with drug-free medium for 24h. Viable 
cells were counted by a haematocytometer.  
Overexpression of PRDM14 showed a higher response rate to 
cisplatin after global demethylation in PRDM14 positive YST cells 
compared with their counterparts. The result revealed that PRDM14 in 
combination with 5-aza can significantly (p= 0.02) induce cisplatin-
induced cytotoxicity (Figure 5.11).  
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Figure 5.11: Sensitivity towards cisplatin concentrations: 
Response of cells to cisplatin after using 5µM 5-aza showed 
that there was increased in response to cisplatin after 
overexpression of PRDM14. Percentage of surviving cells 
showed that PRDM14 with 5-aza significantly improve 
response of cells to cisplatin (10-30µM) (*denotes p-
value<0.05, **denotes p-value <0.01, and ***denotes p-
value < 0.001 using a paired t-test). Error bars represent 
standard deviation of three biological triplicates. 
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5.3 Discussion 
Studies in normal embryonic stem cells (ESCs) revealed that 
PRDM14 is expressed at much lower levels than in PGCs (Yamaji et al., 
2013, Grabole et al., 2013) which suggested that PRDM14 could play 
role in the development or progression of GCTs. Moreover, it was 
pointed that knock-down of PRDM14 led to differentiation of PGCs to 
extraembryonic endoderm (Ma et al., 2011) or embryonic cell (Yamaji et 
al., 2013). This study showed that PRDM14 is differentially methylated 
and expressed in YST compared to SEM cell lines which supports a role 
of PRDM14 in the biological differences between those two types of 
GCTs.          
Recent attention has focused on the importance of PRDM14 
associated demethylation in the differentiation of PGCs (Okashita et al., 
2014). Several studies have demonstrated that overexpression of 
PRDM14 contributes to maintenance of pluripotency in ESCs by 
repressing the methylation machinery (Grabole et al., 2013, Yamaji et 
al., 2013).  
In this chapter, the role of PRDM14, which is methylated and 
silenced in YST, in the biology of GCTs was tested by assessing the 
effects of increasing expression of PRDM14 in three aspects; the 
regulation of the expression of selected genes, the global methylation 
levels, and the sensitivity towards cisplatin.  
The results showed that overexpression of PRDM14 promotes 
upregulation of some pluripotency associated genes (KLF2, KLF4, OCT-
4) as well as RAS associated gene (RASSF2), and TDRD12 (also known 
as ECAT8). This result is consistent with studies that revealed that 
PRDM14 regulates the pluripotency process by regulating pluripotency 
associated genes (Ma et al., 2011, Chan et al., 2013). A recent study 
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reported that PRDM14 is considered a unique regulator for pluripotency 
genes (Nakaki and Saitou, 2014), thus increased expression of  PRDM14 
may maintain seminomas in an undifferentiated state. The effect of 
PRDM14 expression in regulating TDRD12 and RASSF2 has not yet been 
examined in other studies. This work has demonstrated that RASSF2 
and TDRD12 are differentially methylated and expressed in YST 
compared to seminoma (hypomethylated and expressed in seminoma). 
Therefore, PRDM14 may regulate TDRD12 and RASSF2 indirectly by its 
hypomethylation action. Guerrero-Setas et al. (2013) pointed out that 
RASSF2 is silenced by hypermethylation and involved in the progression 
of many cancers so it is hypothesized that there is an underlying 
pathway for progression of GCTs, which could involve upregulated 
RASSF2 by a demethylation action through overexpression of PRDM14. 
With regard to TDRD12 , Almatrafi et al. (2014) revealed that TDRD12 is 
a human cancer germline gene that has expression restricted to the 
germ cells of the gonads, therefore TDRD12 might also be involved in 
GCT biology.  
The second aspect of the role of PRDM14 in the biology of GCTs 
was assessing the methylation level in YST cells when PRDM14 was 
overexpressed. There is a rapidly growing literature supporting a role of 
PRDM14 in epigenetic reprogramming during germ cell development via 
demethylation of DNA in PGCs. Some have suggested that this process 
occurs in combination with expression of other genes such as Blimp-1 
and Prmt5 (Nagamatsu et al., 2011). Our result showed that 
overexpression of PRDM14 alone can decrease the level of methylation 
so our study supports other research that considered PRDM14 alone is a 
key trigger for the genome-wide DNA demethylation in PGCs directly by 
recruiting the chromatin regulator polycomb repressive complex 2 
(PRC2) and PRC2 and repressing Dnmt3b and Dnmt3l resulting in 
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demethylating DNA (Nakaki and Saitou, 2014, Burton et al., 2013, Chan 
et al., 2013).  
Generally, seminoma cells (where PRDM14 is highly expressed 
compared with YST cells) are extremely sensitive to cisplatin-based 
chemotherapy drugs, while YST cells are known as more aggressive and 
chemoresistant. Seminoma is classified as the low/or intermediate risk 
group of GCT types. It responds well to traditional oncology treatments 
based on the characteristic of its cells (Looijenga et al., 2011).  
Some studies have identified a number of genes capable of driving 
chemoresistance or chemosensitivity of cancer cells such as a study by 
Whitehurst and colleagues (2007), which identified a number of cancer 
testis genes that might be involved in chemotherapeutic resistance. 
Others revealed that DNA demethylation increases sensitivity of 
neuroblastoma cancer cells to chemotherapy by controlling the 
expression of specific genes such as CASP8 and RASSF1A, which play a 
critical role in apoptosis and mitotic arrest, resulting in impaired 
resistance to cisplatin treatment thus enhancing cell apoptosis (Charlet 
et al., 2012). Therefore, manipulation of epigenetic modifications may 
provide a novel epigenetic therapy for cancer. 
The effect of overexpressed PRDM14 on sensitivity to 
chemotherapy was investigated in this study after inhibition of DNA 
methylation by 5aza in PRDM14 positive YST cells. The results showed 
that PRDM14 supported the cytotoxic effects and apoptosis of cisplatin 
after using 5-aza on YST cells in culture. But when the sensitivity of 
overexpressed PRDM14 YST cells to cisplatin was assessed without using 
demethylation agent 5-aza, the result showed no effect. In conclusion, 
overexpression of PRDM14 could promote sensitivity of cells towards 
cisplatin in combination with 5-aza. The findings agree with other 
studies showed that using 5-aza in combination with chemotherapeutic 
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drugs could be useful to enhance more sensitivity to chemotherapy 
(Beyrouthy et al., 2009, Charlet et al., 2012, Liu et al., 2015).  
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Chapter 6. Genomic screening for genes upregulated by 
demethylation revealed novel targets of epigenetic 
silencing in GCTs  
6.1 Introduction 
Recently, there is an increased interest in the effect of epigenetic 
alterations on certain diseases where some studies demonstrated that 
epigenetic abnormalities are implicated in the development of many 
different types of cancer and could be more destructive than genetic 
mutations (Rothstein et al., 2009, Charles et al., 2012). Moreover, 
several studies revealed that epigenetic mechanisms such as DNA 
methylation and histone modifications could play a key role in the 
development of chemoresistance to existing drugs (Kelly et al., 2010, 
Crea et al., 2011, Zhang et al., 2014).  
Therefore, epigenetic cancer therapy studies that focus on 
creating new anti-cancer treatments that target the epigenome and 
identification of candidate methylated genes that are implicated in the 
tumourigenesis or drug resistance hold a great promise for overcoming 
such aggressive diseases in the future. Additionally, there is a 
suggestion that inhibition of hypermethylation events that occur early in 
development of tumours could be a good strategy to identify genes that 
are silenced by methylation. Several studies may have a potential 
diagnostic and prognostic significance or could reveal a potential 
mechanistic explanation for why some cells are more resistant to 
chemotherapy than others. 
Therefore, the identification of methylation profiles in many 
cancers (Esteller, 2011) and methylation marker genes of each tumour 
(Hartmann et al., 2009) could be used to further understand and 
diagnose the diseases or treatment plans where each type of cancer has 
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a unique DNA methylation pattern and CGI hypermethylation profile 
(methylotype).  
According to my previous results, that showed a clear difference in 
methylation between YST (as YST showed uniquely distribution of 
methylated region and genes compared with two other types of non-
seminomas) and SEM cell lines, the experiment was carried out focusing 
on comparing the methylation status between SEM and YST cell lines. I 
hypothesised that such methylation differences may reflect functional 
differences between the two common types of GCT, seminomas and 
non-seminomas. 
The aim of my work described in this chapter was to identify 
dysregulated genes which might be silenced by methylation in GCT cell 
lines by treating the hypermethylated YST cell line with the 
demethylating drug (5-aza) then performing a genome wide screen 
using microarray analysis to assess the expression profile of treated and 
untreated cells. 
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6.2 Results 
6.2.1 Cytotoxic assay 
Previous studies have demonstrated that 5-aza treatment leads to 
re-expression of specific genes in different cancer types using a wide 
range of concentrations and treatment regimens. Previous studies using 
5-aza in GCT cell lines also used several regimens, so there was no 
agreed protocol to treat YST cell line with 5-aza. 
 Importantly, the inhibition of methylation by 5-aza should be 
used at a non-toxic concentration to reactivate silenced genes. This drug 
inhibits DNA methylation by incorporating into the DNA during DNA 
synthesis (Chik and Szyf, 2011) and by depletion of DNA 
methyltransferases (Ghoshal et al., 2005). However, 5-aza is highly 
toxic, each type of human cancer cell having a different sensitivity to 5-
aza treatment (Zhu et al., 2004). In addition to concentration of dose, 
Momparler and Goodman (1977) found in their in vitro studies on 5-aza 
that exposure time plays an important role in its activity and cytotoxic 
effect.  
Considering these issues, a cytotoxicity assay was performed to 
determine the half maximal inhibitory concentration (IC50) of this drug 
on the highly methylated cell line (YST) (leading to 50% cell death in 
treated cells compared with untreated cells). Three independent 
experiments were performed, with each experiment performed in three 
triplicates following the protocol described in section 2.2.2.1. Cells were 
plated at 2x104 cells per well in a 6-well plate. After 24/48/72 hours 
(Figure 6.1 -A), cells were treated with different concentrations of 5-aza, 
ranging from 1 to 30 µM. Media were replaced subsequently with a 
drug-free media then cells were harvested in a time course assay. The 
viable cells in each well were counted using a haemocytometer. The 
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results showed that the optimal concentration and time for treatment 
with 5-aza was 10µM for 24 hours then the cells were harvested after 2 
days of treatment  
IC50 tool kit program (www.ic50.tk) was used for dose-response 
experiments to calculate the inhibitory concentrations IC50 value and to 
get sigmoidal curve-fitting. For treated YST compared with untreated 
control, IC50 was approximately 10µM (IC50=8.98169 +/- 1.964) 
(Figure 6.1 B). 
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Figure 6.1: Cytotoxicity assay on the YST cell line.  
A) Cells were treated with different concentrations of 5-aza, then 
harvested at different times. The optimal concentration and time for 
treatment with 5-aza were 10µM for 24 hours, with cells harvested after 
two days. 
B) The IC50 for treated YST compared with untreated controls was 10µM 
(IC50=8.98169 +/- 1.964). 
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6.2.2 Correlation between aberrant DNA methylation and 
silencing of gene expression 
Many studies in recent years have revealed that treatment of cells 
with 5-aza-2-deoxycytidine verifies that 5-methylcytosine plays an 
important role in gene regulation (Luo et al., 2009, Yuan et al., 2004, 
Baylin, 2005, Zheng et al., 2012, Moore et al., 2013).  
To test the hypothesis that aberrant DNA methylation affects GCT 
cells by altering gene expression, the approach used is shown in (Figure 
6.2). Through this approach, YST cells were treated with 10µM 5-aza to 
identify which genes were silenced by methylation. After treatment, RNA 
was extracted and the quality of total RNA in each sample was 
determined by Agilent 2100 Bioanalyzer (Figure 6.3, Figure 6.4, and 
Table 6.1).   
 
 
 
 
 
 
 
 
 
 
5-aza-treated YST cell line Untreated YST cell line 
Gene expression microarray 
After treatment, silenced genes re-expressed 
 
Methylated profile of genes in TGCT cell lines 
(Methylation array Illumina 450K) 
                        + 
Expressed profile of genes in TGCT cell lines 
(Expression array Affymetrix U133) 
Identify which genes are silenced by 
methylation 
Combined 
Figure 6.2 Schematic of the experimental approaches: YST cell line was 
treated with 5-aza then gene expression microarray carried out for treated and 
untreated cells to detect upregulated genes. Combining the data with that 
previously generated, Methylation array Illumina 450K and Affymetrix 
expression array U133 for TGCT cell lines, the genes that silenced by 
methylation were identified. 
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Sample 1b 
rRNA ratio [28s/18s] = 2.0   RIN = 10   RNA conc = 92ng/ul 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.3: The RNA integrity number (RIN) for one YST cell line 
sample (1b): The RNA integrity measurement was performed by 
Agilent 2100 Bioanalyzer software, which showed a high integrity of 
RNA (10). 
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Table 6.1: Concentration and integrity number of RNA samples. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sample Concentration 
(ng/μl) 
RNA integrity 
number (RIN) 
rRNA ratio 
[28s/18s] 
Control- untreated YST (1a) 71 10 2.1 
Control- untreated YST (1b) 92 10 2 
Treated YST-2days (2a) 168 10 2 
Treated YST-2days (2b) 89 10 2 
Treated YST-8days (8a) 129 10 2.1 
Treated YST-8days (8b) 120 10 2.2 
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Figure 6.4: Gel-like image of RNA samples on Agilent 2100 
Bioanalyzer: RNA samples were separated and detected by laser 
fluorescence beam. Bioanalyzer software generated a gel-like 
image that estimated the intactness of RNA based on the size 
distribution of ribosomal RNA subunits (18S and 28S ratios).  
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After determining the concentration and the quality of RNA 
samples, samples (1b, 2b, and 8b) were sent to Nottingham Arabidopsis 
Stock Centre at Sutton Bonington campus at the University of 
Nottingham for further analysis using Affymetrix HumanGeneChip U133 
Plus 2.0 arrays. The raw data of microarray assay was stored as a CEL 
files then pre-processed using the statistical software R (Appendix II). 
Data was filtered such that probes which showed expression below 
control background were excluded. Fold changes in expression between 
each probe of treated cells relative to untreated cells were calculated. 
The data was exported as a txt file then analysed in Excel.  
Analysis of the comparative gene expression before and after 
treatment (for two time-points) identified a set of genes that were re-
expressed following demethylation where the significant differences in 
their expression were more than 2 fold changes at two or eight days 
(Figure 6.5). Twenty-three genes were upregulated after two days of 
treatment and twenty-two genes at eight days, while five genes were 
upregulated at both days (Table 6.2).  
 
 
 
 
 
 
 
 
18 17 5 
2 day 8 day 
Figure 6.5: number of genes 
upregulated after treatment 
at two time points.  
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Table 6.2: List showed some genes re-expressed at one day of 5-aza   
                treatment and others re-expressed at two days.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Gene 
Fold change  Expression level 
Methylation 
level 
(Beta) 
2d 8d 
Untreated 
YST 
treated 
SEM YST SEM 
2day 8day 
EPCAM 0.44 2.16 20.81 28.32 93.23 10631 0.9 0.12 
SOX17 2 1.6 21.5 80.79 69.35 917.1 0.9 0.1 
HIST1H4C 3.65 3.39 37.82 474 396 1605 0.9 0.12 
APOB 3.45 4.56 36.46 397 858 31.43 0.51 0.66 
FIGNL1 2.12 2.27 14.55 63.59 70.19 1071 0.81 0.24 
CTHRC1 1.01 2.04 8.83 17.81 36.32 3138 0.94 0.06 
PTPRO 2.22 1.56 597 2776 1758 334 0.6 0.14 
PPFIA4 2.07 0.72 33.01 138.6 54.3 33.9 0.9 0.9 
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6.2.3 Identification of novel dysregulated genes which might be 
silenced by methylation in TGCT cell lines         
To indicate which methylated genes were upregulated after 
treatment, I combined the results of expression microarrays that were 
performed for testicular GCT cell lines and treated YST cell line to 
compare the expression of genes before and after treatment with 5-aza. 
Then I used the data from published microarray experiments for normal 
testicular cells as a control (GEO accession: GSM380048) for comparing 
the gene expression at normal condition. 
Five methylated genes (APOB, FIGNL1, HIST1H4C, MAGEB2, and 
TCEAL7) were re-expressed after treatment at two time points (2d and 
8d). Three of those genes (FIGNL1, HIST1H4C, and TCEAL7) were 
expressed in normal testicular cells while others were silent. When 
comparing the expression and methylation levels of these genes in YST 
with seminoma, there was a significant difference in expression with fold 
change > 2 in these three genes. FIGNL1 and HIST1H4C were also 
differentially methylated in promoter CGIs between YST and seminoma. 
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6.2.4 Validation of microarray data 
To validate microarray data, some genes were selected, according 
to three criteria; they showed differential expression and differential 
methylation between SEM and YST, their expression were very high in 
SEM, and re-expressed after 5-aza treatment. RT-qPCR was carried out 
for the same RNA samples that were sent for Affymetrix expression 
array analysis. The threshold cycle (Ct) values of each sample were 
defined by automated machine thresholds and the relative expression 
level of each gene was calculated according to the Pfaffl equation 
comparison with the housekeeping gene (β-actin).  
The expression of the first two genes in table 6.2 (EPCAM and 
SOX17) which showed the above three criteria, were examined by PCR 
and qPCR (Figure 6.6 and 6.7) to validate the microarray results. As 
illustrated in figure 6.7 for qPCR analysis, the expression of those two 
genes upregulated after treatment of YST cell lines with (10µM) 5-aza 
comparing to untreated YST but still less than their expression in the 
seminoma cell line. The results of PCR and qPCR expression analysis for 
these candidate genes indicated that Affymetrix expression array data 
truly reflected the gene expression changes in response to 5-aza 
treatment. 
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Figure 6.6: Reverse-Transcriptase PCR was carried out for the 
selected methylated genes in four cell lines.  
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Figure 6.7: RT-qPCR results indicate that Affymetrix expression array data 
truly reflected the expression changes in response to 5-aza treatment. 
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6.3 Discussion  
The role of aberrant DNA methylation in reprogramming gene 
expression and development of cancer has been studied using the 
hypomethylating agent, 5-aza (Beyrouthy et al., 2009) which reduces 
the level of DNA methylation and causes changes in treated cells such 
as activation of silent genes, inhibition of DNA methyltransferases, and 
decondensation of chromatin (Jüttermann et al., 1994). Jones and 
Taylor (1980) suggested that 5-azacytidine experiments could provide 
early clues to the impact of DNA methylation on gene expression. 
Treatment of the hypermethylated YST cell line with 5-aza and analysis 
of the gene expression in these cells before and after treatment using 
microarray assay, showed five methylated genes (APOB, FIGNL1, 
HIST1H4C, MAGEB2, and TCEAL7) re-expressed after treatment and 
three of those genes (FIGNL1, HIST1H4C, and TCEAL7) were expressed 
in normal testicular cells while others were silent. When comparing the 
expression and methylation levels of these genes in YST with seminoma, 
there was a significant difference in expression. FIGNL1 and HIST1H4C 
were also differentially methylated at CGI between YST and seminoma. 
This finding suggested that CGI methylation could be causative of 
reduced gene expression in those genes. Future research should 
therefore be concentrated on those methylated silenced genes that 
showed stable re-expression after DNA demethylation to provide a 
better understanding of the correlation of methylation and expression in 
GCTs. 
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Chapter 7. General discussion 
7.1 Methylation profile of GCT cell lines 
The first conclusion derived from the results in this thesis is that 
non-seminoma cells have more methylated CpGs than seminoma cells, 
which is consistent with previous studies (Smiraglia et al., 2002, 
Jeyapalan et al., 2011). The similarities and differences between the cell 
lines revealed that the YST cell line had the highest number (270 genes) 
of uniquely methylated genes relative to others, whereas only 16 genes 
were uniquely methylated in the SEM cell line. The difference in 
methylation status in two common GCT subtypes (seminomas and non-
seminomas) could be due to the time point of their developmental arrest 
(Okamoto and Kawakami, 2007), where the histological and phenotypic 
characteristics of each type of GCT are dependent on the degree of 
differentiation (Wermann et al., 2010).  
7.2 Progression of GCTs 
The difference of methylation level between SEM and non-
seminoma cell lines support the suggestion that methylation may play a 
critical role in the progression of this tumour and could help to 
determine the degree of differentiation of the tumour cells (Wermann et 
al., 2010) as both subtypes develop and differentiate from the same 
hypomethylated progenitor cells (PGCs) (Almstrup et al., 2010). PGCs 
undergo methylation erasure and become completely unmethylated at 
early phases of migration (Lind et al., 2007). There is evidence that 
mismaturation of PGCs during embryogenesis leads to the formation of 
CIS, then testicular seminomas subsequently arise from CIS (Netto et 
al., 2008). The finding that seminoma cells are similar to normal 
testicular tissue in methylation status and the difference in methylation 
between seminomas and non-seminomas both support the hypothesis 
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that seminomas could be progressed to non-seminomas by gaining 
methylation (Netto et al., 2008) (Figure 7.1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.1: Model representing the progression of testicular GCTs. In 
this current model, mismaturation of PGCs leads to formation of CIS. 
By gaining methylation, it is suggested that non-SEM differentiate from 
SEM or directly from CIS. 
PGCs 
Blocking or delaying 
maturation 
CIS 
SEM 
Non-SEM 
Normal 
germ cells 
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The nonrandom pattern of methylation that is observed during 
development, where DNA methylation is erased during zygote formation 
and re-established after implantation (Jin et al., 2011), demonstrates 
that there is an underlying biological mechanism leading to regulated 
expression of specific genes by methylation. DNA methylation is 
established in early development by de novo methyltransferases 
DNMT3A and DNMT3B and maintenance by DNA methyltransferase 
DNMT1 (Bird, 2002) to regulate gene expression in germ cells during 
embryogenesis (Messerschmidt et al., 2014) (summarised in Figure 
1.3). But the mechanism of gains of methylation in non-seminomas 
types of GCTs remains under investigation. There are some possible 
mechanisms that lead to hypermethylation status of non-seminomas. 
One of them is through overexpression of DNA methyltransferases 
(DNMTs) which has been reported in many cancer studies (Etoh et al., 
2004, Teodoridis et al., 2008). Several studies show that DNMT3L 
expression is very low in many normal cells such as testis, ovary and 
thymus (Aapola et al., 2004) but high in GCTs. DNMT3L is essential for 
normal development during embryogenesis and it is expressed in testis 
to form prospermatogonia during the perinatal period (Aapola et al., 
2004). Its expression then decreases sharply after birth when 
prospermatogonia differentiate to spermatogonia. Okamato (2012) 
found that the presence of embryonal carcinoma is associated with high 
expression of DNMT3L in male mice after birth and suggested that 
DNMT3L could be used as specific marker for the diagnosis of human 
embryonal carcinoma (EC) (where EC in that study was considered as a 
malignant counterpart of human embryonic stem cells that differentiate 
into non-seminoma). DNMT3L is recognised as a regulatory factor for 
the de novo DNA methylation process (Chédin et al., 2002) and 
therefore it could contribute to an increase methylation in the non-
seminomas. 
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Another possible mechanism for hypermethylation is through 
reduced expression of the TET proteins (Williams et al., 2012), leading 
to gain of DNA methylation (Huang and Rao, 2014). Therefore, it is 
suggested that down regulation of TET protein could potentially 
contribute in the hypermethylation status of the non-seminomas. 
However, mechanisms related to increased DNMT or decreased TET 
enzyme expression could also explain the differences in methylation 
level in CGI of specific genes in YST.  
Several studies have reported that aberrant promoter 
hypermethylation leads to suppression of specific tumour suppressor 
genes (TSG) and thus development or progression of different human 
cancers (Astuti et al., 2001, Burbee et al., 2001, Dammann et al., 2001, 
Honorio et al., 2003). Among those genes are MLH1 and MTS1 in 
testicular GCTs (Chaubert et al., 1997, OLASZ et al., 2005). Chaubert et 
al. (1997) suggested that silencing of hypermethylated MTS1 plays a 
role in the development of GCTs, while Olasz et al. (2005) found that 
hMLH1 hypermethylation status correlates with the loss of its protein 
expression leading to microsatellite instability. 
Moreover, Honorio et al. (2003) pointed out that although 
mutations of RASSF1A are rare, promoter hypermethylation and 
transcriptional silencing of RASSF1A were detected in neuroblastoma, 
breast, lung, and kidney cancers (Dammann et al., 2001, Burbee et al., 
2001, Astuti et al., 2001, Morrissey et al., 2001). Four independent 
studies revealed that RASSF1A is hypermethylated in non-seminomas 
versus seminoma (Koul et al., 2002, Lind et al., 2007, Jeyapalan et al., 
2011) and other studies concerned with the role of this gene in GCTs 
found that promotor methylation of RASSF1A occurs early in the 
development of GCTs and it was concluded that the inactivation of 
RASSF1A could play a role in progression of seminoma to non-seminoma 
(Christoph et al., 2007, Tian et al., 2011). Thus, more studies are 
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needed to give evidence about the role of these candidate genes in 
aberrant methylation and progression of GCTs and other cancers. 
7.3 CpG Island Methylator Phenotype (CIMP) 
This study revealed high levels of methylation in or around CGIs of 
a subset of genes in YST correlated well with gene silencing, which 
supports the CpG island methylator phenotype (CIMP) seen in other 
cancers such as colorectal cancers (Toyota et al., 1999) and gliomas 
(Noushmehr et al., 2010). 
Notably, analysis of EC and teratoma cells showed that the 
methylation of most CpGs sites in these cells was higher than 
seminoma, not just in island regions but also across CpGs in all regions 
which means that the hypermethylation status of these cells, EC and 
teratoma did not represent CIMP.  
The cause of CIMP in specific genes and the mechanism for this 
phenomenon, where methylation in CGIs result in gene silencing, 
remains unclear. However, there are some suggestions that need more 
investigation. One acceptable possibility was proposed by Turker (2006) 
who suggested a model to explain the cause and mechanism of aberrant 
DNA methylation at CGIs, leading to silencing of specific gene (Figure 
7.2). The author proposed that genes are more susceptible to CIMP 
when they have a distinct short sequence close to the promoter, called a 
‘methylation center’, which attracts de novo DNA methyltransferases 
based on specific features of this center such as the presence of 
retrotransposons. Aberrant DNA methylation starts in the methylation 
center then spreads to reach the TSS, leading to inactivating of the gene 
if there is no barrier system protecting against such methylation 
spreading.   
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Figure 7.2: A model of proposed CIMP mechanism in cancer: A) A 
gene is not susceptible to CIMP when the methylation center is 
away from the TSS. B) A gene is susceptible to CIMP when the 
methylation center is close to the promoter but there is a specific 
barrier (could be transcription factor or co-activator) that prevents 
spreading methylation to TSS. C) CIMP and transcriptional 
suppression occur when spreading of methylation blocks the 
promoter.  
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7.4 CGI methylation is negatively correlated with gene 
expression 
Methylation of CGIs in or near gene promoters was more strongly 
correlated with reduced gene expression than other regions. However, 
the results showed that increasing methylation of CGIs in the gene body 
was also more strongly associated with gene silencing than activation. 
There was a strong correlation between high methylation of CGIs in the 
gene body with suppression of gene expression, in regardless of 
whether this association was seen also in the CGI promoter region. 
However, this finding is contrary to the results of some other genome-
wide sequencing studies, which revealed that DNA methylation of gene 
bodies correlates with gene activation rather than silencing (Lister and 
Ecker, 2009, Ball et al., 2009, Yang et al., 2014). The expression of 
genes in those studies could be related to the presence of ncRNAs (non-
coding RNA) that regulate gene expression (Mercer et al., 2009, Deaton 
and Bird, 2011) rather than CGI in the body region or may be the CGIs 
in the gene body work functionally as alternative promoters for some 
genes (Carninci et al., 2006, Maunakea et al., 2010)  
Recent studies showed that differential methylation status of 
regions other than CGI to be more closely related to regulation of gene 
expression. Irizarry et al. (2009) found that methylation status of CpG 
shores was associated strongly with gene expression in colon cancer. 
While Rao et al. (2013) showed hypermethylation of CGI shores to be 
negatively correlated with Cav1 expression in breast cancer. More 
recently, a study in medulloblastomas using next-generation-sequencing 
data analysis and whole-genome bisulphite sequencing showed that CGI 
shore methylation is most closely related to gene expression (Hovestadt 
et al., 2014). However, it seems that methylation of specific regions in 
the genome, such as island and shores, is significantly associated with 
control of gene expression but more research is needed to detect if 
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these regions are specific for the same genes in each cancer or varies 
between different cancers. 
7.5 Identification of regulatory genes that most likely 
contribute to the phenotypic differences observed between 
seminomas and non-seminomas 
Combining both methylation and expression data identified genes 
whose expression could be altered by methylation and appeared likely to 
be causative of phenotypic differences between seminomas and non-
seminomas. In depth study of protein pathways and the interaction of 
those genes, that were methylated and silenced in YST relative to SEM 
could reveal potential mechanisms that cause differences in phenotypes 
and sensitivity to chemotherapy between these two types of tumours. 
This study identified a list of genes that were both differentially 
methylated and expressed between GCT types by analysis of Illumina 
450k array and Affymetrix expression array data. Twenty-one out of 108 
genes silenced in the YST cell line were differentially methylated and 
expressed in non-seminoams was relative to seminomas in cell lines and 
in primary tumour samples. Six of them (KLF4, TDRD12, DDX43, MNS1, 
RBMXL2 and PRDM14) are associated with PGCs and/or pluripotency.  
KLF4 is a transcription factor that plays a role in the regulation of 
differentiation and proliferation. KLF4 is highly expressed in PGCs (Behr 
et al., 2007), seminomas, and CIS (Godmann et al., 2009). In our 
expression data, KLF4 expression was high in seminoma and silenced in 
YST, which suggests that repression of KLF4 by methylation in YST may 
represent the differentiation status of this tumour from the pluripotent 
cells in CIS towards differentiated YST cells (Li et al., 2005, Maruyama 
et al., 2005)  
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The other identified genes (TDRD12, DDX43, MNS1, RBMXL2) 
have particular roles in reproductive processes and male gamete 
production and are therefore known as testes specific genes (Mathieu et 
al., 2010, Pandey et al., 2013, Greenbaum et al., 2011, Zhou et al., 
2012). TDRD12 (tudor domain-containing protein) plays a role in the 
biogenesis of piRNAs which are also testis specific (Pandey et al., 2013). 
Expression of DDX43 and MNS1 is restricted to the normal testes tissue. 
DDX43 (also called HAGE), encodes a ‘cancer testis antigen’, and is an 
RNA dependent helicase which is also expressed in many cancers 
(Mathieu et al., 2010). MNS1 (Meiosis-specific nuclear structural1) is 
involved in spermiogenesis (Zhou et al., 2012). RBMXL2 (also called 
hnRNP G-T) is a heterogeneous nuclear ribonucleoprotein and known as 
a germ-cell specific splicing regulator (Greenbaum et al., 2011). 
However, the silencing of these genes by methylation in non-seminomas 
could contribute to phenotypic differences between seminoma and YST 
or may play a role in the differentiation. In order to validate that those 
genes are causative of a phenotypic difference between seminoma and 
YST, overexpression/loss of function studies should be applied.  
PRDM14 is an important gene that needs more analysis because it 
has been demonstrated that PRDM14 plays an important role in germ 
cell development and specification (Magnúsdóttir and Surani, 2014), 
maintenance of germ cell pluripotency (Grabole et al., 2013) and 
recently it was investigated as a demethylation factor in germ cells 
(Okashita et al., 2014). 
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7.6 Role of PRDM14 in demethylation  
PRDM14 is a zinc finger transcription factor that regulates 
pluripotency factors to maintain the pluripotent state in PGCs by 
suppressing the differentiation genes (Grabole et al., 2013). Ma et al. 
(2011) found that knockdown of PRDM14 in mouse ESCs led to 
differentiation to extraembryonic endoderm fates which are similar to 
that observed in YST tumour cells (Oosterhuis and Looijenga, 2005). In 
our data, PRDM14 was expressed in seminoma and silenced in YST, 
which suggests that silencing of PRDM14 by methylation could result in 
progression of seminoma to non-seminomas. 
PRDM14 function is also related to DNA demethylation (Grabole et 
al., 2013) and may inhibit the transcription of DNA methyltransferases, 
in particular DNMT3B and DNMT1. PRDM14 could trigger passive DNA 
demethylation by inhibition of the maintenance activity of DNA 
machinery during de novo DNA synthesis in DNA replication 
(Magnúsdóttir et al., 2013).  
Moreover, PRDM14 may cause active DNA demethylation through 
the TET-BER cycle, but the precise mechanism associated with TET-BER 
cycle remains unclear (Okashita et al., 2014). TET proteins (TET1 and 2) 
enzymatically oxidise 5’methyl-cytosine (5mCpG) to 5 hydroxymethyl-
cytosine (5hmCpG) then 5hmC is further oxidized by TET proteins to 
produce formyl-cytosine and 5 carboxyl-cytosineare, where the later 
forms are subsequently repaired by thymine DNA glycosylase (TDG) and 
the base excision repair (BER) pathway, TDG/BER repair pathway, to 
form 5CpG (Okashita et al., 2014) (Figure 7.3). It has been suggested 
that methylated cytosine is converted to cytosine in an active 
demethylated pathway, therefore PRDM14 could play a critical role in 
this pathway. In addition, differential expression of PRDM14 in 
seminoma relative to non-seminoma could be causative of differential 
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             Pathway    
             Protein expression  
             Gene expression  
methylation seen in seminoma compared with non-seminoma, through 
accelerating TET protein function to active demethylation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5CpG 
5mCpG 
5hCpG 
PRDM14 
TET1/2 
5f CpG/5caCpG 
TET1/2 
DNMT 
Figure 7.3: A scheme for active and passive DNA demethylation by 
PRDM14: Active demethylation action of PRDM14 promotes the 
TET/BER pathway to convert 5mCpG to unmodified 5CpG, while 
passive demethylation based on overexpression of PRDM14 may 
suppress transcriptional expression of DNA methyltransferases.  
TDG/BER 
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7.7 Cell lines as a useful model for methylation studies 
Primary tumour methylation data was analysed and compared 
with the methylation data of the corresponding cell lines. The results 
showed differential methylation between seminoma and non-seminoma 
in both cell lines and primary tumour, supporting the hypothesis that the 
methylation level in the cell lines reflects that seen in primary tumours 
(Barretina et al., 2012). A significant correlation between CGI 
methylation and gene silencing is clear in this study. To determine 
whether DNA methylation is the cause of gene silencing, The cell lines 
was used as a model to verify that removing methylation, by using the 
DNA-demethylating agent 5-aza-2-deoxycytidine, led to re-expression of 
the selected genes. Cell lines provide an advantage for testing drugs or 
compounds because repeating the experiment many times on 
genetically identical cells. Selected genes were found to re-expressed 
after treatment with demethylating agent (5-aza), indicating that 
methylation could be a key factor in silencing of those genes, which 
were differentially expressed in non-seminomas versus seminomas in 
cell lines and were also differentially expressed in primary tumour study 
(Palmer et al., 2008). Comparison of expression data of cell lines with 
expression data from a paediatric GCT samples and primary tumour 
samples, the findings support the hypothesis that expression status in 
the cell lines between seminoma and non-seminoma is similar to that 
seen in primary tumours. This result is consistent with the finding of 
Ueki et al. (2002), who found that the methylation status of most 
tumour suppressor genes in pancreatic cell lines is similar to that in 
corresponding primary tumours. Despite the wide spread use of cell 
lines in cancer research for investigation of genetics and epigenetics 
studies where the results are usually extrapolated to the primary 
tumours, Smiraglia et al. (2001) reported that the hypermethylation 
seen in some cancer cell lines was not reflected in primary tumours. 
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However, an alternative interpretation of the observations in their study 
is that they did not compare cell lines to the actual tumour of origin 
from which those cell lines were derived. For example, they compared 
the NCCIT cell line (non-seminoma cell line) derived from human 
embryo placenta with primary testicular GCTs. Therefore, they found 
differences between cell lines and primary tissue in methylation 
analysis. Another explanation for their observations is that the cell lines 
represent a minority population of tumour cells from which they were 
derived. Moreover, the result of comparing tumour cell lines with normal 
control tissues showed that levels of methylation in seminoma closely 
resemble that of normal tissues, which supported the studies 
demonstrating clustering of seminomas with normal testicular tissue 
based on methylation levels (Jeyapalan et al., 2011). Despite the 
comments of Smiraglia et al. (2001), the use of tumour cancer cell lines 
as a tool, in genetic and epigenetics studies, is widely accepted (Ueki et 
al., 2002, Kao et al., 2009, Gazdar et al., 2010).  
7.8 Potential therapeutic applications targeting DNA methylation 
Many of the results in this study highlighted the potential role of 
DNA methylation in many biological processes and provide further 
insights into the possibility of targeting DNA methylation in the future 
for cancer therapy in several ways.  
First, distinguishing between two subtypes of the same class of 
tumour, seminoma and non-seminomas, depending on the global 
methylation level and identifying uniquely methylated genes for each 
subtype might provide useful therapeutic markers for assisting other 
diagnosis of different types of GCTs.  
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Second, the progression state of GCTs related to methylation level 
could be used for cancer detection or even to identify those at risk of 
developing cancer later in life and detecting treatment purposes. 
Interestingly, in this study only five pluripotency-associated genes 
were identified as a functional group that were silenced by methylation. 
They were differentially methylated and differentially expressed in non-
seminomas relative to seminomas. This suggests that these could be 
considered as biomarkers in GCT development. These genes need 
further validation in a larger number of patient samples to assess their 
reliability before being considered as potential biomarkers in GCTs.  
Furthermore, using DNA methylation and methylated genes as a 
potential biomarkers is a useful tool because a small amount of DNA is 
enough for technical analysis and DNA can be obtained from any 
biological tissue samples or bodily fluid such as blood and urine, where 
tumour DNA can be released. In addition, DNA is highly stable and can 
be stored for a long time, to analyse the samples before and after 
treatment to investigate the response of a tumour to treatment or 
progression of a tumour. For example, it was confirmed that MGMT 
methylation is a useful predictive marker for expected the response of 
glioblastoma patients to treatment with the alkylating agent 
temozolomide, where several clinical trials showed an increase in 
survival rate for those patients who have a methylated CGI promoter of 
MGMT when treated with temozolomide (Schaefer et al., 2010). 
There are still a long way to elucidate the full understanding the 
role of methylation in cancer. This study revealed some insights in the 
correlation between methylation and expression in many genes in GCT 
cell lines. In particular, five of these genes that are closely associated 
with pluripotency and implicated in chemosensitivity might be promising 
targets for potential therapies in germ cell tumours which need further 
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analysis. In addition, these genes could help in understanding the 
reasons for the difference between seminoma and non-seminomas in 
many aspects such as aggressive behavior of non-seminoma or the 
sensitivity feature of seminomas to chemotherapy or the methylation 
difference between these types of GCTs. Moreover, PRDM14 might be 
used as the demethylation therapy to alter YST cells to have a more 
seminoma feature and thus become more sensitive to chemotherapy. 
Summary: 
The present study was designed to determine the correlation 
between DNA methylation and gene expression in two common classes 
of GCTs, seminomas and non-seminomas, using lab experiments and 
both genome expression and methylation data analysis for cell lines and 
primary tumours.  
The most striking finding to emerge from this study was that non-
seminoma cell lines revealed a very different methylator phenotype 
compared with seminomas. New potentially biologically important genes 
associated with the germ cell state and/or pluripotency process were 
identified; PRDM14, KLF4, TDRD12, DDX43, MNS1, and RBMXL2. The 
silenced and methylated genes could play a role in progression of GCTs 
and might provide new potential therapeutic targets for the treatment of 
GCTs. PRDM14 was suggested as a demethylating factor in this tumour 
and may cause an increase in expression of some  pluripotency and/or 
testis genes as well as increase chemosensitivity to cisplatin in 
seminomas.  
For future work, in order to understand more about the function of 
PRDM14 in GCTs, genome expression array analysis following 
overexpression PRDM14 in YST cells in addition to loss of function in 
SEM cells is necessary. In addition, it is useful to study the methylation 
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status of different regions of the identified genes in this study that 
upregulated in overexpressing PRDM14 YST cells and compared them 
with those in untransfected YST cells to assess the role of PRDM14 in 
the regional methylation of these gene.  
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Appendix 
Appendix I. Tables and histograms represent the correlation between 
differential expression and differential methylation between seminoma 
and non-seminoma at islands, shores and shelves: Contingency tables 
and histograms of the observed and expected number of genes 
differentially expressed the ranges of differential methylation between 
YST and seminoma. P-values of the chi-squared test of association 
between methylation and expression are given as well as the observed 
(blue) and expected (red) percentage correlation for each delta-β value. 
The total number of genes in each category is displayed above the bar. 
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EC 
 
TERT 
 
 
 
Genes >2 fold Genes >2 fold No difference No difference Genes >2 fold Genes >2 fold Pvalue
O bserved Expected O bserved Expected O bserved Expected Chi squared(2df)
0.8-0.85 1 0.125 0 0.754071661 0 0.120928339 1 0.030197383 *
0.75-0.8 0 0.5 3 3.016286645 1 0.483713355 4 0.591217871
0.7-0.75 1 0.75 4 4.524429967 1 0.725570033 6 0.883416442
0.65-0.7 1 0.625 4 3.770358306 0 0.604641694 5 0.65585585
0.6-0.65 3 1.75 10 10.55700326 1 1.692996743 14 5.47E-01
0.55-0.6 7 2.75 10 16.58957655 5 2.660423453 22 3.62E-03 **
0.5-0.55 3 2.875 15 17.34364821 5 2.781351792 23 0.351354538
0.45-0.5 3 4 20 24.13029316 9 3.86970684 32 0.020666401 *
0.4-0.45 1 5.625 36 33.93322476 8 5.441775244 45 0.076869112
0.35-0.4 5 8.375 50 50.5228013 12 8.102198697 67 0.197835718
0.3-0.35 17 9.875 55 59.57166124 7 9.553338762 79 0.045636433 *
0.25-0.3 13 13 80 78.42345277 11 12.57654723 104 0.891667837
0.2-0.25 12 15.625 98 94.25895765 15 15.11604235 125 0.609458451
0.15-0.2 19 24.125 142 145.5358306 32 23.33916938 193 0.11143964
0.1-0.15 33 38.125 229 229.9918567 43 36.88314332 305 0.425781639
0.05-0.1 79 68.375 419 412.4771987 49 66.1478013 547 0.045060353 *
0-0.05 109 110.5 677 666.5993485 98 106.9006515 884 0.630111955
Total 307 307 1852 1852 297 297 2456
Delta beta Total Significance
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Appendix II. R commands (performed by Claire Wallace) 
 Input commands in R are shown in blue writing, preceded by >. R outputs 
are shown in black writing, and commentary explanations of the process are shown 
in green writing, preceded by # 
> source("http://bioconductor.org/biocLite.R") .  
Bioconductor version 2.11 (BiocInstaller 1.8.3), ?biocLite for help 
#This instructs R to use the Bioconductor website to install packages to use with 
Affymetrix .CEL files 
> biocLite() 
BioC_mirror: http://bioconductor.org 
Using Bioconductor version 2.11 (BiocInstaller 1.8.3), R version 2.15. 
Installing package(s) 'Biobase' 'IRanges' 'AnnotationDbi' 
The downloaded binary packages are in 
 /var/folders/jy/jy3gx2IrGiCkg48a5WZgH++++TI/-Tmp-
//Rtmp2DsOlq/downloaded_packages 
Old packages: 'cluster', 'foreign', 'KernSmooth', 'lattice', 'Matrix', 'nnet', 'R.oo', 
'rpart', 'survival', 'XML', 'xtable' 
Update all/some/none? [a/s/n]:  
> a 
The downloaded binary packages are in 
 /var/folders/jy/jy3gx2IrGiCkg48a5WZgH++++TI/-Tmp-
//Rtmp2DsOlq/downloaded_packages 
#This downloads and updates all relevant packages 
> biocLite("affy") 
BioC_mirror: http://bioconductor.org 
Using Bioconductor version 2.11 (BiocInstaller 1.8.3), R version 2.15. 
Installing package(s) 'affy' 
trying URL 
'http://bioconductor.org/packages/2.11/bioc/bin/macosx/leopard/contrib/2.15/affy_1.
36.1.tgz' 
Content type 'application/x-gzip' length 1482408 bytes (1.4 Mb) 
opened URL 
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================================================== 
downloaded 1.4 Mb 
The downloaded binary packages are in 
 /var/folders/jy/jy3gx2IrGiCkg48a5WZgH++++TI/-Tmp-
//Rtmp2DsOlq/downloaded_packages 
#This downloads the required package “affy” 
> library(affy) 
Loading required package: BiocGenerics 
Loading required package: Biobase 
Welcome to Bioconductor 
#This loads the specified package “affy” 
> norm <- exprs(justRMA()) 
#This reads the .CEL files present in the working directory and performs RMA 
background correction of the expression intensity levels. 
> dim(norm) 
[1] 54675     4 
#This shows that there are 54 675 probes with expression intensity values for 4 cell 
lines 
> head(norm) 
             EC.CEL Seminoma.CEL Teratoma.CEL  YST.CEL 
1007_s_at 10.516547    10.449916     9.873835 9.447998 
1053_at    9.763713     8.540985     9.519655 9.788232 
117_at     5.420071     5.416785     5.376868 5.389875 
121_at     7.699719     7.634446     7.724840 7.731468 
1255_g_at  4.900915     7.890857     6.144012 4.219233 
1294_at    5.226387     5.435574     5.087242 5.353925 
#The command ‘head()’ shows the first 6 lines of the table of data 
This table shows the probe label and the expression values of each probe in each 
cell line after RMA background correction. Expression intensities are given as log 
(base 2) values.  
> require(simpleaffy) 
Loading required package: simpleaffy 
Loading required package: genefilter 
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Loading required package: gcrma 
No methods found in "Biobase" for requests: geneNames 
#This downloads the relevant package “simpleaffy” 
> raw <- ReadAffy() 
#This reads the .CEL files again, without first background correcting them. We 
performed this step in order to determine which probes give values below the 
background level. 
> call <- detection.p.val(raw)$call 
#This determines whether each probe gives a value above or below a baseline 
intensity value, determined by control probes within the Affymetrix gene chip. A 
value above baseline is labelled “P” (present), and a value below baseline is 
labelled “A” (absent) - see table below.  
> head(call) 
          EC.CEL.present Seminoma.CEL.present Teratoma.CEL.present 
YST.CEL.present 
1007_s_at "P"            "P"                  "P"                  "P"             
1053_at   "P"            "P"                  "P"                  "P"             
117_at    "A"            "A"                  "A"                  "A"             
121_at    "P"            "P"                  "P"                  "P"             
1255_g_at "P"            "P"                  "P"                  "A"             
1294_at   "A"            "A"                  "A"                  "A"             
> calldet <- rowSums(call=="A") 
#This counts, for each probe, the number of cell lines which show an intensity level 
below baseline (see table below) 
> head(calldet) 
1007_s_at   1053_at    117_at    121_at 1255_g_at   1294_at  
 0          0          4          0        1          4  
> sum(calldet == 4) 
[1] 24733 
#24 733 probes (out of 54 675) were labelled as “absent” in all four cell lines 
> filt.probe <- norm[calldet < 4, ] 
#This creates a new table of genes which were “present” in at least one cell line 
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> dim(filt.probe) 
[1] 29942     4 
#29 942 probes remained in our dataset after this filtering process 
> head(filt.probe) 
             EC.CEL Seminoma.CEL Teratoma.CEL  YST.CEL 
1007_s_at 10.516547    10.449916     9.873835 9.447998 
1053_at    9.763713     8.540985     9.519655 9.788232 
121_at     7.699719     7.634446     7.724840 7.731468 
1255_g_at  4.900915     7.890857     6.144012 4.219233 
1316_at    5.336027     5.095768     5.298631 5.617900 
1431_at    4.092673     4.500429     4.860048 4.206779 
>  sEC <- filt.probe[, 2] - filt.probe[, 1] 
> sTER <- filt.probe[, 2] - filt.probe[, 3] 
> sYST <- filt.probe[, 2] - filt.probe[, 4] 
> FC <- data.frame(sEC=sEC, sTER=sTER, sYST=sYST) 
#The above four commands create a new table showing the fold change 
differences in expression intensity values between the EC, Teratoma and YST cell 
lines relative to the Seminoma cell line (see table below)                                                                                                                              
> head(FC) 
                  sEC        sTER        sYST 
1007_s_at -0.06663077  0.57608158  1.00191860 
1053_at   -1.22272832 -0.97867038 -1.24724738 
121_at    -0.06527352 -0.09039394 -0.09702187 
1255_g_at  2.98994200  1.74684446  3.67162365 
1316_at   -0.24025831 -0.20286311 -0.52213145 
1431_at    0.40775594 -0.35961902  0.29365011 
> require("hgu133plus2.db") 
Loading required package: hgu133plus2.db 
Loading required package: org.Hs.eg.db 
Loading required package: DBI 
#This downloads the package required for probe annotation with gene information. 
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> ann <- merge(toTable(hgu133plus2SYMBOL), 
merge(toTable(hgu133plus2ENTREZID), toTable(hgu133plus2GENENAME), 
by=1), by=1) 
#This creates a table of gene information for each probe, detailing the gene 
symbol, Entrez ID and full gene name (see table below) 
> head(ann) 
   probe_id symbol gene_id                                   gene_name 
1 1007_s_at   DDR1     780 discoidin domain receptor tyrosine kinase 1 
2   1053_at   RFC2    5982 replication factor C (activator 1) 2, 40kDa 
3    117_at  HSPA6    3310        heat shock 70kDa protein 6 (HSP70B') 
4    121_at   PAX8    7849                                paired box 8 
5 1255_g_at GUCA1A    2978     guanylate cyclase activator 1A (retina) 
6   1294_at   UBA7    7318 ubiquitin-like modifier activating enzyme 7                                                                                                                                  
> all <- cbind(FC, filt.probe) 
#This merges the tables detailing the intensity level expression value and the fold 
changes for each probe (all given as log (base 2)) - see table below: 
> head(all) 
                  sEC        sTER        sYST    EC.CEL Seminoma.CEL Teratoma.CEL  
YST.CEL 
1007_s_at -0.06663077  0.57608158  1.00191860 10.516547    10.449916     
9.873835 9.447998 
1053_at   -1.22272832 -0.97867038 -1.24724738  9.763713     8.540985     
9.519655 9.788232 
121_at    -0.06527352 -0.09039394 -0.09702187  7.699719     7.634446     
7.724840 7.731468 
1255_g_at  2.98994200  1.74684446  3.67162365  4.900915     7.890857     
6.144012 4.219233 
1316_at   -0.24025831 -0.20286311 -0.52213145  5.336027     5.095768     
5.298631 5.617900 
1431_at    0.40775594 -0.35961902  0.29365011  4.092673     4.500429     
4.860048 4.206779 
> all.ann <- merge(ann, all, by.x=1, by.y=0, sort=FALSE) 
#This merges the gene annotations to the above table (see table below) 
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> head(all.ann) 
   probe_id symbol gene_id                                             gene_name         sEC        
sTER        sYST    EC.CEL Seminoma.CEL Teratoma.CEL  YST.CEL 
1 1007_s_at   DDR1     780           discoidin domain receptor tyrosine kinase 1 -
0.06663077  0.57608158  1.00191860 10.516547    10.449916     9.873835 
9.447998 
2   1053_at   RFC2    5982           replication factor C (activator 1) 2, 40kDa -
1.22272832 -0.97867038 -1.24724738  9.763713     8.540985     9.519655 
9.788232 
3    121_at   PAX8    7849                                          paired box 8 -0.06527352 -
0.09039394 -0.09702187  7.699719     7.634446     7.724840 7.731468 
4 1255_g_at GUCA1A    2978               guanylate cyclase activator 1A (retina)  
2.98994200  1.74684446  3.67162365  4.900915     7.890857     6.144012 
4.219233 
5   1316_at   THRA    7067                       thyroid hormone receptor, alpha -
0.24025831 -0.20286311 -0.52213145  5.336027     5.095768     5.298631 
5.617900 
6   1431_at CYP2E1    1571 cytochrome P450, family 2, subfamily E, polypeptide 1  
0.40775594 -0.35961902  0.29365011  4.092673     4.500429     4.860048 
4.206779 
> write.table(all.ann, file="results.txt", sep="\t", quote=FALSE) 
#This writes the above table as a .txt file, and saves it in the working directory. The 
file can then be opened in Excel to view the table and further analyse the data. 
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Appendix III. Sequencing for Myc-pcDNA3.1-PRDM14  
BamH1 
BstX 1 
EcoR 1 
START CODON 
 
NNNNNNNNANNNNNNNNNTNNNCTTACCNTGGGGGGTTCTCATCATCATCATCATCATGGTATGGCTAGCATG
ACTGGTGGACAGCAAATGGGTCGGGATCTGTACGACGATGACGATAAGGTACCAGGATCTCGACGGTATCGAT
TTAAAGCTATGGAGCAAAAGCTCATTTCTGAAGAGGACTTGAATGAAATGGAGCAAAAGCTCATTTCTGAAGA
GGACTTGAATGAAATGGAGCAAAAGCTCATTTCTGAAGAGGACTTGAATGAAATGGAGCAAAAGCTCATTTCT
GAAGAGGACTTGAATGAAATGGAGCAAAAGCTCATTTCTGAAGAGGACTTGAATGAAATGGAGAGCTTGGGCG
ACCTCACCATGGAGCAAAAGCTCATTTCTGAAGAGGACTTGGGATCCAGTGTGGTGGAATTCATGGCTCTACC
CCGGCCAAGTGAGGCCGTGCCTCAGGACAAGGTGTGCTACCCGCCGGAGAGCAGCCCGCAGAACCTGGCCGCG
TACTACACGCCTTTCCCGTCCTATGGACACTACAGAAACAGCCTGGCCACCGTGGAGGAAGACTTCCAACCTT
TCCGGCAGCTGGAGGCCGCAGCGTCTGCTGCCCCCGCCATGCCCCCCTTCCCCTTCCGGATGGCGCCTCCCTT
GCTGAGCCCGGGTCTGGGCCTACAGAGGGAGCCTCTCTACGATCTGCCCTGGTACAGCAAGCTGCCACCGTGG
TACCCAATTCCCCACGTCCCCAGGGAAGTGCCGCCCTTCCTGAGCAGCAGCCACGAGTACGCGGGTGCCAGCA
GTGAAGATCTGGGCCACCAAATCATTGGTGGCGACAACGAGAGTGGCCCGTGTTGTGGACCTGACACTTTAAT
TCCACCGCCCCCTGCGGATGCTTCTCTGTTACCTGAGGGGCTGAGGACCTCCCAGTTANTACCTTGCTCACCC
AGCAAGCAGTCAGAGGATGGTCCCAAACCCTCCAACCAAGAAGGGAAGTCCCCTGCTCGGTTCCAGTTCACGG
AGGAGGACCTGCACTTCGTTCNGTANGGGGTCACTCCNGCCTNNNCACCCAGCCAGCCTGCACCATGCGATTT
CNNGNTCNGGTNCCCCCAGACAGCTCTGGANNTGATNNTCTTCNCAAACTCTGGANAAAGACTCCCNTNANTT
CNNNNNCTNNNCCTCATGCAGANNNNNNNNNNNANTCCCNNNTTTTNGNNGNGTTCTGCAGNANTTTNNCNNN
NNNNNNNNNNNNNNNNNNTCNNNNAANNGNCATGNCAGNNANNNNACNNCGNANNNNATNNNNNNNANGNGGN
NATCTTNNAANANNGNNCNTTNNNNNNTTNNNNNNNNNNNGNGNTANGGAANNGANNNNNNNTNNNNANNNNN
NNNNNCNGNNCNANNNNNNNNNNNNNNGNNNNNNNNN 
Blast 
Query  1     ATGGCTCTACCCCGGCCAAGTGAGGCCGTGCCTCAGGACAAGGTGTGCTACCCGCCGGAG  60 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  428   ATGGCTCTACCCCGGCCAAGTGAGGCCGTGCCTCAGGACAAGGTGTGCTACCCGCCGGAG  487 
 
Query  61    AGCAGCCCGCAGAACCTGGCCGCGTACTACACGCCTTTCCCGTCCTATGGACACTACAGA  120 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  488   AGCAGCCCGCAGAACCTGGCCGCGTACTACACGCCTTTCCCGTCCTATGGACACTACAGA  547 
 
Query  121   AACAGCCTGGCCACCGTGGAGGAAGACTTCCAACCTTTCCGGCAGCTGGAGGCCGCAGCG  180 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  548   AACAGCCTGGCCACCGTGGAGGAAGACTTCCAACCTTTCCGGCAGCTGGAGGCCGCAGCG  607 
 
Query  181   TCTGCTGCCCCCGCCATGCCCCCCTTCCCCTTCCGGATGGCGCCTCCCTTGCTGAGCCCG  240 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  608   TCTGCTGCCCCCGCCATGCCCCCCTTCCCCTTCCGGATGGCGCCTCCCTTGCTGAGCCCG  667 
 
Query  241   GGTCTGGGCCTACAGAGGGAGCCTCTCTACGATCTGCCCTGGTACAGCAAGCTGCCACCG  300 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  668   GGTCTGGGCCTACAGAGGGAGCCTCTCTACGATCTGCCCTGGTACAGCAAGCTGCCACCG  727 
 
Query  301   TGGTACCCAATTCCCCACGTCCCCAGGGAAGTGCCGCCCTTCCTGAGCAGCAGCCACGAG  360 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  728   TGGTACCCAATTCCCCACGTCCCCAGGGAAGTGCCGCCCTTCCTGAGCAGCAGCCACGAG  787 
 
Query  361   TACGCGGGTGCCAGCAGTGAAGATCTGGGCCACCAAATCATTGGTGGCGACAACGAGAGT  420 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  788   TACGCGGGTGCCAGCAGTGAAGATCTGGGCCACCAAATCATTGGTGGCGACAACGAGAGT  847 
 217 
 
Query  421   GGCCCGTGTTGTGGACCTGACACTTTAATTCCACCGCCCCCTGCGGATGCTTCTCTGTTA  480 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  848   GGCCCGTGTTGTGGACCTGACACTTTAATTCCACCGCCCCCTGCGGATGCTTCTCTGTTA  907 
 
Query  481   CCTGAGGGGCTGAGGACCTCCCAGTTATTACCTTGCTCACCCAGCAAGCAGTCAGAGGAT  540 
             ||||||||||||||||||||||||||| |||||||||||||||||||||||||||||||| 
Sbjct  908   CCTGAGGGGCTGAGGACCTCCCAGTTANTACCTTGCTCACCCAGCAAGCAGTCAGAGGAT  967 
 
Query  541   GGTCCCAAACCCTCCAACCAAGAAGGGAAGTCCCCTGCTCGGTTCCAGTTCACGGAGGAG  600 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  968   GGTCCCAAACCCTCCAACCAAGAAGGGAAGTCCCCTGCTCGGTTCCAGTTCACGGAGGAG  1027 
 
Query  601   GACCTGCACTTCGTTCTGTACGGGGTCACTCCCAGCCTGGAGCACCCAGCCAGCCTGCAC  660 
             |||||||||||||||| ||| |||||||||||  ||||    |||||||||||||||||| 
Sbjct  1028  GACCTGCACTTCGTTCNGTANGGGGTCACTCCN-GCCTNNN-CACCCAGCCAGCCTGCAC  1085 
 
Query  661   CATGCGATTTCAGGCCTCCTGGTCCCCCCAGACAGCTCTGGATCTGATTCTCTTCCTCAA  720 
             |||||||||||  |  ||  ||| ||||||||||||||||||  ||||  |||||  ||| 
Sbjct  1086  CATGCGATTTCNNGN-TCN-GGTNCCCCCAGACAGCTCTGGANNTGATNNTCTTCN-CAA  1142 
 
Query  721   ACTCTGGATAAAGACTCCC  739 
             |||||||| |||||||||| 
Sbjct  1143  ACTCTGGANAAAGACTCCC  1161 
 
 
 
5'3' Frame 1 
 
atggctctaccccggccaagtgaggccgtgcctcaggacaaggtgtgctacccgccggag 
 M  A  L  P  R  P  S  E  A  V  P  Q  D  K  V  C  Y  P  P  E  
agcagcccgcagaacctggccgcgtactacacgcctttcccgtcctatggacactacaga 
 S  S  P  Q  N  L  A  A  Y  Y  T  P  F  P  S  Y  G  H  Y  R  
aacagcctggccaccgtggaggaagacttccaacctttccggcagctggaggccgcagcg 
 N  S  L  A  T  V  E  E  D  F  Q  P  F  R  Q  L  E  A  A  A  
tctgctgcccccgccatgccccccttccccttccggatggcgcctcccttgctgagcccg 
 S  A  A  P  A  M  P  P  F  P  F  R  M  A  P  P  L  L  S  P  
ggtctgggcctacagagggagcctctctacgatctgccctggtacagcaagctgccaccg 
 G  L  G  L  Q  R  E  P  L  Y  D  L  P  W  Y  S  K  L  P  P  
tggtacccaattccccacgtccccagggaagtgccgcccttcctgagcagcagccacgag 
 W  Y  P  I  P  H  V  P  R  E  V  P  P  F  L  S  S  S  H  E  
tacgcgggtgccagcagtgaagatctgggccaccaaatcattggtggcgacaacgagagt 
 Y  A  G  A  S  S  E  D  L  G  H  Q  I  I  G  G  D  N  E  S  
ggcccgtgttgtggacctgacactttaattccaccgccccctgcggatgcttctctgtta 
 G  P  C  C  G  P  D  T  L  I  P  P  P  P  A  D  A  S  L  L  
cctgaggggctgaggacctcccagttattaccttgctcacccagcaagcagtcagaggat 
 P  E  G  L  R  T  S  Q  L  L  P  C  S  P  S  K  Q  S  E  D  
ggtcccaaaccctccaaccaagaagggaagtcccctgctcggttccagttcacggaggag 
 G  P  K  P  S  N  Q  E  G  K  S  P  A  R  F  Q  F  T  E  E  
gacctgcacttcgttctgtacggggtcactcccagcctggagcacccagccagcctgcac 
 D  L  H  F  V  L  Y  G  V  T  P  S  L  E  H  P  A  S  L  H  
catgcgatttcaggcctcctggtccccccagacagctctggatctgattctcttcctcaa 
 H  A  I  S  G  L  L  V  P  P  D  S  S  G  S  D  S  L  P  Q  
actctggataaagactcccttcaacttccagaaggtctatgcctcatgcagacggtgttt 
 T  L  D  K  D  S  L  Q  L  P  E  G  L  C  L  M  Q  T  V  F  
ggtgaagtcccacattttggtgtgttctgcagtagttttatcgccaaaggagtcaggttt 
 G  E  V  P  H  F  G  V  F  C  S  S  F  I  A  K  G  V  R  F  
gggccctttcaaggtaaagtggtcaatgccagtgaagtgaagacctacggagacaattct 
 G  P  F  Q  G  K  V  V  N  A  S  E  V  K  T  Y  G  D  N  S  
gtgatgtgggagatctttgaagatggtcatttgagccactttatagatggaaaaggaggt 
 218 
 V  M  W  E  I  F  E  D  G  H  L  S  H  F  I  D  G  K  G  G  
acggggaactggatgtcctatgtcaactgtgcccgcttccccaaggagcagaacctagtt 
 T  G  N  W  M  S  Y  V  N  C  A  R  F  P  K  E  Q  N  L  V  
gctgtgcagtgtcaagggcatatattttatgagagctgcaaagagatccatcagaaccaa 
 A  V  Q  C  Q  G  H  I  F  Y  E  S  C  K  E  I  H  Q  N  Q  
gagctccttgtgtggtatggagactgctatgagaaatttctggatattcctgtgagcctt 
 E  L  L  V  W  Y  G  D  C  Y  E  K  F  L  D  I  P  V  S  L  
caggtcacagagccggggaagcagccatctgggccctctgaagagtctgcagaaggctac 
 Q  V  T  E  P  G  K  Q  P  S  G  P  S  E  E  S  A  E  G  Y  
agatgtgaaagatgtgggaaggtatttacctacaaatattacagagataagcacctcaag 
 R  C  E  R  C  G  K  V  F  T  Y  K  Y  Y  R  D  K  H  L  K  
tacaccccctgtgtggacaagggcgataggaaatttccctgttctctctgcaaacgatcc 
 Y  T  P  C  V  D  K  G  D  R  K  F  P  C  S  L  C  K  R  S  
tttgagaagcgggaccggcttcggatccacattcttcatgttcatgagaagcaccggcct 
 F  E  K  R  D  R  L  R  I  H  I  L  H  V  H  E  K  H  R  P  
cacaagtgttctacatgtgggaaatgtttctctcaatcttccagcctaaacaaacacatg 
 H  K  C  S  T  C  G  K  C  F  S  Q  S  S  S  L  N  K  H  M  
cgagtccactctggagacagaccataccagtgtgtgtattgtactaagaggttcacagcc 
 R  V  H  S  G  D  R  P  Y  Q  C  V  Y  C  T  K  R  F  T  A  
tccagcatactccgcacacacatcaggcagcactccggggagaagcccttcaaatgcaag 
 S  S  I  L  R  T  H  I  R  Q  H  S  G  E  K  P  F  K  C  K  
tactgtggtaaatcttttgcatcccatgctgcccatgacagccatgtccggcgttcacac 
 Y  C  G  K  S  F  A  S  H  A  A  H  D  S  H  V  R  R  S  H  
aaggaggatgatggctgctcatgcagcatctgtgggaaaatcttctcagatcaagaaaca 
 K  E  D  D  G  C  S  C  S  I  C  G  K  I  F  S  D  Q  E  T  
ttctactcccacatgaagtttcatgaagactactagcc 
 F  Y  S  H  M  K  F  H  E  D  Y  -     
 
A-G      Q-Q 
T-C      D-D 
 
 
 
 
 
 
 
origin mutation Type of mutation 
Caa- Gln cag - Gln silent 
Gat- Asp gac - Asp silent 
